{"PMC3510238": [["IntroductionThe brain has unique structures in place to limit access of immune cells and molecules.", [["brain", "ANATOMY", 16, 21], ["immune cells", "ANATOMY", 72, 84], ["brain", "ORGAN", 16, 21], ["immune cells", "CELL", 72, 84], ["immune cells", "CELL_TYPE", 72, 84], ["brain", "ANATOMY", 16, 21], ["immune cells", "OBSERVATION", 72, 84]]], ["Although this can provide protection against an overambitious inflammatory response it may also lead to the high prevalence of latent and chronic infections that can persist at this site.", [["infections", "DISEASE", 146, 156], ["protection", "TREATMENT", 26, 36], ["an overambitious inflammatory response", "PROBLEM", 45, 83], ["latent and chronic infections", "PROBLEM", 127, 156], ["inflammatory", "OBSERVATION", 62, 74], ["latent", "OBSERVATION_MODIFIER", 127, 133], ["chronic", "OBSERVATION_MODIFIER", 138, 145], ["infections", "OBSERVATION", 146, 156]]], ["Removal of such pathogens has its own particular problems in an organ dense with sensitive neurons and stringent gateways for immune cell infiltration.", [["organ", "ANATOMY", 64, 69], ["neurons", "ANATOMY", 91, 98], ["immune cell", "ANATOMY", 126, 137], ["organ", "ORGAN", 64, 69], ["neurons", "CELL", 91, 98], ["immune cell", "CELL", 126, 137], ["Removal", "TREATMENT", 0, 7], ["such pathogens", "PROBLEM", 11, 25], ["sensitive neurons", "PROBLEM", 81, 98], ["immune cell infiltration", "PROBLEM", 126, 150], ["organ", "ANATOMY", 64, 69], ["dense", "OBSERVATION", 70, 75], ["immune cell infiltration", "OBSERVATION", 126, 150]]], ["Toxoplasma gondii is a common intracellular protozoan parasite that forms a chronic infection in the brain for the lifetime of the host.", [["intracellular", "ANATOMY", 30, 43], ["brain", "ANATOMY", 101, 106], ["Toxoplasma gondii", "DISEASE", 0, 17], ["protozoan parasite", "DISEASE", 44, 62], ["chronic infection", "DISEASE", 76, 93], ["Toxoplasma gondii", "ORGANISM", 0, 17], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["brain", "ORGAN", 101, 106], ["Toxoplasma gondii", "SPECIES", 0, 17], ["Toxoplasma gondii", "SPECIES", 0, 17], ["Toxoplasma gondii", "PROBLEM", 0, 17], ["a common intracellular protozoan parasite", "PROBLEM", 21, 62], ["a chronic infection in the brain", "PROBLEM", 74, 106], ["gondii", "OBSERVATION", 11, 17], ["protozoan", "OBSERVATION_MODIFIER", 44, 53], ["parasite", "OBSERVATION", 54, 62], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["infection", "OBSERVATION", 84, 93], ["brain", "ANATOMY", 101, 106]]], ["The infection is controlled, in part, through the effector mechanisms of macrophages that result in the conversion of fast replicating tachyzoites to the slow replicating, cyst forming bradyzoites [1]\u2013[3].", [["macrophages", "ANATOMY", 73, 84], ["tachyzoites", "ANATOMY", 135, 146], ["cyst", "ANATOMY", 172, 176], ["infection", "DISEASE", 4, 13], ["macrophages", "CELL", 73, 84], ["macrophages", "CELL_TYPE", 73, 84], ["The infection", "PROBLEM", 0, 13], ["fast replicating tachyzoites", "PROBLEM", 118, 146], ["cyst forming bradyzoites", "PROBLEM", 172, 196], ["infection", "OBSERVATION", 4, 13], ["macrophages", "OBSERVATION", 73, 84], ["cyst", "OBSERVATION", 172, 176]]], ["Cysts can form in all tissues but exist predominantly in the brain for the lifetime of the host requiring a continuous immune response to prevent cyst reactivation and Toxoplasmic encephalitis, a common cause of AIDS related fatalities [4], [5].", [["Cysts", "ANATOMY", 0, 5], ["tissues", "ANATOMY", 22, 29], ["brain", "ANATOMY", 61, 66], ["cyst", "ANATOMY", 146, 150], ["Toxoplasmic encephalitis", "DISEASE", 168, 192], ["AIDS", "DISEASE", 212, 216], ["fatalities", "DISEASE", 225, 235], ["tissues", "TISSUE", 22, 29], ["brain", "ORGAN", 61, 66], ["cyst", "CANCER", 146, 150], ["Cysts", "PROBLEM", 0, 5], ["a continuous immune response", "TREATMENT", 106, 134], ["cyst reactivation", "PROBLEM", 146, 163], ["Toxoplasmic encephalitis", "PROBLEM", 168, 192], ["AIDS", "PROBLEM", 212, 216], ["all tissues", "OBSERVATION_MODIFIER", 18, 29], ["brain", "ANATOMY", 61, 66], ["cyst", "OBSERVATION", 146, 150], ["Toxoplasmic encephalitis", "OBSERVATION", 168, 192]]], ["The infection-induced immune response in the brain consists of activated CNS resident cells including astrocytes and microglia, infiltrating CD4+ and CD8+ T cells, peripheral macrophages and substantial tissue remodeling [6]\u2013[8].", [["brain", "ANATOMY", 45, 50], ["CNS resident cells", "ANATOMY", 73, 91], ["astrocytes", "ANATOMY", 102, 112], ["microglia", "ANATOMY", 117, 126], ["CD4+ and CD8+ T cells", "ANATOMY", 141, 162], ["peripheral macrophages", "ANATOMY", 164, 186], ["tissue", "ANATOMY", 203, 209], ["infection", "DISEASE", 4, 13], ["brain", "ORGAN", 45, 50], ["CNS resident cells", "CELL", 73, 91], ["astrocytes", "CELL", 102, 112], ["microglia", "CELL", 117, 126], ["CD4", "GENE_OR_GENE_PRODUCT", 141, 144], ["CD8", "GENE_OR_GENE_PRODUCT", 150, 153], ["peripheral macrophages", "CELL", 164, 186], ["tissue", "TISSUE", 203, 209], ["activated CNS resident cells", "CELL_TYPE", 63, 91], ["astrocytes", "CELL_TYPE", 102, 112], ["microglia", "CELL_TYPE", 117, 126], ["infiltrating CD4+ and CD8+ T cells", "CELL_TYPE", 128, 162], ["peripheral macrophages", "CELL_TYPE", 164, 186], ["The infection", "PROBLEM", 0, 13], ["astrocytes", "TEST", 102, 112], ["microglia", "TEST", 117, 126], ["infiltrating CD4", "TEST", 128, 144], ["CD8", "TEST", 150, 153], ["T cells", "PROBLEM", 155, 162], ["peripheral macrophages", "PROBLEM", 164, 186], ["substantial tissue remodeling", "PROBLEM", 191, 220], ["infection", "OBSERVATION", 4, 13], ["immune response", "OBSERVATION", 22, 37], ["brain", "ANATOMY", 45, 50], ["CNS", "ANATOMY", 73, 76], ["peripheral", "ANATOMY_MODIFIER", 164, 174], ["macrophages", "ANATOMY", 175, 186], ["substantial tissue remodeling", "OBSERVATION", 191, 220]]], ["Such immune activity in the brain is often associated with a pathological outcome yet despite the high prevalence of infection Toxoplasma is seemingly controlled without adverse neurological damage.", [["brain", "ANATOMY", 28, 33], ["neurological", "ANATOMY", 178, 190], ["infection", "DISEASE", 117, 126], ["Toxoplasma", "DISEASE", 127, 137], ["adverse neurological damage", "DISEASE", 170, 197], ["brain", "ORGAN", 28, 33], ["Toxoplasma", "ORGANISM", 127, 137], ["Toxoplasma", "SPECIES", 127, 137], ["Such immune activity in the brain", "PROBLEM", 0, 33], ["a pathological outcome", "PROBLEM", 59, 81], ["infection Toxoplasma", "PROBLEM", 117, 137], ["adverse neurological damage", "PROBLEM", 170, 197], ["immune activity", "OBSERVATION", 5, 20], ["brain", "ANATOMY", 28, 33], ["infection", "OBSERVATION", 117, 126]]], ["The mechanisms that are involved in the trafficking and control of such a potentially pathological immune response within the CNS are only beginning to be understood [6], [8]\u2013[11].", [["CNS", "ANATOMY", 126, 129], ["CNS", "ANATOMICAL_SYSTEM", 126, 129], ["[8]\u2013[11]", "SIMPLE_CHEMICAL", 171, 179], ["a potentially pathological immune response", "PROBLEM", 72, 114]]], ["The cyst and cyst-forming bradyzoites are poorly immunogenic [12], [13] and although we have known for some time that T cells are required to prevent cyst reactivation [4], [5], [14], very little is understood about the biology of this structure in the brain.", [["cyst", "ANATOMY", 4, 8], ["bradyzoites", "ANATOMY", 26, 37], ["T cells", "ANATOMY", 118, 125], ["cyst", "ANATOMY", 150, 154], ["brain", "ANATOMY", 253, 258], ["cyst", "CANCER", 4, 8], ["T cells", "CELL", 118, 125], ["cyst", "ORGAN", 150, 154], ["brain", "ORGAN", 253, 258], ["T cells", "CELL_TYPE", 118, 125], ["The cyst", "PROBLEM", 0, 8], ["cyst-forming bradyzoites", "PROBLEM", 13, 37], ["poorly immunogenic", "PROBLEM", 42, 60], ["T cells", "PROBLEM", 118, 125], ["cyst reactivation", "PROBLEM", 150, 167], ["cyst", "OBSERVATION", 4, 8], ["bradyzoites", "OBSERVATION", 26, 37], ["cyst", "OBSERVATION", 150, 154], ["brain", "ANATOMY", 253, 258]]], ["Although anti-Toxoplasma drugs are available that efficiently control the tachyzoite, there are as yet no therapies available that can effectively remove the cyst form of the parasite.", [["cyst", "ANATOMY", 158, 162], ["anti-Toxoplasma drugs", "SIMPLE_CHEMICAL", 9, 30], ["cyst", "CANCER", 158, 162], ["anti-Toxoplasma drugs", "TREATMENT", 9, 30], ["the tachyzoite", "PROBLEM", 70, 84], ["therapies", "TREATMENT", 106, 115], ["cyst", "OBSERVATION", 158, 162]]], ["Thus, the continuous presence of Toxoplasma cysts in the brain presents a critical and constant danger for the immune compromised patient.IntroductionIt is widely believed that cysts remain intracellular within neurons possibly minimizing their contact with host defense systems [15].", [["cysts", "ANATOMY", 44, 49], ["brain", "ANATOMY", 57, 62], ["cysts", "ANATOMY", 177, 182], ["intracellular", "ANATOMY", 190, 203], ["neurons", "ANATOMY", 211, 218], ["Toxoplasma cysts", "DISEASE", 33, 49], ["Toxoplasma", "ORGANISM", 33, 43], ["cysts", "PATHOLOGICAL_FORMATION", 44, 49], ["brain", "ORGAN", 57, 62], ["patient", "ORGANISM", 130, 137], ["cysts", "PATHOLOGICAL_FORMATION", 177, 182], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 203], ["neurons", "CELL", 211, 218], ["patient", "SPECIES", 130, 137], ["Toxoplasma cysts in the brain", "PROBLEM", 33, 62], ["cysts", "PROBLEM", 177, 182], ["Toxoplasma cysts", "OBSERVATION", 33, 49], ["brain", "ANATOMY", 57, 62], ["cysts", "OBSERVATION", 177, 182]]], ["However it has been known for some time that cyst burden reaches a peak, declines and becomes stable over time pointing to some form of effector mechanism that can target this stage of the parasite [16].", [["cyst", "ANATOMY", 45, 49], ["cyst", "PATHOLOGICAL_FORMATION", 45, 49], ["cyst burden", "PROBLEM", 45, 56], ["effector mechanism", "PROBLEM", 136, 154], ["cyst", "OBSERVATION", 45, 49], ["peak", "OBSERVATION_MODIFIER", 67, 71], ["stable", "OBSERVATION_MODIFIER", 94, 100]]], ["Studies have implicated CD8+ T cell production of perforin in cyst clearance with perforin deficient mice exhibiting higher cyst burden and susceptibility at the chronic stage of infection [17], [18].", [["CD8+ T cell", "ANATOMY", 24, 35], ["cyst", "ANATOMY", 62, 66], ["cyst", "ANATOMY", 124, 128], ["infection", "DISEASE", 179, 188], ["CD8", "GENE_OR_GENE_PRODUCT", 24, 27], ["perforin", "GENE_OR_GENE_PRODUCT", 50, 58], ["cyst", "CANCER", 62, 66], ["perforin", "GENE_OR_GENE_PRODUCT", 82, 90], ["mice", "ORGANISM", 101, 105], ["cyst", "CANCER", 124, 128], ["CD8", "PROTEIN", 24, 27], ["perforin", "PROTEIN", 50, 58], ["perforin", "PROTEIN", 82, 90], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["Studies", "TEST", 0, 7], ["CD8", "TEST", 24, 27], ["perforin in cyst clearance", "PROBLEM", 50, 76], ["perforin deficient mice", "PROBLEM", 82, 105], ["higher cyst burden", "PROBLEM", 117, 135], ["susceptibility at the chronic stage of infection", "PROBLEM", 140, 188], ["T cell", "OBSERVATION", 29, 35], ["cyst", "OBSERVATION", 62, 66], ["higher", "OBSERVATION_MODIFIER", 117, 123], ["cyst", "OBSERVATION", 124, 128], ["burden", "OBSERVATION_MODIFIER", 129, 135], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["stage", "OBSERVATION_MODIFIER", 170, 175], ["infection", "OBSERVATION", 179, 188]]], ["Nevertheless, histological analysis from these studies as well as recent live imaging of cell interactions in the CNS [19] demonstrates monocyte accumulation and contact with cysts.IntroductionIn recent years, our understanding of macrophages has expanded and we now appreciate these cells' remarkable plasticity.", [["cell", "ANATOMY", 89, 93], ["CNS", "ANATOMY", 114, 117], ["monocyte", "ANATOMY", 136, 144], ["cysts", "ANATOMY", 175, 180], ["macrophages", "ANATOMY", 231, 242], ["cells", "ANATOMY", 284, 289], ["cell", "CELL", 89, 93], ["monocyte", "CELL", 136, 144], ["cysts", "PATHOLOGICAL_FORMATION", 175, 180], ["macrophages", "CELL", 231, 242], ["cells", "CELL", 284, 289], ["macrophages", "CELL_TYPE", 231, 242], ["histological analysis", "TEST", 14, 35], ["these studies", "TEST", 41, 54], ["recent live imaging", "TEST", 66, 85], ["monocyte accumulation", "PROBLEM", 136, 157], ["cysts", "PROBLEM", 175, 180], ["macrophages", "PROBLEM", 231, 242], ["monocyte accumulation", "OBSERVATION", 136, 157], ["cysts", "OBSERVATION", 175, 180], ["macrophages", "OBSERVATION", 231, 242]]], ["Thus, although whole populations of macrophages can become polarized to classical or alternative phenotypes associated with protection against protozoan and helminth pathogens respectively, the ability to respond and adapt to local stimuli in the environment is paramount [20]\u2013[24].", [["macrophages", "ANATOMY", 36, 47], ["protozoan and helminth pathogens", "DISEASE", 143, 175], ["macrophages", "CELL", 36, 47], ["macrophages", "CELL_TYPE", 36, 47], ["macrophages", "PROBLEM", 36, 47], ["alternative phenotypes", "PROBLEM", 85, 107], ["protozoan", "PROBLEM", 143, 152], ["helminth pathogens", "PROBLEM", 157, 175], ["local stimuli", "TEST", 226, 239]]], ["The role of classically activated macrophages in the control of T. gondii infection is well documented.", [["macrophages", "ANATOMY", 34, 45], ["T. gondii infection", "DISEASE", 64, 83], ["macrophages", "CELL", 34, 45], ["T. gondii", "ORGANISM", 64, 73], ["classically activated macrophages", "CELL_TYPE", 12, 45], ["T. gondii", "SPECIES", 64, 73], ["T. gondii", "SPECIES", 64, 73], ["classically activated macrophages", "PROBLEM", 12, 45], ["T. gondii infection", "PROBLEM", 64, 83], ["macrophages", "OBSERVATION", 34, 45], ["gondii infection", "OBSERVATION", 67, 83]]], ["These cells are a source of IL-12, reactive oxygen and nitrogen species, and GTPases that enable the direct killing of the parasite [6], [25]\u2013[30].", [["cells", "ANATOMY", 6, 11], ["oxygen", "CHEMICAL", 44, 50], ["oxygen", "CHEMICAL", 44, 50], ["nitrogen", "CHEMICAL", 55, 63], ["cells", "CELL", 6, 11], ["IL-12", "GENE_OR_GENE_PRODUCT", 28, 33], ["reactive oxygen", "SIMPLE_CHEMICAL", 35, 50], ["nitrogen species", "SIMPLE_CHEMICAL", 55, 71], ["GTPases", "GENE_OR_GENE_PRODUCT", 77, 84], ["[25]\u2013[30]", "SIMPLE_CHEMICAL", 137, 146], ["IL-12", "PROTEIN", 28, 33], ["GTPases", "PROTEIN", 77, 84], ["IL", "TEST", 28, 30], ["reactive oxygen and nitrogen species", "PROBLEM", 35, 71], ["GTPases", "TREATMENT", 77, 84], ["reactive oxygen", "OBSERVATION", 35, 50], ["nitrogen species", "OBSERVATION", 55, 71]]], ["However, here we describe a population of CXCR3+ macrophages in the brain following T. gondii infection.", [["CXCR3+ macrophages", "ANATOMY", 42, 60], ["brain", "ANATOMY", 68, 73], ["T. gondii infection", "DISEASE", 84, 103], ["CXCR3", "GENE_OR_GENE_PRODUCT", 42, 47], ["brain", "ORGAN", 68, 73], ["T. gondii", "ORGANISM", 84, 93], ["CXCR3", "PROTEIN", 42, 47], ["macrophages", "CELL_TYPE", 49, 60], ["T. gondii", "SPECIES", 84, 93], ["T. gondii", "SPECIES", 84, 93], ["macrophages in the brain", "PROBLEM", 49, 73], ["T. gondii infection", "PROBLEM", 84, 103], ["CXCR3", "OBSERVATION", 42, 47], ["macrophages", "OBSERVATION", 49, 60], ["brain", "ANATOMY", 68, 73], ["gondii infection", "OBSERVATION", 87, 103]]], ["These cells express the scavenger receptors MMR and stabilin-1 and produce arginase in response to the presence of Toxoplasma cysts.", [["cells", "ANATOMY", 6, 11], ["cysts", "ANATOMY", 126, 131], ["Toxoplasma cysts", "DISEASE", 115, 131], ["cells", "CELL", 6, 11], ["MMR", "GENE_OR_GENE_PRODUCT", 44, 47], ["stabilin-1", "GENE_OR_GENE_PRODUCT", 52, 62], ["arginase", "GENE_OR_GENE_PRODUCT", 75, 83], ["Toxoplasma", "ORGANISM", 115, 125], ["cysts", "PATHOLOGICAL_FORMATION", 126, 131], ["scavenger receptors", "PROTEIN", 24, 43], ["MMR", "PROTEIN", 44, 47], ["stabilin-1", "PROTEIN", 52, 62], ["arginase", "PROTEIN", 75, 83], ["stabilin", "TEST", 52, 60], ["arginase", "PROBLEM", 75, 83], ["Toxoplasma cysts", "PROBLEM", 115, 131], ["arginase", "OBSERVATION", 75, 83], ["Toxoplasma cysts", "OBSERVATION", 115, 131]]], ["In addition to these traditional signs of alternative activation, these studies demonstrate that macrophages respond to chitin present in the cyst wall and produce the true mammalian chitinase, AMCase.", [["macrophages", "ANATOMY", 97, 108], ["cyst wall", "ANATOMY", 142, 151], ["chitin", "CHEMICAL", 120, 126], ["macrophages", "CELL", 97, 108], ["chitin", "GENE_OR_GENE_PRODUCT", 120, 126], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 142, 151], ["chitinase", "GENE_OR_GENE_PRODUCT", 183, 192], ["AMCase", "GENE_OR_GENE_PRODUCT", 194, 200], ["macrophages", "CELL_TYPE", 97, 108], ["mammalian chitinase", "PROTEIN", 173, 192], ["AMCase", "PROTEIN", 194, 200], ["alternative activation", "PROBLEM", 42, 64], ["these studies", "TEST", 66, 79], ["macrophages", "PROBLEM", 97, 108], ["chitin", "TREATMENT", 120, 126], ["macrophages", "OBSERVATION", 97, 108], ["cyst", "OBSERVATION", 142, 146]]], ["Finally we show that this chitinase activity destroys cysts and is essential for the control of cyst burden within the chronically infected brain.A population of AAM\u00d8 in the T. gondii infected brain ::: ResultsRecent studies have identified a substantial increase in tissue remodeling in the brain during chronic T. gondii infection [8].", [["cysts", "ANATOMY", 54, 59], ["cyst", "ANATOMY", 96, 100], ["brain", "ANATOMY", 140, 145], ["brain", "ANATOMY", 193, 198], ["tissue", "ANATOMY", 267, 273], ["brain", "ANATOMY", 292, 297], ["chronically infected brain", "DISEASE", 119, 145], ["T. gondii infected", "DISEASE", 174, 192], ["T. gondii infection", "DISEASE", 313, 332], ["chitinase", "GENE_OR_GENE_PRODUCT", 26, 35], ["cysts", "PATHOLOGICAL_FORMATION", 54, 59], ["cyst", "CANCER", 96, 100], ["brain", "ORGAN", 140, 145], ["AAM\u00d8", "CANCER", 162, 166], ["T. gondii", "ORGANISM", 174, 183], ["brain", "ORGAN", 193, 198], ["tissue", "TISSUE", 267, 273], ["brain", "ORGAN", 292, 297], ["T. gondii", "ORGANISM", 313, 322], ["chitinase", "PROTEIN", 26, 35], ["T. gondii", "SPECIES", 174, 183], ["T. gondii", "SPECIES", 313, 322], ["T. gondii", "SPECIES", 174, 183], ["T. gondii", "SPECIES", 313, 322], ["this chitinase activity destroys cysts", "PROBLEM", 21, 59], ["cyst burden within the chronically infected brain", "PROBLEM", 96, 145], ["ResultsRecent studies", "TEST", 203, 224], ["a substantial increase in tissue remodeling in the brain", "PROBLEM", 241, 297], ["chronic T. gondii infection", "PROBLEM", 305, 332], ["cysts", "OBSERVATION", 54, 59], ["cyst", "OBSERVATION", 96, 100], ["chronically", "OBSERVATION_MODIFIER", 119, 130], ["infected", "OBSERVATION", 131, 139], ["brain", "ANATOMY", 140, 145], ["infected", "OBSERVATION", 184, 192], ["brain", "ANATOMY", 193, 198], ["substantial", "OBSERVATION_MODIFIER", 243, 254], ["increase", "OBSERVATION_MODIFIER", 255, 263], ["tissue remodeling", "OBSERVATION", 267, 284], ["brain", "ANATOMY", 292, 297], ["chronic", "OBSERVATION_MODIFIER", 305, 312], ["gondii infection", "OBSERVATION", 316, 332]]], ["Additionally, there is a continuous need for the clearance of debris from ruptured cysts and dead cells in the brain [31].", [["cysts", "ANATOMY", 83, 88], ["cells", "ANATOMY", 98, 103], ["brain", "ANATOMY", 111, 116], ["cells", "CELL", 98, 103], ["brain", "ORGAN", 111, 116], ["dead cells", "CELL_TYPE", 93, 103], ["debris", "PROBLEM", 62, 68], ["ruptured cysts", "PROBLEM", 74, 88], ["dead cells in the brain", "PROBLEM", 93, 116], ["debris", "OBSERVATION", 62, 68], ["ruptured", "OBSERVATION_MODIFIER", 74, 82], ["cysts", "OBSERVATION", 83, 88], ["dead cells", "OBSERVATION", 93, 103], ["brain", "ANATOMY", 111, 116]]], ["To investigate if AAM\u00d8, known for their role in tissue remodeling and homeostatic clearance, are present during such an event in the CNS, macrophage populations from the infected brain were phenotypically analyzed for the expression of known markers of alternative activation.", [["tissue", "ANATOMY", 48, 54], ["CNS", "ANATOMY", 133, 136], ["macrophage", "ANATOMY", 138, 148], ["brain", "ANATOMY", 179, 184], ["AAM\u00d8", "CHEMICAL", 18, 22], ["AAM\u00d8", "GENE_OR_GENE_PRODUCT", 18, 22], ["tissue", "TISSUE", 48, 54], ["CNS", "ANATOMICAL_SYSTEM", 133, 136], ["macrophage populations", "CELL", 138, 160], ["brain", "ORGAN", 179, 184], ["AAM\u00d8", "PROTEIN", 18, 22], ["macrophage populations", "CELL_TYPE", 138, 160], ["macrophage populations", "PROBLEM", 138, 160], ["the infected brain", "PROBLEM", 166, 184], ["alternative activation", "PROBLEM", 253, 275], ["tissue", "ANATOMY", 48, 54], ["remodeling", "OBSERVATION", 55, 65], ["CNS", "ANATOMY", 133, 136], ["infected", "OBSERVATION", 170, 178], ["brain", "ANATOMY", 179, 184]]], ["One of the key molecules that has been associated with a tissue remodeling macrophage phenotype in the CNS is the expression of CXCR3 on microglia [32], [33].", [["tissue", "ANATOMY", 57, 63], ["macrophage", "ANATOMY", 75, 85], ["CNS", "ANATOMY", 103, 106], ["microglia", "ANATOMY", 137, 146], ["tissue", "TISSUE", 57, 63], ["macrophage", "CELL", 75, 85], ["CNS", "ANATOMICAL_SYSTEM", 103, 106], ["CXCR3", "GENE_OR_GENE_PRODUCT", 128, 133], ["microglia", "CELL", 137, 146], ["CXCR3", "PROTEIN", 128, 133], ["microglia", "CELL_TYPE", 137, 146], ["a tissue remodeling macrophage phenotype", "PROBLEM", 55, 95], ["molecules", "OBSERVATION", 15, 24], ["associated with", "UNCERTAINTY", 39, 54], ["tissue remodeling", "OBSERVATION_MODIFIER", 57, 74], ["macrophage phenotype", "OBSERVATION", 75, 95], ["CNS", "ANATOMY", 103, 106]]], ["CXCR3 is required for protective immune responses to T. gondii primarily due to its role in Th1 cell recruitment and most recently for T cell search strategies in the brain [34]\u2013[37].", [["Th1 cell", "ANATOMY", 92, 100], ["T cell", "ANATOMY", 135, 141], ["brain", "ANATOMY", 167, 172], ["CXCR3", "GENE_OR_GENE_PRODUCT", 0, 5], ["T. gondii", "ORGANISM", 53, 62], ["Th1 cell", "CELL", 92, 100], ["T cell", "CELL", 135, 141], ["brain", "ORGAN", 167, 172], ["CXCR3", "PROTEIN", 0, 5], ["T. gondii", "SPECIES", 53, 62], ["T. gondii", "SPECIES", 53, 62], ["CXCR3", "TEST", 0, 5], ["protective immune responses", "TREATMENT", 22, 49], ["T. gondii", "PROBLEM", 53, 62], ["Th1 cell recruitment", "TREATMENT", 92, 112], ["Th1 cell recruitment", "OBSERVATION", 92, 112], ["brain", "ANATOMY", 167, 172]]], ["Indeed CXCR3 and its ligands are significantly upregulated in the brain at a timepoint associated with significant T cell influx into the CNS following infection (Figure S1A, B) with \u223c35% of T cells expressing CXCR3 (Figure 1A).", [["brain", "ANATOMY", 66, 71], ["T cell", "ANATOMY", 115, 121], ["CNS", "ANATOMY", 138, 141], ["T cells", "ANATOMY", 191, 198], ["infection", "DISEASE", 152, 161], ["CXCR3", "GENE_OR_GENE_PRODUCT", 7, 12], ["brain", "ORGAN", 66, 71], ["T cell", "CELL", 115, 121], ["CNS", "ANATOMICAL_SYSTEM", 138, 141], ["T cells", "CELL", 191, 198], ["CXCR3", "GENE_OR_GENE_PRODUCT", 210, 215], ["Figure 1A", "GENE_OR_GENE_PRODUCT", 217, 226], ["CXCR3", "PROTEIN", 7, 12], ["T cells", "CELL_TYPE", 191, 198], ["CXCR3", "PROTEIN", 210, 215], ["Figure 1A", "PROTEIN", 217, 226], ["CXCR3", "TEST", 7, 12], ["significant T cell influx", "PROBLEM", 103, 128], ["infection", "PROBLEM", 152, 161], ["CXCR3", "TEST", 210, 215], ["CXCR3", "OBSERVATION", 7, 12], ["significantly", "OBSERVATION_MODIFIER", 33, 46], ["upregulated", "OBSERVATION", 47, 58], ["brain", "ANATOMY", 66, 71], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["T cell influx", "OBSERVATION", 115, 128], ["CNS", "ANATOMY", 138, 141], ["infection", "OBSERVATION", 152, 161]]], ["However, in addition to this well characterized role on T cells, there is a small but distinct population of macrophages that express high levels of CXCR3 (\u223c10% of total macrophages)(Figure 1B).", [["T cells", "ANATOMY", 56, 63], ["macrophages", "ANATOMY", 109, 120], ["macrophages", "ANATOMY", 170, 181], ["T cells", "CELL", 56, 63], ["macrophages", "CELL", 109, 120], ["CXCR3", "GENE_OR_GENE_PRODUCT", 149, 154], ["macrophages", "CELL", 170, 181], ["T cells", "CELL_TYPE", 56, 63], ["macrophages", "CELL_TYPE", 109, 120], ["CXCR3", "PROTEIN", 149, 154], ["macrophages", "CELL_TYPE", 170, 181], ["a small but distinct population of macrophages", "PROBLEM", 74, 120], ["CXCR3", "TEST", 149, 154], ["small", "OBSERVATION_MODIFIER", 76, 81], ["distinct", "OBSERVATION_MODIFIER", 86, 94], ["population", "OBSERVATION_MODIFIER", 95, 105], ["macrophages", "OBSERVATION", 109, 120], ["high", "OBSERVATION_MODIFIER", 134, 138], ["levels", "OBSERVATION_MODIFIER", 139, 145]]], ["There is also constitutive, although lower, expression of CXCR3 by CNS resident microglia, which remains unchanged following infection (Figure S1C).A population of AAM\u00d8 in the T. gondii infected brain ::: ResultsTo confirm that expression of CXCR3 is associated with alternative activation of macrophages the expression of the scavenger receptor \u2018macrophage mannose receptor\u2019 (MMR; also known as Mrc1 and CD206), a key indicator of the AAM\u00d8 phenotype [38] was analyzed.", [["CNS resident microglia", "ANATOMY", 67, 89], ["brain", "ANATOMY", 195, 200], ["macrophages", "ANATOMY", 293, 304], ["infection", "DISEASE", 125, 134], ["T. gondii infected", "DISEASE", 176, 194], ["mannose", "CHEMICAL", 358, 365], ["CXCR3", "GENE_OR_GENE_PRODUCT", 58, 63], ["CNS resident microglia", "CELL", 67, 89], ["AAM\u00d8", "CANCER", 164, 168], ["T. gondii", "ORGANISM", 176, 185], ["brain", "ORGAN", 195, 200], ["CXCR3", "GENE_OR_GENE_PRODUCT", 242, 247], ["macrophages", "CELL", 293, 304], ["\u2018macrophage mannose receptor\u2019", "GENE_OR_GENE_PRODUCT", 346, 375], ["MMR", "GENE_OR_GENE_PRODUCT", 377, 380], ["Mrc1", "GENE_OR_GENE_PRODUCT", 396, 400], ["CD206", "GENE_OR_GENE_PRODUCT", 405, 410], ["AAM\u00d8", "GENE_OR_GENE_PRODUCT", 436, 440], ["CXCR3", "PROTEIN", 58, 63], ["CNS resident microglia", "CELL_TYPE", 67, 89], ["CXCR3", "PROTEIN", 242, 247], ["macrophages", "CELL_TYPE", 293, 304], ["scavenger receptor \u2018macrophage mannose receptor", "PROTEIN", 327, 374], ["MMR", "PROTEIN", 377, 380], ["Mrc1", "PROTEIN", 396, 400], ["CD206", "PROTEIN", 405, 410], ["T. gondii", "SPECIES", 176, 185], ["T. gondii", "SPECIES", 176, 185], ["infection", "PROBLEM", 125, 134], ["CXCR3", "TEST", 242, 247], ["alternative activation of macrophages", "TREATMENT", 267, 304], ["the scavenger receptor", "TREATMENT", 323, 345], ["constitutive", "OBSERVATION_MODIFIER", 14, 26], ["lower", "OBSERVATION_MODIFIER", 37, 42], ["CXCR3", "OBSERVATION", 58, 63], ["unchanged", "OBSERVATION_MODIFIER", 105, 114], ["infection", "OBSERVATION", 125, 134], ["infected", "OBSERVATION", 186, 194], ["brain", "ANATOMY", 195, 200]]], ["Here we show that MMR expression is limited to macrophages and microglia that also express CXCR3 (Figures 1C and S1D).", [["macrophages", "ANATOMY", 47, 58], ["microglia", "ANATOMY", 63, 72], ["MMR", "GENE_OR_GENE_PRODUCT", 18, 21], ["macrophages", "CELL", 47, 58], ["microglia", "CELL", 63, 72], ["CXCR3", "GENE_OR_GENE_PRODUCT", 91, 96], ["Figures 1C", "GENE_OR_GENE_PRODUCT", 98, 108], ["S1D", "GENE_OR_GENE_PRODUCT", 113, 116], ["MMR", "PROTEIN", 18, 21], ["macrophages", "CELL_TYPE", 47, 58], ["microglia", "CELL_TYPE", 63, 72], ["CXCR3", "PROTEIN", 91, 96], ["S1D", "PROTEIN", 113, 116], ["MMR expression", "PROBLEM", 18, 32], ["macrophages", "PROBLEM", 47, 58], ["microglia", "PROBLEM", 63, 72], ["CXCR3", "TEST", 91, 96], ["macrophages", "OBSERVATION", 47, 58]]], ["In contrast these cells did not express IL-10 ruling out an anti-inflammatory phenotype (Figure S1E) [39].", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["IL-10", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL", "PROTEIN", 40, 42], ["IL", "TEST", 40, 42], ["anti-inflammatory phenotype", "OBSERVATION", 60, 87]]], ["Depletion using blocking antibodies to CXCR3 or its ligand, CXCL10 led to a significant decrease in T cell recruitment and a reciprocal increase in parasite burden (Figure S2).", [["T cell", "ANATOMY", 100, 106], ["CXCR3", "GENE_OR_GENE_PRODUCT", 39, 44], ["CXCL10", "GENE_OR_GENE_PRODUCT", 60, 66], ["T cell", "CELL", 100, 106], ["CXCR3", "PROTEIN", 39, 44], ["CXCL10", "PROTEIN", 60, 66], ["Depletion", "PROBLEM", 0, 9], ["blocking antibodies", "TREATMENT", 16, 35], ["CXCR3", "TEST", 39, 44], ["CXCL10", "TEST", 60, 66], ["a significant decrease in T cell recruitment", "PROBLEM", 74, 118], ["a reciprocal increase in parasite burden", "PROBLEM", 123, 163], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["decrease", "OBSERVATION_MODIFIER", 88, 96], ["T cell recruitment", "OBSERVATION", 100, 118], ["increase", "OBSERVATION_MODIFIER", 136, 144], ["parasite", "OBSERVATION_MODIFIER", 148, 156], ["burden", "OBSERVATION_MODIFIER", 157, 163]]], ["However, in addition, the proportion of macrophages in the brain was significantly reduced (Figure 1D) despite no defect in macrophage-attracting chemokines (Figures 1E, F), confirming a role for CXCR3 in the maintenance of this cell population.A population of AAM\u00d8 in the T. gondii infected brain ::: ResultsTo quantify MMR expression by macrophages and microglia in the infected brain, qRT-PCR was performed on magnetically isolated CD11b+ cells from the brains of naive and infected animals.", [["macrophages", "ANATOMY", 40, 51], ["brain", "ANATOMY", 59, 64], ["macrophage", "ANATOMY", 124, 134], ["cell", "ANATOMY", 229, 233], ["brain", "ANATOMY", 292, 297], ["macrophages", "ANATOMY", 339, 350], ["microglia", "ANATOMY", 355, 364], ["brain", "ANATOMY", 381, 386], ["CD11b+ cells", "ANATOMY", 435, 447], ["brains", "ANATOMY", 457, 463], ["T. gondii infected", "DISEASE", 273, 291], ["macrophages", "CELL", 40, 51], ["brain", "ORGAN", 59, 64], ["macrophage", "CELL", 124, 134], ["CXCR3", "GENE_OR_GENE_PRODUCT", 196, 201], ["cell", "CELL", 229, 233], ["AAM\u00d8", "CANCER", 261, 265], ["T. gondii", "ORGANISM", 273, 282], ["brain", "ORGAN", 292, 297], ["macrophages", "CELL", 339, 350], ["microglia", "CELL", 355, 364], ["brain", "ORGAN", 381, 386], ["CD11b+ cells", "CELL", 435, 447], ["brains", "ORGAN", 457, 463], ["macrophages", "CELL_TYPE", 40, 51], ["macrophage-attracting chemokines", "PROTEIN", 124, 156], ["Figures 1E, F", "PROTEIN", 158, 171], ["CXCR3", "PROTEIN", 196, 201], ["macrophages", "CELL_TYPE", 339, 350], ["microglia", "CELL_TYPE", 355, 364], ["CD11b+ cells", "CELL_TYPE", 435, 447], ["T. gondii", "SPECIES", 273, 282], ["T. gondii", "SPECIES", 273, 282], ["macrophages in the brain", "PROBLEM", 40, 64], ["defect in macrophage", "PROBLEM", 114, 134], ["CXCR3", "TREATMENT", 196, 201], ["this cell population", "TREATMENT", 224, 244], ["microglia in the infected brain", "PROBLEM", 355, 386], ["qRT-PCR", "TEST", 388, 395], ["macrophages", "OBSERVATION", 40, 51], ["brain", "ANATOMY", 59, 64], ["significantly", "OBSERVATION_MODIFIER", 69, 82], ["reduced", "OBSERVATION_MODIFIER", 83, 90], ["no", "UNCERTAINTY", 111, 113], ["defect", "OBSERVATION", 114, 120], ["macrophage", "ANATOMY", 124, 134], ["infected", "OBSERVATION", 283, 291], ["brain", "ANATOMY", 292, 297], ["macrophages", "OBSERVATION", 339, 350], ["infected brain", "ANATOMY", 372, 386], ["brains", "ANATOMY", 457, 463], ["infected", "OBSERVATION_MODIFIER", 477, 485]]], ["Our results show an approximate 3-fold increase in MMR expression in macrophage populations from infected mice over na\u00efve (Figure 1G).", [["macrophage populations", "ANATOMY", 69, 91], ["MMR", "GENE_OR_GENE_PRODUCT", 51, 54], ["macrophage populations", "CELL", 69, 91], ["mice", "ORGANISM", 106, 110], ["MMR", "PROTEIN", 51, 54], ["macrophage populations", "CELL_TYPE", 69, 91], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["an approximate 3-fold increase", "PROBLEM", 17, 47], ["MMR expression in macrophage populations", "PROBLEM", 51, 91], ["approximate 3-fold", "OBSERVATION_MODIFIER", 20, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["MMR expression", "OBSERVATION", 51, 65], ["macrophage", "OBSERVATION_MODIFIER", 69, 79], ["populations", "OBSERVATION_MODIFIER", 80, 91], ["infected", "OBSERVATION_MODIFIER", 97, 105], ["mice", "OBSERVATION_MODIFIER", 106, 110]]], ["Confirmation of this population in the brain was revealed by immunohistochemical analysis.", [["brain", "ANATOMY", 39, 44], ["brain", "ORGAN", 39, 44], ["this population in the brain", "TEST", 16, 44], ["immunohistochemical analysis", "TEST", 61, 89], ["brain", "ANATOMY", 39, 44]]], ["MMR+ macrophages were observed as small and discrete populations of IBA-1+ or tomato lectin+ cells confirming the source of MMR on macrophages or microglia (Figures 1H, I).", [["MMR+ macrophages", "ANATOMY", 0, 16], ["tomato lectin+ cells", "ANATOMY", 78, 98], ["macrophages", "ANATOMY", 131, 142], ["microglia", "ANATOMY", 146, 155], ["IBA-1", "GENE_OR_GENE_PRODUCT", 68, 73], ["tomato", "ORGANISM", 78, 84], ["MMR", "GENE_OR_GENE_PRODUCT", 124, 127], ["macrophages", "CELL", 131, 142], ["microglia", "CELL", 146, 155], ["MMR", "PROTEIN", 0, 3], ["macrophages", "CELL_TYPE", 5, 16], ["lectin", "PROTEIN", 85, 91], ["MMR", "PROTEIN", 124, 127], ["macrophages", "CELL_TYPE", 131, 142], ["microglia", "CELL_TYPE", 146, 155], ["tomato", "SPECIES", 78, 84], ["tomato", "SPECIES", 78, 84], ["macrophages", "PROBLEM", 5, 16], ["IBA", "TEST", 68, 71], ["tomato lectin+ cells", "PROBLEM", 78, 98], ["MMR on macrophages", "PROBLEM", 124, 142], ["macrophages", "OBSERVATION", 5, 16], ["small", "OBSERVATION_MODIFIER", 34, 39], ["discrete", "OBSERVATION_MODIFIER", 44, 52], ["populations", "OBSERVATION_MODIFIER", 53, 64], ["lectin+ cells", "OBSERVATION", 85, 98], ["macrophages", "OBSERVATION", 131, 142]]], ["A further functional marker of alternative activation is the scavenger receptor stabilin-1 [40].", [["stabilin-1", "GENE_OR_GENE_PRODUCT", 80, 90], ["stabilin", "PROTEIN", 80, 88]]], ["Stabilin-1 is involved in the clearance of cell corpses as well as the uptake of extracellular matrix components [41], [42].", [["cell corpses", "ANATOMY", 43, 55], ["extracellular matrix", "ANATOMY", 81, 101], ["Stabilin-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["cell", "CELL", 43, 47], ["extracellular matrix", "CELLULAR_COMPONENT", 81, 101], ["Stabilin-1", "PROTEIN", 0, 10], ["the uptake of extracellular matrix components", "PROBLEM", 67, 112]]], ["Expression of MMR co-localized with stabilin-1 and microglia/macrophage markers, confirming that these cells display an alternatively activated phenotype (Figures 1H, I).", [["microglia", "ANATOMY", 51, 60], ["macrophage", "ANATOMY", 61, 71], ["cells", "ANATOMY", 103, 108], ["MMR", "GENE_OR_GENE_PRODUCT", 14, 17], ["stabilin-1", "GENE_OR_GENE_PRODUCT", 36, 46], ["microglia", "CELL", 51, 60], ["macrophage", "CELL", 61, 71], ["cells", "CELL", 103, 108], ["MMR", "PROTEIN", 14, 17], ["stabilin-1", "PROTEIN", 36, 46], ["microglia", "CELL_TYPE", 51, 60], ["macrophage markers", "PROTEIN", 61, 79], ["MMR", "PROBLEM", 14, 17], ["stabilin", "TEST", 36, 44], ["microglia/macrophage markers", "TEST", 51, 79], ["these cells", "PROBLEM", 97, 108]]], ["These cell populations were frequently found in close proximity with intact and degrading T. gondii cysts in the CNS (Figure 1J and S3).A population of AAM\u00d8 in the T. gondii infected brain ::: ResultsAn important feature of AAM\u00d8 is the cell's ability to produce arginase-1, which acts on its substrate, L-arginine to produce L-ornithine, a precursor to collagen [43].", [["cell", "ANATOMY", 6, 10], ["cysts", "ANATOMY", 100, 105], ["CNS", "ANATOMY", 113, 116], ["brain", "ANATOMY", 183, 188], ["cell", "ANATOMY", 236, 240], ["T. gondii infected", "DISEASE", 164, 182], ["L-arginine", "CHEMICAL", 303, 313], ["L-ornithine", "CHEMICAL", 325, 336], ["L-arginine", "CHEMICAL", 303, 313], ["L-ornithine", "CHEMICAL", 325, 336], ["cell populations", "CELL", 6, 22], ["T. gondii", "ORGANISM", 90, 99], ["CNS", "ANATOMICAL_SYSTEM", 113, 116], ["AAM\u00d8", "CANCER", 152, 156], ["T. gondii", "ORGANISM", 164, 173], ["brain", "ORGAN", 183, 188], ["AAM\u00d8", "GENE_OR_GENE_PRODUCT", 224, 228], ["cell", "CELL", 236, 240], ["arginase-1", "GENE_OR_GENE_PRODUCT", 262, 272], ["L-arginine", "SIMPLE_CHEMICAL", 303, 313], ["L-ornithine", "SIMPLE_CHEMICAL", 325, 336], ["collagen", "GENE_OR_GENE_PRODUCT", 353, 361], ["AAM\u00d8", "PROTEIN", 224, 228], ["arginase-1", "PROTEIN", 262, 272], ["collagen", "PROTEIN", 353, 361], ["T. gondii", "SPECIES", 90, 99], ["T. gondii", "SPECIES", 164, 173], ["T. gondii", "SPECIES", 90, 99], ["T. gondii", "SPECIES", 164, 173], ["These cell populations", "TEST", 0, 22], ["degrading T. gondii cysts", "PROBLEM", 80, 105], ["AAM\u00d8", "PROBLEM", 224, 228], ["arginase", "TEST", 262, 270], ["L-arginine", "TREATMENT", 303, 313], ["L-ornithine", "TREATMENT", 325, 336], ["cell populations", "OBSERVATION", 6, 22], ["intact", "OBSERVATION", 69, 75], ["gondii cysts", "OBSERVATION", 93, 105], ["CNS", "ANATOMY", 113, 116], ["S3", "ANATOMY", 132, 134], ["infected", "OBSERVATION", 174, 182], ["brain", "ANATOMY", 183, 188]]], ["L-arginine is also the substrate for NO synthase and the two enzymes compete for substrate availability and are regulated by Th1 and Th2 type cytokines [44], [45].", [["L-arginine", "CHEMICAL", 0, 10], ["NO", "CHEMICAL", 37, 39], ["L-arginine", "CHEMICAL", 0, 10], ["NO", "CHEMICAL", 37, 39], ["L-arginine", "SIMPLE_CHEMICAL", 0, 10], ["NO synthase", "GENE_OR_GENE_PRODUCT", 37, 48], ["Th1", "GENE_OR_GENE_PRODUCT", 125, 128], ["NO synthase", "PROTEIN", 37, 48], ["Th1 and Th2 type cytokines", "PROTEIN", 125, 151], ["the two enzymes", "TEST", 53, 68]]], ["Previous studies have demonstrated that direct infection of macrophages by T. gondii tachyzoites can induce arginase expression via STAT-6 dependent and independent pathways [46]\u2013[48].", [["macrophages", "ANATOMY", 60, 71], ["infection", "DISEASE", 47, 56], ["macrophages", "CELL", 60, 71], ["T. gondii tachyzoites", "ORGANISM", 75, 96], ["arginase", "GENE_OR_GENE_PRODUCT", 108, 116], ["STAT-6", "GENE_OR_GENE_PRODUCT", 132, 138], ["macrophages", "CELL_TYPE", 60, 71], ["arginase", "PROTEIN", 108, 116], ["STAT-6", "PROTEIN", 132, 138], ["T. gondii", "SPECIES", 75, 84], ["T. gondii", "SPECIES", 75, 84], ["Previous studies", "TEST", 0, 16], ["direct infection of macrophages", "PROBLEM", 40, 71], ["T. gondii tachyzoites", "PROBLEM", 75, 96], ["infection", "OBSERVATION", 47, 56]]], ["Furthermore these studies imply that such an induction is a survival strategy enlisted by the parasite to inhibit killing via NO.", [["NO", "CHEMICAL", 126, 128], ["NO", "CHEMICAL", 126, 128], ["NO", "SIMPLE_CHEMICAL", 126, 128], ["these studies", "TEST", 12, 25], ["a survival strategy", "TREATMENT", 58, 77]]], ["To assess whether or not macrophages and microglia in the infected brain produce arginase, CD11b+ BMNCs from infected mice were isolated and analyzed for arginase-1 expression by qRT-PCR.", [["macrophages", "ANATOMY", 25, 36], ["microglia", "ANATOMY", 41, 50], ["brain", "ANATOMY", 67, 72], ["CD11b+ BMNCs", "ANATOMY", 91, 103], ["macrophages", "CELL", 25, 36], ["microglia", "CELL", 41, 50], ["brain", "ORGAN", 67, 72], ["arginase", "GENE_OR_GENE_PRODUCT", 81, 89], ["CD11b", "GENE_OR_GENE_PRODUCT", 91, 96], ["BMNCs", "GENE_OR_GENE_PRODUCT", 98, 103], ["mice", "ORGANISM", 118, 122], ["arginase-1", "GENE_OR_GENE_PRODUCT", 154, 164], ["macrophages", "CELL_TYPE", 25, 36], ["microglia", "CELL_TYPE", 41, 50], ["arginase", "PROTEIN", 81, 89], ["CD11b", "PROTEIN", 91, 96], ["BMNCs", "CELL_TYPE", 98, 103], ["arginase", "PROTEIN", 154, 162], ["mice", "SPECIES", 118, 122], ["mice", "SPECIES", 118, 122], ["macrophages", "PROBLEM", 25, 36], ["microglia", "PROBLEM", 41, 50], ["BMNCs", "PROBLEM", 98, 103], ["infected mice", "PROBLEM", 109, 122], ["arginase", "TEST", 154, 162], ["qRT", "TEST", 179, 182], ["PCR", "TEST", 183, 186], ["macrophages", "OBSERVATION", 25, 36], ["infected", "OBSERVATION", 58, 66], ["brain", "ANATOMY", 67, 72]]], ["Our results show almost a 2-fold increase in arginase-1 expression in cells from infected brains over na\u00efve (Figure 1K).", [["cells", "ANATOMY", 70, 75], ["brains", "ANATOMY", 90, 96], ["arginase-1", "GENE_OR_GENE_PRODUCT", 45, 55], ["cells", "CELL", 70, 75], ["brains", "ORGAN", 90, 96], ["arginase-1", "PROTEIN", 45, 55], ["a 2-fold increase in arginase", "PROBLEM", 24, 53], ["1 expression in cells", "PROBLEM", 54, 75], ["infected brains", "PROBLEM", 81, 96], ["2-fold", "OBSERVATION_MODIFIER", 26, 32], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["arginase", "OBSERVATION", 45, 53], ["1 expression", "OBSERVATION_MODIFIER", 54, 66], ["infected brains", "OBSERVATION", 81, 96]]], ["Thus, during chronic T. gondii infection there is a population of AAM\u00d8 in the CNS characterized by expression of CXCR3, MMR, stabilin-1 and the production of arginase-1.Alternatively activated macrophages secrete an active chitinase in the CNS in response to chitin in the cyst wall ::: ResultsDuring chronic infection there are several forms of the parasite that could be the source of the infection-associated stimulus for alternative activation of macrophages in the CNS.", [["CNS", "ANATOMY", 78, 81], ["macrophages", "ANATOMY", 193, 204], ["CNS", "ANATOMY", 240, 243], ["cyst wall", "ANATOMY", 273, 282], ["macrophages", "ANATOMY", 451, 462], ["CNS", "ANATOMY", 470, 473], ["T. gondii infection", "DISEASE", 21, 40], ["chronic infection", "DISEASE", 301, 318], ["infection", "DISEASE", 391, 400], ["T. gondii", "ORGANISM", 21, 30], ["AAM\u00d8", "CANCER", 66, 70], ["CNS", "ANATOMICAL_SYSTEM", 78, 81], ["CXCR3", "GENE_OR_GENE_PRODUCT", 113, 118], ["MMR", "GENE_OR_GENE_PRODUCT", 120, 123], ["stabilin-1", "GENE_OR_GENE_PRODUCT", 125, 135], ["arginase-1", "GENE_OR_GENE_PRODUCT", 158, 168], ["macrophages", "CELL", 193, 204], ["chitinase", "GENE_OR_GENE_PRODUCT", 223, 232], ["CNS", "ANATOMICAL_SYSTEM", 240, 243], ["chitin", "SIMPLE_CHEMICAL", 259, 265], ["cyst wall", "PATHOLOGICAL_FORMATION", 273, 282], ["macrophages", "CELL", 451, 462], ["CNS", "ANATOMICAL_SYSTEM", 470, 473], ["CXCR3", "PROTEIN", 113, 118], ["MMR", "PROTEIN", 120, 123], ["stabilin", "PROTEIN", 125, 133], ["arginase-1", "PROTEIN", 158, 168], ["activated macrophages", "CELL_TYPE", 183, 204], ["chitinase", "PROTEIN", 223, 232], ["macrophages", "CELL_TYPE", 451, 462], ["T. gondii", "SPECIES", 21, 30], ["T. gondii", "SPECIES", 21, 30], ["chronic T. gondii infection", "PROBLEM", 13, 40], ["CXCR3", "TEST", 113, 118], ["MMR", "TEST", 120, 123], ["stabilin", "TEST", 125, 133], ["arginase", "TEST", 158, 166], ["activated macrophages", "PROBLEM", 183, 204], ["an active chitinase in the CNS", "PROBLEM", 213, 243], ["chronic infection", "PROBLEM", 301, 318], ["the parasite", "PROBLEM", 346, 358], ["the infection", "PROBLEM", 387, 400], ["alternative activation of macrophages", "TREATMENT", 425, 462], ["chronic", "OBSERVATION_MODIFIER", 13, 20], ["gondii infection", "OBSERVATION", 24, 40], ["CNS", "ANATOMY", 78, 81], ["macrophages", "OBSERVATION", 193, 204], ["active", "OBSERVATION_MODIFIER", 216, 222], ["chitinase", "OBSERVATION_MODIFIER", 223, 232], ["CNS", "ANATOMY", 240, 243], ["cyst", "OBSERVATION", 273, 277], ["chronic", "OBSERVATION_MODIFIER", 301, 308], ["infection", "OBSERVATION", 309, 318], ["several forms", "OBSERVATION_MODIFIER", 329, 342], ["parasite", "OBSERVATION", 350, 358], ["infection", "OBSERVATION", 391, 400], ["macrophages", "OBSERVATION", 451, 462], ["CNS", "ANATOMY", 470, 473]]], ["Since latent cysts are the most prevalent form of infection in the brain, an attractive candidate for the source of this stimulus is the presence of chitin in the cyst wall [49], [50] as it has been shown that the presence of chitin induces the recruitment of macrophages that have an alternatively activated phenotype [51], [52].", [["cysts", "ANATOMY", 13, 18], ["brain", "ANATOMY", 67, 72], ["cyst wall", "ANATOMY", 163, 172], ["macrophages", "ANATOMY", 260, 271], ["latent cysts", "DISEASE", 6, 18], ["infection", "DISEASE", 50, 59], ["chitin", "CHEMICAL", 226, 232], ["cysts", "PATHOLOGICAL_FORMATION", 13, 18], ["brain", "ORGAN", 67, 72], ["chitin", "GENE_OR_GENE_PRODUCT", 149, 155], ["chitin", "GENE_OR_GENE_PRODUCT", 226, 232], ["macrophages", "CELL", 260, 271], ["chitin", "PROTEIN", 149, 155], ["chitin", "PROTEIN", 226, 232], ["macrophages", "CELL_TYPE", 260, 271], ["latent cysts", "PROBLEM", 6, 18], ["infection in the brain", "PROBLEM", 50, 72], ["this stimulus", "PROBLEM", 116, 129], ["chitin in the cyst wall", "PROBLEM", 149, 172], ["chitin", "TREATMENT", 226, 232], ["latent", "OBSERVATION_MODIFIER", 6, 12], ["cysts", "OBSERVATION", 13, 18], ["most prevalent", "OBSERVATION_MODIFIER", 27, 41], ["infection", "OBSERVATION", 50, 59], ["brain", "ANATOMY", 67, 72], ["chitin", "OBSERVATION_MODIFIER", 149, 155], ["cyst", "OBSERVATION", 163, 167]]], ["To determine if sources of T. gondii can induce alternative activation, tachyzoites, bradyzoites, and cysts were added to bone marrow derived macrophage (BMDM) cultures and the production of urea, a downstream product of arginase activity, was measured [53].", [["tachyzoites", "ANATOMY", 72, 83], ["bradyzoites", "ANATOMY", 85, 96], ["cysts", "ANATOMY", 102, 107], ["bone marrow derived macrophage", "ANATOMY", 122, 152], ["BMDM", "ANATOMY", 154, 158], ["cultures", "ANATOMY", 160, 168], ["urea", "CHEMICAL", 191, 195], ["urea", "CHEMICAL", 191, 195], ["T. gondii", "ORGANISM", 27, 36], ["tachyzoites", "ORGANISM_SUBSTANCE", 72, 83], ["bone marrow derived macrophage", "CELL", 122, 152], ["BMDM) cultures", "CELL", 154, 168], ["urea", "SIMPLE_CHEMICAL", 191, 195], ["arginase", "GENE_OR_GENE_PRODUCT", 221, 229], ["bone marrow derived macrophage (BMDM) cultures", "CELL_LINE", 122, 168], ["arginase", "PROTEIN", 221, 229], ["T. gondii", "SPECIES", 27, 36], ["T. gondii", "SPECIES", 27, 36], ["T. gondii", "PROBLEM", 27, 36], ["tachyzoites", "PROBLEM", 72, 83], ["bradyzoites", "PROBLEM", 85, 96], ["cysts", "PROBLEM", 102, 107], ["cultures", "TEST", 160, 168], ["the production of urea", "PROBLEM", 173, 195], ["arginase activity", "PROBLEM", 221, 238], ["cysts", "OBSERVATION", 102, 107], ["arginase activity", "OBSERVATION", 221, 238]]], ["In addition, soluble antigen derived from freeze-thawed tachyzoites (sTAg) and whole cysts (cystAg) was assessed for their ability to induce urea (Figure 2A).", [["tachyzoites", "ANATOMY", 56, 67], ["TAg", "ANATOMY", 70, 73], ["whole cysts", "ANATOMY", 79, 90], ["urea", "CHEMICAL", 141, 145], ["urea", "CHEMICAL", 141, 145], ["tachyzoites", "ORGANISM_SUBSTANCE", 56, 67], ["TAg", "ORGANISM", 70, 73], ["cystAg", "SIMPLE_CHEMICAL", 92, 98], ["urea", "SIMPLE_CHEMICAL", 141, 145], ["soluble antigen", "PROTEIN", 13, 28], ["soluble antigen", "TEST", 13, 28], ["whole cysts (cystAg)", "PROBLEM", 79, 99], ["cysts", "OBSERVATION", 85, 90]]], ["Our results show a baseline production of urea in unstimulated (media) macrophage cultures, possibly due to the presence of M-CSF [54].", [["macrophage cultures", "ANATOMY", 71, 90], ["urea", "CHEMICAL", 42, 46], ["urea", "CHEMICAL", 42, 46], ["urea", "SIMPLE_CHEMICAL", 42, 46], ["macrophage cultures", "CELL", 71, 90], ["M-CSF", "GENE_OR_GENE_PRODUCT", 124, 129], ["unstimulated (media) macrophage cultures", "CELL_LINE", 50, 90], ["a baseline production of urea in unstimulated (media) macrophage cultures", "PROBLEM", 17, 90]]], ["This significantly increased (p<0.001) during AAM\u00d8 polarization with IL-4.", [["IL-4", "GENE_OR_GENE_PRODUCT", 69, 73], ["IL-4", "PROTEIN", 69, 73], ["significantly", "OBSERVATION_MODIFIER", 5, 18], ["increased", "OBSERVATION_MODIFIER", 19, 28]]], ["Despite the known ability of tachyzoites to induce arginase production [46], tachyzoite infection of macrophages did not lead to significant production of urea (Figure 2A).", [["tachyzoites", "ANATOMY", 29, 40], ["macrophages", "ANATOMY", 101, 112], ["infection", "DISEASE", 88, 97], ["urea", "CHEMICAL", 155, 159], ["urea", "CHEMICAL", 155, 159], ["tachyzoites", "ORGANISM_SUBSTANCE", 29, 40], ["arginase", "GENE_OR_GENE_PRODUCT", 51, 59], ["macrophages", "CELL", 101, 112], ["urea", "SIMPLE_CHEMICAL", 155, 159], ["arginase", "PROTEIN", 51, 59], ["macrophages", "CELL_TYPE", 101, 112], ["tachyzoites", "PROBLEM", 29, 40], ["arginase production", "PROBLEM", 51, 70], ["tachyzoite infection of macrophages", "PROBLEM", 77, 112], ["significant production of urea", "PROBLEM", 129, 159]]], ["This can be attributed to the use of a type II strain which is a weak inducer of arginase-1 [47], [48].", [["arginase-1", "GENE_OR_GENE_PRODUCT", 81, 91], ["arginase", "PROTEIN", 81, 89], ["a type II strain", "PROBLEM", 37, 53], ["a weak inducer of arginase", "PROBLEM", 63, 89]]], ["Importantly, addition of cysts or cyst antigen but not \u201cnaked\u201d bradyzoites, did lead to a significant increase in urea production although not as great as induction of alternative activation by IL-4 [38], [55].", [["cysts", "ANATOMY", 25, 30], ["cyst", "ANATOMY", 34, 38], ["urea", "CHEMICAL", 114, 118], ["urea", "CHEMICAL", 114, 118], ["cysts", "PATHOLOGICAL_FORMATION", 25, 30], ["cyst antigen", "GENE_OR_GENE_PRODUCT", 34, 46], ["urea", "SIMPLE_CHEMICAL", 114, 118], ["IL-4", "GENE_OR_GENE_PRODUCT", 194, 198], ["IL", "PROTEIN", 194, 196], ["cysts", "PROBLEM", 25, 30], ["cyst antigen", "PROBLEM", 34, 46], ["bradyzoites", "PROBLEM", 63, 74], ["a significant increase in urea production", "PROBLEM", 88, 129], ["cysts", "OBSERVATION", 25, 30], ["cyst", "OBSERVATION", 34, 38], ["bradyzoites", "OBSERVATION", 63, 74], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["increase", "OBSERVATION_MODIFIER", 102, 110], ["urea production", "OBSERVATION", 114, 129]]], ["This points to components of the cyst wall as the stimulus for AAM\u00d8.", [["cyst wall", "ANATOMY", 33, 42], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 33, 42], ["AAM\u00d8", "PROTEIN", 63, 67], ["the cyst wall", "PROBLEM", 29, 42], ["cyst", "OBSERVATION", 33, 37], ["wall", "ANATOMY_MODIFIER", 38, 42]]], ["Taken together, these data demonstrate that macrophages can be alternatively activated by the presence of T. gondii cysts, but not free replicating parasites.Alternatively activated macrophages secrete an active chitinase in the CNS in response to chitin in the cyst wall ::: ResultsChitinase activity has been demonstrated in certain populations of AAM\u00d8 in both mice and humans [52], [56], [57].", [["macrophages", "ANATOMY", 44, 55], ["cysts", "ANATOMY", 116, 121], ["macrophages", "ANATOMY", 182, 193], ["CNS", "ANATOMY", 229, 232], ["cyst wall", "ANATOMY", 262, 271], ["T. gondii cysts", "DISEASE", 106, 121], ["macrophages", "CELL", 44, 55], ["T. gondii", "ORGANISM", 106, 115], ["macrophages", "CELL", 182, 193], ["chitinase", "GENE_OR_GENE_PRODUCT", 212, 221], ["CNS", "ANATOMICAL_SYSTEM", 229, 232], ["chitin", "SIMPLE_CHEMICAL", 248, 254], ["cyst wall", "PATHOLOGICAL_FORMATION", 262, 271], ["Chitinase", "GENE_OR_GENE_PRODUCT", 283, 292], ["AAM\u00d8", "GENE_OR_GENE_PRODUCT", 350, 354], ["mice", "ORGANISM", 363, 367], ["humans", "ORGANISM", 372, 378], ["macrophages", "CELL_TYPE", 44, 55], ["activated macrophages", "CELL_TYPE", 172, 193], ["chitinase", "PROTEIN", 212, 221], ["Chitinase", "PROTEIN", 283, 292], ["T. gondii", "SPECIES", 106, 115], ["mice", "SPECIES", 363, 367], ["humans", "SPECIES", 372, 378], ["T. gondii", "SPECIES", 106, 115], ["mice", "SPECIES", 363, 367], ["humans", "SPECIES", 372, 378], ["macrophages", "PROBLEM", 44, 55], ["T. gondii cysts", "PROBLEM", 106, 121], ["activated macrophages", "PROBLEM", 172, 193], ["an active chitinase in the CNS", "PROBLEM", 202, 232], ["macrophages", "OBSERVATION", 44, 55], ["gondii cysts", "OBSERVATION", 109, 121], ["parasites", "OBSERVATION", 148, 157], ["macrophages", "OBSERVATION", 182, 193], ["active", "OBSERVATION_MODIFIER", 205, 211], ["chitinase", "OBSERVATION_MODIFIER", 212, 221], ["CNS", "ANATOMY", 229, 232], ["cyst", "OBSERVATION", 262, 266]]], ["Chitinolytic activity by macrophages has also been implicated in host defense against chitin-containing fungal pathogens [56], [58].", [["macrophages", "ANATOMY", 25, 36], ["chitin", "CHEMICAL", 86, 92], ["macrophages", "CELL", 25, 36], ["chitin", "SIMPLE_CHEMICAL", 86, 92], ["macrophages", "CELL_TYPE", 25, 36], ["chitin", "PROTEIN", 86, 92], ["fungal pathogens", "PROBLEM", 104, 120], ["macrophages", "OBSERVATION", 25, 36], ["host defense", "OBSERVATION_MODIFIER", 65, 77]]], ["To test whether or not chitinase activity is induced by Toxoplasma infection, a chitinase assay was performed on whole brain lysates from na\u00efve and infected animals.", [["brain lysates", "ANATOMY", 119, 132], ["Toxoplasma infection", "DISEASE", 56, 76], ["chitinase", "GENE_OR_GENE_PRODUCT", 23, 32], ["Toxoplasma", "ORGANISM", 56, 66], ["brain lysates", "ORGANISM_SUBSTANCE", 119, 132], ["chitinase", "PROTEIN", 23, 32], ["chitinase", "PROTEIN", 80, 89], ["Toxoplasma", "SPECIES", 56, 66], ["chitinase activity", "PROBLEM", 23, 41], ["Toxoplasma infection", "PROBLEM", 56, 76], ["a chitinase assay", "TEST", 78, 95], ["whole brain lysates", "TREATMENT", 113, 132], ["Toxoplasma infection", "OBSERVATION", 56, 76], ["infected", "OBSERVATION", 148, 156]]], ["Three chitin substrates labeled with 4-methylumbelliferone (4MU) were used to assess the type of chitinase activity present.", [["4-methylumbelliferone", "CHEMICAL", 37, 58], ["4-methylumbelliferone", "CHEMICAL", 37, 58], ["chitin", "SIMPLE_CHEMICAL", 6, 12], ["4-methylumbelliferone", "SIMPLE_CHEMICAL", 37, 58], ["chitinase", "GENE_OR_GENE_PRODUCT", 97, 106], ["chitinase", "PROTEIN", 97, 106], ["Three chitin substrates", "TREATMENT", 0, 23], ["4-methylumbelliferone", "TREATMENT", 37, 58], ["chitinase activity", "OBSERVATION", 97, 115]]], ["Upon hydrolysis, 4MU is released and can be measured fluorometrically to determine chitolytic activity.", [["4MU", "CHEMICAL", 17, 20], ["4MU", "CHEMICAL", 17, 20], ["4MU", "SIMPLE_CHEMICAL", 17, 20]]], ["Our data reveal that chitinase activity is significantly increased in the brains of infected mice as compared to the na\u00efve group in only one of the three substrates (Figure 2B).", [["brains", "ANATOMY", 74, 80], ["chitinase", "GENE_OR_GENE_PRODUCT", 21, 30], ["brains", "ORGAN", 74, 80], ["mice", "ORGANISM", 93, 97], ["chitinase", "PROTEIN", 21, 30], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["Our data", "TEST", 0, 8], ["chitinase activity", "PROBLEM", 21, 39], ["chitinase activity", "OBSERVATION", 21, 39], ["significantly", "OBSERVATION_MODIFIER", 43, 56], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["infected mice", "OBSERVATION", 84, 97]]], ["This substrate, 4MU N-acetyl-\u03b2-D-glucosaminide, is suitable for detection of exochitinase activity where the enzyme degrades the non-reducing end of the chitin [59].", [["4MU N-acetyl-\u03b2-D-glucosaminide", "CHEMICAL", 16, 46], ["4MU N-acetyl-\u03b2-D-glucosaminide", "CHEMICAL", 16, 46], ["4MU N-acetyl-\u03b2-D-glucosaminide", "SIMPLE_CHEMICAL", 16, 46], ["exochitinase", "GENE_OR_GENE_PRODUCT", 77, 89], ["exochitinase", "PROTEIN", 77, 89], ["non-reducing end", "PROTEIN", 129, 145], ["This substrate", "TEST", 0, 14], ["4MU N-acetyl-\u03b2-D-glucosaminide", "TREATMENT", 16, 46], ["exochitinase activity", "PROBLEM", 77, 98], ["the enzyme", "TEST", 105, 115]]], ["Several studies have linked chitinases and chitinase-like proteins to inflammation [58]\u2013[60].", [["inflammation", "DISEASE", 70, 82], ["chitinases", "GENE_OR_GENE_PRODUCT", 28, 38], ["chitinase-like proteins", "GENE_OR_GENE_PRODUCT", 43, 66], ["chitinases", "PROTEIN", 28, 38], ["chitinase-like proteins", "PROTEIN", 43, 66], ["Several studies", "TEST", 0, 15], ["chitinases", "TEST", 28, 38], ["chitinase", "TEST", 43, 52], ["inflammation", "TEST", 70, 82]]], ["This family of 18 glycosyl hydrolases is typically induced during Th2 type immune responses and plays a role in tissue remodeling, fibrosis, and the modulation of both the innate and adaptive immune response [60].", [["tissue", "ANATOMY", 112, 118], ["fibrosis", "DISEASE", 131, 139], ["glycosyl", "CHEMICAL", 18, 26], ["tissue", "TISSUE", 112, 118], ["18 glycosyl hydrolases", "PROTEIN", 15, 37], ["18 glycosyl hydrolases", "TREATMENT", 15, 37], ["tissue remodeling", "PROBLEM", 112, 129], ["fibrosis", "PROBLEM", 131, 139], ["remodeling", "OBSERVATION", 119, 129], ["fibrosis", "OBSERVATION", 131, 139]]], ["Acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1) are unique members of this family in that they possess an enzymatically active domain that hydrolyzes the \u03b2 1\u20134 linkages that exist in chitin [56], [58].", [["mammalian chitinase", "GENE_OR_GENE_PRODUCT", 7, 26], ["AMCase", "GENE_OR_GENE_PRODUCT", 28, 34], ["chitotriosidase", "GENE_OR_GENE_PRODUCT", 40, 55], ["CHIT1", "GENE_OR_GENE_PRODUCT", 57, 62], ["chitin [56]", "SIMPLE_CHEMICAL", 199, 210], ["[58]", "SIMPLE_CHEMICAL", 212, 216], ["Acidic mammalian chitinase", "PROTEIN", 0, 26], ["AMCase", "PROTEIN", 28, 34], ["chitotriosidase", "PROTEIN", 40, 55], ["CHIT1", "PROTEIN", 57, 62], ["enzymatically active domain", "PROTEIN", 122, 149], ["\u03b2 1\u20134 linkages", "PROTEIN", 170, 184]]], ["Analysis using qRT-PCR demonstrated a significant upregulation of AMCase but not CHIT1.", [["AMCase", "GENE_OR_GENE_PRODUCT", 66, 72], ["CHIT1", "GENE_OR_GENE_PRODUCT", 81, 86], ["AMCase", "PROTEIN", 66, 72], ["CHIT1", "PROTEIN", 81, 86], ["Analysis", "TEST", 0, 8], ["qRT", "TEST", 15, 18], ["PCR", "TEST", 19, 22], ["a significant upregulation of AMCase", "PROBLEM", 36, 72], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["upregulation", "OBSERVATION", 50, 62]]], ["In addition, the chitinase-like protein, Ym-1 (Chi313) was also upregulated following infection (Figure S4).", [["infection", "DISEASE", 86, 95], ["chitinase-like protein", "GENE_OR_GENE_PRODUCT", 17, 39], ["Ym-1", "GENE_OR_GENE_PRODUCT", 41, 45], ["Chi313", "GENE_OR_GENE_PRODUCT", 47, 53], ["chitinase-like protein", "PROTEIN", 17, 39], ["Ym-1", "PROTEIN", 41, 45], ["Chi313", "PROTEIN", 47, 53], ["the chitinase", "TEST", 13, 26], ["infection", "PROBLEM", 86, 95], ["infection", "OBSERVATION", 86, 95]]], ["This molecule is known to inhibit IL-12 production and induce alternative activation in macrophages [25], [61], [62].", [["macrophages", "ANATOMY", 88, 99], ["IL-12", "GENE_OR_GENE_PRODUCT", 34, 39], ["macrophages", "CELL", 88, 99], ["[61]", "SIMPLE_CHEMICAL", 106, 110], ["IL-12", "PROTEIN", 34, 39], ["macrophages", "CELL_TYPE", 88, 99], ["alternative activation in macrophages", "PROBLEM", 62, 99]]], ["In contrast to Ym-1, that has been associated with AMCase production by macrophages in the lung and airway [63], Ym-2 and BRP-39 were not upregulated in infected brains (Figure 2C, S4).", [["macrophages", "ANATOMY", 72, 83], ["lung", "ANATOMY", 91, 95], ["airway", "ANATOMY", 100, 106], ["brains", "ANATOMY", 162, 168], ["Ym-1", "GENE_OR_GENE_PRODUCT", 15, 19], ["AMCase", "GENE_OR_GENE_PRODUCT", 51, 57], ["macrophages", "CELL", 72, 83], ["lung", "ORGAN", 91, 95], ["airway", "MULTI-TISSUE_STRUCTURE", 100, 106], ["Ym-2", "GENE_OR_GENE_PRODUCT", 113, 117], ["BRP-39", "GENE_OR_GENE_PRODUCT", 122, 128], ["brains", "ORGAN", 162, 168], ["Ym", "PROTEIN", 15, 17], ["AMCase", "PROTEIN", 51, 57], ["macrophages", "CELL_TYPE", 72, 83], ["airway", "TEST", 100, 106], ["Ym", "TEST", 113, 115], ["BRP", "TEST", 122, 125], ["macrophages", "OBSERVATION", 72, 83], ["lung", "ANATOMY", 91, 95], ["airway", "ANATOMY", 100, 106], ["infected", "OBSERVATION", 153, 161]]], ["Since chitin has been shown to activate and recruit AAM\u00d8, it is possible that the cyst wall may serve as the stimulus for chitinase activity in this population of cells.", [["cyst wall", "ANATOMY", 82, 91], ["cells", "ANATOMY", 163, 168], ["chitin", "CHEMICAL", 6, 12], ["chitin", "GENE_OR_GENE_PRODUCT", 6, 12], ["AAM\u00d8", "GENE_OR_GENE_PRODUCT", 52, 56], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 82, 91], ["chitinase", "GENE_OR_GENE_PRODUCT", 122, 131], ["cells", "CELL", 163, 168], ["chitin", "PROTEIN", 6, 12], ["AAM\u00d8", "PROTEIN", 52, 56], ["chitinase", "PROTEIN", 122, 131], ["the cyst wall", "PROBLEM", 78, 91], ["chitinase activity", "PROBLEM", 122, 140], ["cyst", "OBSERVATION", 82, 86]]], ["To test this further, BMDM were co-cultured with different forms of the parasite.", [["BMDM", "ANATOMY", 22, 26], ["BMDM", "CELL", 22, 26], ["BMDM", "CELL_TYPE", 22, 26], ["BMDM", "TEST", 22, 26]]], ["The addition of tachyzoites, bradyzoites or sTAg did not lead to chitinase production (Figure 2D).", [["tachyzoites", "ANATOMY", 16, 27], ["bradyzoites", "ANATOMY", 29, 40], ["tachyzoites", "ORGANISM_SUBSTANCE", 16, 27], ["chitinase", "GENE_OR_GENE_PRODUCT", 65, 74], ["chitinase", "PROTEIN", 65, 74], ["tachyzoites", "PROBLEM", 16, 27], ["bradyzoites", "PROBLEM", 29, 40], ["sTAg", "PROBLEM", 44, 48], ["chitinase production", "PROBLEM", 65, 85], ["tachyzoites", "OBSERVATION", 16, 27]]], ["In contrast, live cysts and cyst antigen led to a significant increase in chitinase activity that was abolished following chitinase treatment of cysts (Figure 2D, S4).", [["cysts", "ANATOMY", 18, 23], ["cyst", "ANATOMY", 28, 32], ["cysts", "ANATOMY", 145, 150], ["cyst antigen", "GENE_OR_GENE_PRODUCT", 28, 40], ["chitinase", "GENE_OR_GENE_PRODUCT", 74, 83], ["chitinase", "GENE_OR_GENE_PRODUCT", 122, 131], ["cysts", "PATHOLOGICAL_FORMATION", 145, 150], ["cyst antigen", "PROTEIN", 28, 40], ["chitinase", "PROTEIN", 74, 83], ["chitinase", "PROTEIN", 122, 131], ["live cysts", "PROBLEM", 13, 23], ["cyst antigen", "PROBLEM", 28, 40], ["a significant increase in chitinase activity", "PROBLEM", 48, 92], ["chitinase treatment", "TREATMENT", 122, 141], ["cysts", "PROBLEM", 145, 150], ["live", "ANATOMY", 13, 17], ["cysts", "OBSERVATION", 18, 23], ["cyst", "OBSERVATION", 28, 32], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["chitinase activity", "OBSERVATION", 74, 92], ["cysts", "OBSERVATION", 145, 150]]], ["Furthermore, treatment with IL-4 to induce alternative activation in macrophages did not lead to increased chitinase activity.", [["macrophages", "ANATOMY", 69, 80], ["IL-4", "GENE_OR_GENE_PRODUCT", 28, 32], ["macrophages", "CELL", 69, 80], ["chitinase", "GENE_OR_GENE_PRODUCT", 107, 116], ["IL-4", "PROTEIN", 28, 32], ["macrophages", "CELL_TYPE", 69, 80], ["chitinase", "PROTEIN", 107, 116], ["IL-4", "TREATMENT", 28, 32], ["alternative activation in macrophages", "PROBLEM", 43, 80], ["increased chitinase activity", "PROBLEM", 97, 125], ["chitinase activity", "OBSERVATION", 107, 125]]], ["Indeed measurement of IL-4, IL-4R\u03b1 and the IL-4-dependent RELM-\u03b1 [64]\u2013[66] in the brains of chronically infected mice showed no significant increase over na\u00efve mice (Figure S4).", [["brains", "ANATOMY", 82, 88], ["RELM-\u03b1 [64]\u2013[66]", "CHEMICAL", 58, 74], ["IL-4", "GENE_OR_GENE_PRODUCT", 22, 26], ["IL-4R\u03b1", "GENE_OR_GENE_PRODUCT", 28, 34], ["IL-4", "GENE_OR_GENE_PRODUCT", 43, 47], ["RELM", "GENE_OR_GENE_PRODUCT", 58, 62], ["\u03b1 [64]\u2013[66]", "SIMPLE_CHEMICAL", 63, 74], ["brains", "ORGANISM", 82, 88], ["mice", "ORGANISM", 113, 117], ["mice", "ORGANISM", 160, 164], ["IL-4", "PROTEIN", 22, 26], ["IL-4R\u03b1", "PROTEIN", 28, 34], ["IL-4", "PROTEIN", 43, 47], ["RELM", "PROTEIN", 58, 62], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 160, 164], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 160, 164], ["IL", "TEST", 22, 24], ["IL", "TEST", 28, 30], ["the IL", "TEST", 39, 45], ["chronically", "OBSERVATION_MODIFIER", 92, 103], ["infected", "OBSERVATION", 104, 112], ["no", "UNCERTAINTY", 125, 127], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["increase", "OBSERVATION_MODIFIER", 140, 148]]], ["These data suggest that the presence of chitin in the cyst wall induces a phenotype of macrophage characterized by the production of the enzymatically active chitinase, AMCase and is distinct from IL-4 induced activation.Alternatively activated macrophages secrete an active chitinase in the CNS in response to chitin in the cyst wall ::: ResultsPrevious work has shown macrophages in close association with rupturing cysts [17], [31] and the presence of an active chitinase could point to a role for these cells in the breakdown of cysts within the brain.", [["cyst wall", "ANATOMY", 54, 63], ["macrophage", "ANATOMY", 87, 97], ["macrophages", "ANATOMY", 245, 256], ["CNS", "ANATOMY", 292, 295], ["cyst wall", "ANATOMY", 325, 334], ["macrophages", "ANATOMY", 370, 381], ["cysts", "ANATOMY", 418, 423], ["cells", "ANATOMY", 507, 512], ["cysts", "ANATOMY", 533, 538], ["brain", "ANATOMY", 550, 555], ["chitin", "CHEMICAL", 40, 46], ["chitin", "GENE_OR_GENE_PRODUCT", 40, 46], ["cyst wall", "PATHOLOGICAL_FORMATION", 54, 63], ["macrophage", "CELL", 87, 97], ["chitinase", "GENE_OR_GENE_PRODUCT", 158, 167], ["AMCase", "GENE_OR_GENE_PRODUCT", 169, 175], ["IL-4", "GENE_OR_GENE_PRODUCT", 197, 201], ["macrophages", "CELL", 245, 256], ["chitinase", "GENE_OR_GENE_PRODUCT", 275, 284], ["CNS", "ANATOMICAL_SYSTEM", 292, 295], ["chitin", "SIMPLE_CHEMICAL", 311, 317], ["cyst wall", "PATHOLOGICAL_FORMATION", 325, 334], ["macrophages", "CELL", 370, 381], ["chitinase", "GENE_OR_GENE_PRODUCT", 465, 474], ["cells", "CELL", 507, 512], ["cysts", "PATHOLOGICAL_FORMATION", 533, 538], ["brain", "ORGAN", 550, 555], ["chitinase", "PROTEIN", 158, 167], ["AMCase", "PROTEIN", 169, 175], ["IL-4", "PROTEIN", 197, 201], ["activated macrophages", "CELL_TYPE", 235, 256], ["chitinase", "PROTEIN", 275, 284], ["macrophages", "CELL_TYPE", 370, 381], ["chitinase", "PROTEIN", 465, 474], ["chitin in the cyst wall", "PROBLEM", 40, 63], ["a phenotype of macrophage", "PROBLEM", 72, 97], ["activated macrophages", "PROBLEM", 235, 256], ["an active chitinase in the CNS", "PROBLEM", 265, 295], ["macrophages", "PROBLEM", 370, 381], ["rupturing cysts", "PROBLEM", 408, 423], ["an active chitinase", "PROBLEM", 455, 474], ["these cells", "PROBLEM", 501, 512], ["cysts within the brain", "PROBLEM", 533, 555], ["chitin", "OBSERVATION_MODIFIER", 40, 46], ["cyst", "OBSERVATION", 54, 58], ["wall", "ANATOMY_MODIFIER", 59, 63], ["phenotype", "OBSERVATION_MODIFIER", 74, 83], ["macrophage", "OBSERVATION", 87, 97], ["active", "OBSERVATION_MODIFIER", 151, 157], ["chitinase", "OBSERVATION", 158, 167], ["distinct", "OBSERVATION_MODIFIER", 183, 191], ["macrophages", "OBSERVATION", 245, 256], ["active", "OBSERVATION_MODIFIER", 268, 274], ["chitinase", "OBSERVATION_MODIFIER", 275, 284], ["CNS", "ANATOMY", 292, 295], ["cyst", "OBSERVATION", 325, 329], ["macrophages", "OBSERVATION", 370, 381], ["rupturing", "OBSERVATION_MODIFIER", 408, 417], ["cysts", "OBSERVATION", 418, 423], ["active", "OBSERVATION", 458, 464], ["cysts", "OBSERVATION", 533, 538], ["brain", "ANATOMY", 550, 555]]], ["Recognition of chitin by macrophages is size dependent and likely contact dependent [49], [58], [67].", [["macrophages", "ANATOMY", 25, 36], ["chitin", "GENE_OR_GENE_PRODUCT", 15, 21], ["macrophages", "CELL", 25, 36], ["chitin", "PROTEIN", 15, 21], ["macrophages", "CELL_TYPE", 25, 36], ["size dependent", "PROBLEM", 40, 54], ["macrophages", "OBSERVATION", 25, 36], ["size", "OBSERVATION_MODIFIER", 40, 44], ["likely", "UNCERTAINTY", 59, 65], ["contact dependent", "OBSERVATION_MODIFIER", 66, 83]]], ["To test this, we co-cultured cysts separated from macrophages using 5 \u00b5m transwell inserts and assayed for urea and chitinase activity as previously described (Fig. 2A, 2D).", [["cysts", "ANATOMY", 29, 34], ["macrophages", "ANATOMY", 50, 61], ["urea", "CHEMICAL", 107, 111], ["urea", "CHEMICAL", 107, 111], ["macrophages", "CELL", 50, 61], ["urea", "SIMPLE_CHEMICAL", 107, 111], ["chitinase", "GENE_OR_GENE_PRODUCT", 116, 125], ["macrophages", "CELL_TYPE", 50, 61], ["chitinase", "PROTEIN", 116, 125], ["cysts", "PROBLEM", 29, 34], ["5 \u00b5m transwell inserts", "TREATMENT", 68, 90], ["urea and chitinase activity", "TREATMENT", 107, 134], ["cysts", "OBSERVATION", 29, 34]]], ["Our results show no increase in either urea production or chitinase activity from macrophages that have been separated from cysts, confirming that the observed alternative activation is dependent on contact with cysts or cyst antigen.Alternatively activated macrophages secrete an active chitinase in the CNS in response to chitin in the cyst wall ::: ResultsImmunohistochemical analysis of the location of AMCase secreting macrophages in the infected brain shows them in close proximity with tissues cysts (Figures 3A\u2013C).", [["macrophages", "ANATOMY", 82, 93], ["cysts", "ANATOMY", 124, 129], ["cysts", "ANATOMY", 212, 217], ["cyst", "ANATOMY", 221, 225], ["macrophages", "ANATOMY", 258, 269], ["CNS", "ANATOMY", 305, 308], ["cyst wall", "ANATOMY", 338, 347], ["macrophages", "ANATOMY", 424, 435], ["brain", "ANATOMY", 452, 457], ["tissues cysts", "ANATOMY", 493, 506], ["urea", "CHEMICAL", 39, 43], ["urea", "CHEMICAL", 39, 43], ["urea", "SIMPLE_CHEMICAL", 39, 43], ["chitinase", "GENE_OR_GENE_PRODUCT", 58, 67], ["macrophages", "CELL", 82, 93], ["cysts", "PATHOLOGICAL_FORMATION", 124, 129], ["cyst antigen", "GENE_OR_GENE_PRODUCT", 221, 233], ["macrophages", "CELL", 258, 269], ["chitinase", "GENE_OR_GENE_PRODUCT", 288, 297], ["CNS", "ANATOMICAL_SYSTEM", 305, 308], ["chitin", "SIMPLE_CHEMICAL", 324, 330], ["cyst wall", "PATHOLOGICAL_FORMATION", 338, 347], ["AMCase", "GENE_OR_GENE_PRODUCT", 407, 413], ["macrophages", "CELL", 424, 435], ["brain", "ORGAN", 452, 457], ["tissues cysts", "TISSUE", 493, 506], ["chitinase", "PROTEIN", 58, 67], ["macrophages", "CELL_TYPE", 82, 93], ["cyst antigen", "PROTEIN", 221, 233], ["activated macrophages", "CELL_TYPE", 248, 269], ["chitinase", "PROTEIN", 288, 297], ["AMCase secreting macrophages", "CELL_TYPE", 407, 435], ["increase in either urea production", "PROBLEM", 20, 54], ["chitinase activity from macrophages", "PROBLEM", 58, 93], ["cysts", "PROBLEM", 124, 129], ["cysts", "PROBLEM", 212, 217], ["cyst antigen", "PROBLEM", 221, 233], ["activated macrophages", "PROBLEM", 248, 269], ["an active chitinase in the CNS", "PROBLEM", 278, 308], ["ResultsImmunohistochemical analysis", "TEST", 352, 387], ["AMCase secreting macrophages in the infected brain", "PROBLEM", 407, 457], ["tissues cysts", "PROBLEM", 493, 506], ["no", "UNCERTAINTY", 17, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["urea production", "OBSERVATION", 39, 54], ["chitinase activity", "OBSERVATION", 58, 76], ["macrophages", "OBSERVATION", 82, 93], ["cysts", "OBSERVATION", 124, 129], ["alternative activation", "OBSERVATION", 160, 182], ["dependent", "OBSERVATION_MODIFIER", 186, 195], ["cysts", "OBSERVATION", 212, 217], ["cyst", "OBSERVATION", 221, 225], ["macrophages", "OBSERVATION", 258, 269], ["active", "OBSERVATION_MODIFIER", 281, 287], ["chitinase", "OBSERVATION_MODIFIER", 288, 297], ["CNS", "ANATOMY", 305, 308], ["cyst", "OBSERVATION", 338, 342], ["secreting macrophages", "OBSERVATION", 414, 435], ["infected", "OBSERVATION", 443, 451], ["brain", "ANATOMY", 452, 457], ["tissues", "ANATOMY", 493, 500], ["cysts", "OBSERVATION", 501, 506]]], ["As a proportion of macrophages and microglia in the brain, alternatively activated cells are in the minority and it was not possible to find such cells in the na\u00efve brain.", [["macrophages", "ANATOMY", 19, 30], ["microglia", "ANATOMY", 35, 44], ["brain", "ANATOMY", 52, 57], ["cells", "ANATOMY", 83, 88], ["cells", "ANATOMY", 146, 151], ["brain", "ANATOMY", 165, 170], ["macrophages", "CELL", 19, 30], ["microglia", "CELL", 35, 44], ["brain", "ORGAN", 52, 57], ["cells", "CELL", 83, 88], ["cells", "CELL", 146, 151], ["brain", "ORGAN", 165, 170], ["macrophages", "CELL_TYPE", 19, 30], ["microglia", "CELL_TYPE", 35, 44], ["activated cells", "CELL_TYPE", 73, 88], ["macrophages", "PROBLEM", 19, 30], ["microglia in the brain", "PROBLEM", 35, 57], ["activated cells", "PROBLEM", 73, 88], ["such cells in the na\u00efve brain", "PROBLEM", 141, 170], ["macrophages", "OBSERVATION", 19, 30], ["microglia", "OBSERVATION", 35, 44], ["brain", "ANATOMY", 52, 57], ["activated cells", "OBSERVATION", 73, 88], ["not possible", "UNCERTAINTY", 120, 132], ["na\u00efve", "ANATOMY_MODIFIER", 159, 164], ["brain", "ANATOMY", 165, 170]]], ["However, cysts are easily identifiable with a highly spherical distinct morphology, can stain non-specifically and specifically with antibodies and individual bradyzoites within the cyst are visible by DAPI staining.", [["cysts", "ANATOMY", 9, 14], ["cyst", "ANATOMY", 182, 186], ["DAPI", "CHEMICAL", 202, 206], ["cysts", "PATHOLOGICAL_FORMATION", 9, 14], ["cyst", "CANCER", 182, 186], ["DAPI", "SIMPLE_CHEMICAL", 202, 206], ["antibodies", "PROTEIN", 133, 143], ["cysts", "PROBLEM", 9, 14], ["antibodies", "TEST", 133, 143], ["individual bradyzoites within the cyst", "PROBLEM", 148, 186], ["DAPI staining", "TEST", 202, 215], ["cysts", "OBSERVATION", 9, 14], ["highly", "OBSERVATION_MODIFIER", 46, 52], ["spherical", "OBSERVATION_MODIFIER", 53, 62], ["distinct", "OBSERVATION_MODIFIER", 63, 71], ["morphology", "OBSERVATION_MODIFIER", 72, 82], ["bradyzoites", "OBSERVATION", 159, 170], ["cyst", "OBSERVATION", 182, 186], ["DAPI staining", "OBSERVATION", 202, 215]]], ["Examination of chitinase localization in the infected brain revealed distinct cytoplasmic staining of several cells, nearly all of which were within 75 \u00b5m of a cyst (Fig. 3A).", [["brain", "ANATOMY", 54, 59], ["cytoplasmic", "ANATOMY", 78, 89], ["cells", "ANATOMY", 110, 115], ["cyst", "ANATOMY", 160, 164], ["chitinase", "GENE_OR_GENE_PRODUCT", 15, 24], ["brain", "ORGAN", 54, 59], ["cytoplasmic", "ORGANISM_SUBSTANCE", 78, 89], ["cells", "CELL", 110, 115], ["cyst", "PATHOLOGICAL_FORMATION", 160, 164], ["chitinase", "PROTEIN", 15, 24], ["Examination of chitinase localization", "TEST", 0, 37], ["the infected brain", "TEST", 41, 59], ["distinct cytoplasmic staining of several cells", "PROBLEM", 69, 115], ["a cyst", "PROBLEM", 158, 164], ["brain", "ANATOMY", 54, 59], ["distinct", "OBSERVATION_MODIFIER", 69, 77], ["cytoplasmic staining", "OBSERVATION", 78, 98], ["several cells", "OBSERVATION", 102, 115], ["75 \u00b5m", "OBSERVATION_MODIFIER", 149, 154], ["cyst", "OBSERVATION", 160, 164]]], ["Although there were cells that were AMCase positive yet did not stain positively for macrophage/microglial markers, there were clearly several macrophages in close association with cysts that displayed chitinase activity polarized to the cyst wall (Figure S5, arrows).", [["cells", "ANATOMY", 20, 25], ["macrophage", "ANATOMY", 85, 95], ["microglial", "ANATOMY", 96, 106], ["macrophages", "ANATOMY", 143, 154], ["cysts", "ANATOMY", 181, 186], ["cyst wall", "ANATOMY", 238, 247], ["cells", "CELL", 20, 25], ["AMCase", "GENE_OR_GENE_PRODUCT", 36, 42], ["macrophage", "CELL", 85, 95], ["microglial", "CELL", 96, 106], ["macrophages", "CELL", 143, 154], ["chitinase", "GENE_OR_GENE_PRODUCT", 202, 211], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 238, 247], ["AMCase", "PROTEIN", 36, 42], ["macrophage/microglial markers", "PROTEIN", 85, 114], ["macrophages", "CELL_TYPE", 143, 154], ["chitinase", "PROTEIN", 202, 211], ["cells", "PROBLEM", 20, 25], ["macrophage/microglial markers", "TEST", 85, 114], ["several macrophages", "PROBLEM", 135, 154], ["cysts", "PROBLEM", 181, 186], ["chitinase activity", "PROBLEM", 202, 220], ["microglial markers", "OBSERVATION", 96, 114], ["several", "OBSERVATION_MODIFIER", 135, 142], ["macrophages", "OBSERVATION", 143, 154], ["cysts", "OBSERVATION", 181, 186], ["chitinase activity", "OBSERVATION", 202, 220], ["cyst", "OBSERVATION", 238, 242], ["wall", "ANATOMY_MODIFIER", 243, 247]]], ["AmCase activity was also observed in macrophages surrounding cysts that seemed to be in the process of lysing or cysts that had been lysed (Figures 3B,C and Video S1).", [["macrophages", "ANATOMY", 37, 48], ["cysts", "ANATOMY", 61, 66], ["cysts", "ANATOMY", 113, 118], ["AmCase", "GENE_OR_GENE_PRODUCT", 0, 6], ["macrophages", "CELL", 37, 48], ["cysts", "CANCER", 61, 66], ["AmCase", "PROTEIN", 0, 6], ["macrophages", "CELL_TYPE", 37, 48], ["AmCase activity", "PROBLEM", 0, 15], ["macrophages surrounding cysts", "PROBLEM", 37, 66], ["cysts", "PROBLEM", 113, 118], ["macrophages", "OBSERVATION_MODIFIER", 37, 48], ["cysts", "OBSERVATION", 61, 66], ["seemed to be", "UNCERTAINTY", 72, 84], ["lysing", "OBSERVATION", 103, 109], ["cysts", "OBSERVATION", 113, 118]]], ["The examples provided show the destruction of the spherical cyst (Video S1) and escaping parasites visualized using anti-Toxoplasma antibodies.", [["cyst", "ANATOMY", 60, 64], ["anti-Toxoplasma antibodies", "GENE_OR_GENE_PRODUCT", 116, 142], ["anti-Toxoplasma antibodies", "PROTEIN", 116, 142], ["the destruction of the spherical cyst", "PROBLEM", 27, 64], ["escaping parasites", "PROBLEM", 80, 98], ["anti-Toxoplasma antibodies", "TEST", 116, 142], ["destruction", "OBSERVATION", 31, 42], ["spherical", "OBSERVATION_MODIFIER", 50, 59], ["cyst", "OBSERVATION", 60, 64], ["anti-Toxoplasma antibodies", "OBSERVATION", 116, 142]]], ["Directly at the point of rupture there are AMCase expressing macrophages (Figures 3B).", [["macrophages", "ANATOMY", 61, 72], ["rupture", "DISEASE", 25, 32], ["AMCase", "GENE_OR_GENE_PRODUCT", 43, 49], ["macrophages", "CELL", 61, 72], ["AMCase expressing macrophages", "CELL_TYPE", 43, 72], ["rupture", "PROBLEM", 25, 32], ["rupture", "OBSERVATION", 25, 32], ["macrophages", "OBSERVATION", 61, 72]]], ["Taken together, these data suggest that the induction of chitinase activity in macrophages occurs in close proximity with the cyst wall and that this distinct population of macrophages is responsible for attacking the long-term chronic cyst stage of Toxoplasma via chitinase activity.Macrophage chitinase activity is required to lyse cysts in vitro ::: ResultsThe prevailing view is that cysts in the brain remain intracellular within neurons and that CD8+ T cell production of perforin is responsible for cyst clearance in the brain although the exact mechanism of cyst destruction has yet to be described [17], [18].", [["macrophages", "ANATOMY", 79, 90], ["cyst wall", "ANATOMY", 126, 135], ["macrophages", "ANATOMY", 173, 184], ["cyst", "ANATOMY", 236, 240], ["cysts", "ANATOMY", 334, 339], ["cysts", "ANATOMY", 388, 393], ["brain", "ANATOMY", 401, 406], ["intracellular", "ANATOMY", 414, 427], ["neurons", "ANATOMY", 435, 442], ["CD8+", "ANATOMY", 452, 456], ["T cell", "ANATOMY", 457, 463], ["cyst", "ANATOMY", 506, 510], ["brain", "ANATOMY", 528, 533], ["cyst", "ANATOMY", 566, 570], ["cyst destruction", "DISEASE", 566, 582], ["chitinase", "GENE_OR_GENE_PRODUCT", 57, 66], ["macrophages", "CELL", 79, 90], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 126, 135], ["macrophages", "CELL", 173, 184], ["Toxoplasma", "ORGANISM", 250, 260], ["chitinase", "GENE_OR_GENE_PRODUCT", 265, 274], ["Macrophage chitinase", "GENE_OR_GENE_PRODUCT", 284, 304], ["cysts", "PATHOLOGICAL_FORMATION", 334, 339], ["cysts", "CANCER", 388, 393], ["brain", "ORGAN", 401, 406], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 414, 427], ["neurons", "CELL", 435, 442], ["CD8", "GENE_OR_GENE_PRODUCT", 452, 455], ["T cell", "CELL", 457, 463], ["perforin", "GENE_OR_GENE_PRODUCT", 478, 486], ["cyst", "PATHOLOGICAL_FORMATION", 506, 510], ["brain", "ORGAN", 528, 533], ["cyst", "ORGAN", 566, 570], ["chitinase", "PROTEIN", 57, 66], ["macrophages", "CELL_TYPE", 79, 90], ["macrophages", "CELL_TYPE", 173, 184], ["chitinase", "PROTEIN", 265, 274], ["chitinase", "PROTEIN", 295, 304], ["CD8", "PROTEIN", 452, 455], ["perforin", "PROTEIN", 478, 486], ["Toxoplasma", "SPECIES", 250, 260], ["chitinase activity in macrophages", "PROBLEM", 57, 90], ["the cyst wall", "PROBLEM", 122, 135], ["macrophages", "PROBLEM", 173, 184], ["the long-term chronic cyst", "PROBLEM", 214, 240], ["Toxoplasma", "PROBLEM", 250, 260], ["Macrophage chitinase activity", "PROBLEM", 284, 313], ["cysts in the brain", "PROBLEM", 388, 406], ["cyst clearance in the brain", "PROBLEM", 506, 533], ["cyst destruction", "PROBLEM", 566, 582], ["cyst", "OBSERVATION", 126, 130], ["wall", "ANATOMY_MODIFIER", 131, 135], ["distinct", "OBSERVATION_MODIFIER", 150, 158], ["population", "OBSERVATION", 159, 169], ["macrophages", "OBSERVATION", 173, 184], ["responsible for", "UNCERTAINTY", 188, 203], ["long-term", "OBSERVATION_MODIFIER", 218, 227], ["chronic", "OBSERVATION_MODIFIER", 228, 235], ["cyst", "OBSERVATION", 236, 240], ["chitinase activity", "OBSERVATION", 265, 283], ["cysts", "OBSERVATION", 388, 393], ["brain", "ANATOMY", 401, 406], ["intracellular", "OBSERVATION", 414, 427], ["cell production", "OBSERVATION", 459, 474], ["responsible for", "UNCERTAINTY", 490, 505], ["cyst", "OBSERVATION", 506, 510], ["brain", "ANATOMY", 528, 533], ["cyst", "OBSERVATION", 566, 570]]], ["In order to determine whether or not macrophage chitinase activity could be responsible for the direct lysis of cysts, BMDM were co-cultured with cysts; with and without the chitinase inhibitor allosamidin.", [["cysts", "ANATOMY", 112, 117], ["BMDM", "ANATOMY", 119, 123], ["cysts", "ANATOMY", 146, 151], ["allosamidin", "CHEMICAL", 194, 205], ["allosamidin", "CHEMICAL", 194, 205], ["macrophage", "CELL", 37, 47], ["BMDM", "CELL", 119, 123], ["chitinase", "GENE_OR_GENE_PRODUCT", 174, 183], ["allosamidin", "SIMPLE_CHEMICAL", 194, 205], ["macrophage chitinase", "PROTEIN", 37, 57], ["BMDM", "CELL_TYPE", 119, 123], ["chitinase", "PROTEIN", 174, 183], ["macrophage chitinase activity", "PROBLEM", 37, 66], ["the direct lysis of cysts", "PROBLEM", 92, 117], ["BMDM", "PROBLEM", 119, 123], ["cysts", "PROBLEM", 146, 151], ["the chitinase inhibitor allosamidin", "TREATMENT", 170, 205], ["cysts", "OBSERVATION", 112, 117]]], ["Cultures were observed for 14 hours capturing images every 10 minutes.", [["Cultures", "TEST", 0, 8]]], ["Cysts observed in the absence of macrophages remained intact for the entire time course suggesting no parasite intrinsic mechanism of cyst destruction (Figure 4A; Video S2).", [["Cysts", "ANATOMY", 0, 5], ["macrophages", "ANATOMY", 33, 44], ["cyst", "ANATOMY", 134, 138], ["cyst destruction", "DISEASE", 134, 150], ["macrophages", "CELL", 33, 44], ["cyst", "TISSUE", 134, 138], ["macrophages", "CELL_TYPE", 33, 44], ["Cysts", "PROBLEM", 0, 5], ["macrophages", "PROBLEM", 33, 44], ["parasite", "PROBLEM", 102, 110], ["cyst destruction", "PROBLEM", 134, 150], ["macrophages", "OBSERVATION", 33, 44], ["intact", "OBSERVATION", 54, 60], ["no", "UNCERTAINTY", 99, 101], ["parasite", "OBSERVATION_MODIFIER", 102, 110], ["cyst", "OBSERVATION", 134, 138]]], ["In contrast, the addition of 20 \u00b5g/ml trichoderma chitinase to cyst cultures led to rapid rupture of the cysts within an average of 4 hrs, releasing bradyzoites into the media (Figure 4B; Video S3).", [["cyst cultures", "ANATOMY", 63, 76], ["cysts", "ANATOMY", 105, 110], ["rupture of the cysts", "DISEASE", 90, 110], ["trichoderma chitinase", "GENE_OR_GENE_PRODUCT", 38, 59], ["cyst cultures", "CELL", 63, 76], ["cysts", "PATHOLOGICAL_FORMATION", 105, 110], ["trichoderma chitinase", "PROTEIN", 38, 59], ["cyst cultures", "CELL_LINE", 63, 76], ["20 \u00b5g/ml trichoderma chitinase", "TREATMENT", 29, 59], ["cyst cultures", "TEST", 63, 76], ["rapid rupture of the cysts", "PROBLEM", 84, 110], ["cyst", "OBSERVATION", 63, 67], ["rapid", "OBSERVATION_MODIFIER", 84, 89], ["rupture", "OBSERVATION", 90, 97], ["cysts", "OBSERVATION", 105, 110]]], ["Strikingly, cysts that were cultured with macrophages came under vigorous attack.", [["cysts", "ANATOMY", 12, 17], ["macrophages", "ANATOMY", 42, 53], ["cysts", "PATHOLOGICAL_FORMATION", 12, 17], ["macrophages", "CELL", 42, 53], ["macrophages", "CELL_TYPE", 42, 53], ["cysts", "PROBLEM", 12, 17], ["macrophages", "PROBLEM", 42, 53], ["cysts", "OBSERVATION", 12, 17], ["vigorous", "OBSERVATION_MODIFIER", 65, 73]]], ["This involved efficient and rapid migration of macrophages toward the cyst creating clusters of macrophages that could be seen pulling at the cyst wall (Figure 4C; Video S4).", [["macrophages", "ANATOMY", 47, 58], ["cyst", "ANATOMY", 70, 74], ["macrophages", "ANATOMY", 96, 107], ["cyst wall", "ANATOMY", 142, 151], ["macrophages", "CELL", 47, 58], ["cyst", "PATHOLOGICAL_FORMATION", 70, 74], ["macrophages", "CELL", 96, 107], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 142, 151], ["macrophages", "CELL_TYPE", 47, 58], ["macrophages", "CELL_TYPE", 96, 107], ["rapid migration of macrophages", "PROBLEM", 28, 58], ["the cyst", "PROBLEM", 66, 74], ["macrophages", "PROBLEM", 96, 107], ["rapid", "OBSERVATION_MODIFIER", 28, 33], ["migration", "OBSERVATION_MODIFIER", 34, 43], ["macrophages", "OBSERVATION_MODIFIER", 47, 58], ["cyst", "OBSERVATION", 70, 74], ["clusters", "OBSERVATION_MODIFIER", 84, 92], ["macrophages", "OBSERVATION", 96, 107], ["cyst", "OBSERVATION", 142, 146], ["wall", "ANATOMY_MODIFIER", 147, 151]]], ["In these cultures most of the cysts were destroyed during the observation period with the average survival time of 9.5 hours (Figure 4E).", [["cysts", "ANATOMY", 30, 35], ["cysts", "PATHOLOGICAL_FORMATION", 30, 35], ["these cultures", "TEST", 3, 17], ["the cysts", "PROBLEM", 26, 35], ["cysts", "OBSERVATION", 30, 35]]], ["In contrast cysts cultured in the presence of macrophages and the chitinase inhibitor allosamidin survived significantly longer than in untreated cultures.", [["cysts", "ANATOMY", 12, 17], ["macrophages", "ANATOMY", 46, 57], ["cultures", "ANATOMY", 146, 154], ["allosamidin", "CHEMICAL", 86, 97], ["allosamidin", "CHEMICAL", 86, 97], ["macrophages", "CELL", 46, 57], ["chitinase", "GENE_OR_GENE_PRODUCT", 66, 75], ["allosamidin", "SIMPLE_CHEMICAL", 86, 97], ["macrophages", "CELL_TYPE", 46, 57], ["chitinase", "PROTEIN", 66, 75], ["untreated cultures", "CELL_LINE", 136, 154], ["contrast cysts", "PROBLEM", 3, 17], ["macrophages", "PROBLEM", 46, 57], ["the chitinase inhibitor allosamidin", "TREATMENT", 62, 97], ["untreated cultures", "TEST", 136, 154], ["contrast", "OBSERVATION_MODIFIER", 3, 11], ["cysts", "OBSERVATION", 12, 17], ["macrophages", "OBSERVATION", 46, 57]]], ["Although there appeared to be no defect in the recruitment and activity of macrophages to cysts with similar clustering and \u2018pulling\u2019 of the cyst wall, the majority of cysts survived the entire 14 hour period when treated with either 100 \u00b5M or 10 \u00b5M allosamidin (Figure 4D; Video S5).", [["macrophages", "ANATOMY", 75, 86], ["cysts", "ANATOMY", 90, 95], ["cyst wall", "ANATOMY", 141, 150], ["cysts", "ANATOMY", 168, 173], ["allosamidin", "CHEMICAL", 250, 261], ["allosamidin", "CHEMICAL", 250, 261], ["macrophages", "CELL", 75, 86], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 141, 150], ["cysts", "PATHOLOGICAL_FORMATION", 168, 173], ["allosamidin", "SIMPLE_CHEMICAL", 250, 261], ["macrophages", "CELL_TYPE", 75, 86], ["defect", "PROBLEM", 33, 39], ["macrophages", "PROBLEM", 75, 86], ["cysts", "PROBLEM", 90, 95], ["the cyst wall", "PROBLEM", 137, 150], ["cysts", "PROBLEM", 168, 173], ["appeared to be", "UNCERTAINTY", 15, 29], ["no", "UNCERTAINTY", 30, 32], ["defect", "OBSERVATION", 33, 39], ["recruitment", "OBSERVATION_MODIFIER", 47, 58], ["activity", "OBSERVATION_MODIFIER", 63, 71], ["cysts", "OBSERVATION", 90, 95], ["similar", "OBSERVATION_MODIFIER", 101, 108], ["clustering", "OBSERVATION_MODIFIER", 109, 119], ["cyst", "OBSERVATION", 141, 145], ["wall", "ANATOMY_MODIFIER", 146, 150], ["majority", "OBSERVATION_MODIFIER", 156, 164], ["cysts", "OBSERVATION", 168, 173]]], ["Decreasing concentrations of allosamidin led to a dose dependent decrease in cyst survival time (Figure 4E).", [["cyst", "ANATOMY", 77, 81], ["allosamidin", "CHEMICAL", 29, 40], ["allosamidin", "CHEMICAL", 29, 40], ["allosamidin", "SIMPLE_CHEMICAL", 29, 40], ["cyst", "PATHOLOGICAL_FORMATION", 77, 81], ["allosamidin", "TREATMENT", 29, 40], ["a dose dependent decrease in cyst survival", "TREATMENT", 48, 90], ["decrease", "OBSERVATION_MODIFIER", 65, 73], ["cyst", "OBSERVATION", 77, 81]]], ["These results demonstrate that macrophages can induce cyst lysis in a chitinase dependent manner.Macrophage chitinase activity is required to lyse cysts in vitro ::: ResultsAlthough both AMCase and CHIT1 are upregulated in certain bacterial and nematode infections [68], [69] only AMCase was significantly increased in the brain following Toxoplasma infection (Figure 2C).", [["macrophages", "ANATOMY", 31, 42], ["cyst", "ANATOMY", 54, 58], ["cysts", "ANATOMY", 147, 152], ["brain", "ANATOMY", 323, 328], ["infections", "DISEASE", 254, 264], ["Toxoplasma infection", "DISEASE", 339, 359], ["macrophages", "CELL", 31, 42], ["chitinase", "GENE_OR_GENE_PRODUCT", 70, 79], ["Macrophage chitinase", "GENE_OR_GENE_PRODUCT", 97, 117], ["cysts", "PATHOLOGICAL_FORMATION", 147, 152], ["AMCase", "GENE_OR_GENE_PRODUCT", 187, 193], ["CHIT1", "GENE_OR_GENE_PRODUCT", 198, 203], ["AMCase", "GENE_OR_GENE_PRODUCT", 281, 287], ["brain", "ORGAN", 323, 328], ["Toxoplasma", "ORGANISM", 339, 349], ["macrophages", "CELL_TYPE", 31, 42], ["chitinase", "PROTEIN", 70, 79], ["chitinase", "PROTEIN", 108, 117], ["AMCase", "PROTEIN", 187, 193], ["CHIT1", "PROTEIN", 198, 203], ["Toxoplasma", "SPECIES", 339, 349], ["macrophages", "PROBLEM", 31, 42], ["cyst lysis", "PROBLEM", 54, 64], ["Macrophage chitinase activity", "PROBLEM", 97, 126], ["lyse cysts", "PROBLEM", 142, 152], ["AMCase", "TEST", 187, 193], ["CHIT1", "TEST", 198, 203], ["nematode infections", "PROBLEM", 245, 264], ["AMCase", "TEST", 281, 287], ["Toxoplasma infection", "PROBLEM", 339, 359], ["macrophages", "OBSERVATION", 31, 42], ["cyst", "OBSERVATION", 54, 58], ["chitinase dependent", "OBSERVATION_MODIFIER", 70, 89], ["significantly", "OBSERVATION_MODIFIER", 292, 305], ["increased", "OBSERVATION", 306, 315], ["brain", "ANATOMY", 323, 328], ["Toxoplasma infection", "OBSERVATION", 339, 359]]], ["To confirm that AMCase is responsible for the observed chitinase activity, we performed a chitinase assay similar to that in Figure 1D using BMDM from WT and AMCase null mice (Figure 5A).", [["AMCase", "GENE_OR_GENE_PRODUCT", 16, 22], ["chitinase", "GENE_OR_GENE_PRODUCT", 55, 64], ["BMDM", "CELL", 141, 145], ["AMCase null mice", "ORGANISM", 158, 174], ["AMCase", "PROTEIN", 16, 22], ["chitinase", "PROTEIN", 55, 64], ["chitinase", "PROTEIN", 90, 99], ["BMDM", "CELL_TYPE", 141, 145], ["mice", "SPECIES", 170, 174], ["mice", "SPECIES", 170, 174], ["the observed chitinase activity", "PROBLEM", 42, 73], ["a chitinase assay", "TEST", 88, 105]]], ["Our results reveal a severe defect in chitinase production by AMCase null macrophages.", [["macrophages", "ANATOMY", 74, 85], ["chitinase", "GENE_OR_GENE_PRODUCT", 38, 47], ["AMCase", "GENE_OR_GENE_PRODUCT", 62, 68], ["chitinase", "PROTEIN", 38, 47], ["AMCase null macrophages", "CELL_LINE", 62, 85], ["a severe defect in chitinase production", "PROBLEM", 19, 58], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["defect", "OBSERVATION", 28, 34], ["chitinase production", "OBSERVATION", 38, 58], ["null macrophages", "OBSERVATION", 69, 85]]], ["Indeed, these cells showed a significantly lower baseline level of chitinase and were unresponsive to the addition of cysts.", [["cells", "ANATOMY", 14, 19], ["cysts", "ANATOMY", 118, 123], ["cells", "CELL", 14, 19], ["chitinase", "GENE_OR_GENE_PRODUCT", 67, 76], ["cysts", "PATHOLOGICAL_FORMATION", 118, 123], ["chitinase", "PROTEIN", 67, 76], ["these cells", "TEST", 8, 19], ["a significantly lower baseline level of chitinase", "PROBLEM", 27, 76], ["cysts", "PROBLEM", 118, 123], ["significantly", "OBSERVATION_MODIFIER", 29, 42], ["lower", "OBSERVATION_MODIFIER", 43, 48], ["cysts", "OBSERVATION", 118, 123]]], ["To test whether the ability to destroy cysts is dependent on this enzyme, BMDM from WT and AMCase\u2212/\u2212 mice were fluorescently labeled and cultured with Me49-RFP expressing cysts and cyst lysis time imaged as before.", [["cysts", "ANATOMY", 39, 44], ["BMDM", "ANATOMY", 74, 78], ["cysts", "ANATOMY", 171, 176], ["cyst", "ANATOMY", 181, 185], ["cysts", "DISEASE", 39, 44], ["cysts", "CANCER", 39, 44], ["BMDM", "CELL", 74, 78], ["AMCase\u2212/\u2212 mice", "ORGANISM", 91, 105], ["Me49", "GENE_OR_GENE_PRODUCT", 151, 155], ["RFP", "GENE_OR_GENE_PRODUCT", 156, 159], ["cysts", "CANCER", 171, 176], ["BMDM", "CELL_TYPE", 74, 78], ["Me49", "PROTEIN", 151, 155], ["RFP", "PROTEIN", 156, 159], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["destroy cysts", "PROBLEM", 31, 44], ["this enzyme", "TEST", 61, 72], ["BMDM", "TEST", 74, 78], ["WT", "TEST", 84, 86], ["AMCase\u2212/\u2212 mice", "TREATMENT", 91, 105], ["Me49", "TEST", 151, 155], ["cysts", "PROBLEM", 171, 176], ["cyst lysis", "PROBLEM", 181, 191], ["cysts", "OBSERVATION", 39, 44], ["cysts", "OBSERVATION", 171, 176], ["cyst lysis", "OBSERVATION", 181, 191]]], ["Using fluorescently labeled parasites enhanced the ability to see escaping parasites from lysing cysts.", [["cysts", "ANATOMY", 97, 102], ["cysts", "CANCER", 97, 102], ["escaping parasites", "PROBLEM", 66, 84], ["lysing cysts", "PROBLEM", 90, 102], ["lysing", "OBSERVATION_MODIFIER", 90, 96], ["cysts", "OBSERVATION", 97, 102]]], ["Results, as before, demonstrated that WT non-polarized macrophages were able to lyse cysts in \u223c10 hours (Figures 5B and 5D; Videos S6 and S10).", [["macrophages", "ANATOMY", 55, 66], ["cysts", "ANATOMY", 85, 90], ["macrophages", "CELL", 55, 66], ["WT non-polarized macrophages", "CELL_TYPE", 38, 66], ["S6", "PROTEIN", 131, 133], ["S10", "PROTEIN", 138, 141], ["WT non-polarized macrophages", "PROBLEM", 38, 66], ["lyse cysts", "PROBLEM", 80, 90], ["Figures", "TEST", 105, 112]]], ["In contrast, cysts cultured with AMCase\u2212/\u2212 macrophages had a significantly increased survival time over WT macrophages consistent with AMCase being the source of chitinase activity required to lyse cysts (Figures 5C and 5D; Videos S7 and S11).", [["cysts", "ANATOMY", 13, 18], ["AMCase\u2212/\u2212 macrophages", "ANATOMY", 33, 54], ["macrophages", "ANATOMY", 107, 118], ["cysts", "ANATOMY", 198, 203], ["cysts", "PATHOLOGICAL_FORMATION", 13, 18], ["AMCase\u2212/\u2212 macrophages", "CELL", 33, 54], ["macrophages", "CELL", 107, 118], ["AMCase", "GENE_OR_GENE_PRODUCT", 135, 141], ["chitinase", "GENE_OR_GENE_PRODUCT", 162, 171], ["AMCase\u2212/\u2212 macrophages", "CELL_LINE", 33, 54], ["WT macrophages", "CELL_TYPE", 104, 118], ["AMCase", "PROTEIN", 135, 141], ["chitinase", "PROTEIN", 162, 171], ["S11", "PROTEIN", 238, 241], ["cysts", "PROBLEM", 13, 18], ["AMCase\u2212", "TEST", 33, 40], ["macrophages", "PROBLEM", 43, 54], ["WT macrophages", "PROBLEM", 104, 118], ["chitinase activity", "PROBLEM", 162, 180], ["lyse cysts", "PROBLEM", 193, 203], ["cysts", "OBSERVATION", 13, 18], ["consistent with", "UNCERTAINTY", 119, 134]]], ["To determine the requirement for macrophage polarization in their ability to lyse cysts, macrophages were treated with cytokines to polarize them to classical or alternative phenotypes prior to cyst addition.", [["macrophage", "ANATOMY", 33, 43], ["cysts", "ANATOMY", 82, 87], ["macrophages", "ANATOMY", 89, 100], ["cyst", "ANATOMY", 194, 198], ["macrophage", "CELL", 33, 43], ["macrophages", "CELL", 89, 100], ["cyst", "CANCER", 194, 198], ["macrophages", "CELL_TYPE", 89, 100], ["cytokines", "PROTEIN", 119, 128], ["macrophage polarization", "TREATMENT", 33, 56], ["lyse cysts", "PROBLEM", 77, 87], ["macrophages", "PROBLEM", 89, 100], ["cytokines", "TREATMENT", 119, 128], ["alternative phenotypes", "PROBLEM", 162, 184], ["cyst addition", "TREATMENT", 194, 207], ["cysts", "OBSERVATION", 82, 87]]], ["In line with the lack of chitinase induction, IL-4 priming had no effect on cyst survival time, suggesting that cytokine-induced alternative activation does not enhance the ability to destroy cysts (Figures 5D; Video S9).", [["cyst", "ANATOMY", 76, 80], ["cysts", "ANATOMY", 192, 197], ["chitinase", "GENE_OR_GENE_PRODUCT", 25, 34], ["IL-4", "GENE_OR_GENE_PRODUCT", 46, 50], ["cyst", "ORGAN", 76, 80], ["cysts", "PATHOLOGICAL_FORMATION", 192, 197], ["chitinase", "PROTEIN", 25, 34], ["IL-4", "PROTEIN", 46, 50], ["cytokine", "PROTEIN", 112, 120], ["chitinase induction", "TREATMENT", 25, 44], ["IL-4 priming", "TREATMENT", 46, 58], ["cyst survival time", "PROBLEM", 76, 94], ["cytokine-induced alternative activation", "PROBLEM", 112, 151], ["destroy cysts", "PROBLEM", 184, 197], ["cyst", "OBSERVATION", 76, 80]]], ["In contrast, macrophages that were classically polarized with LPS and IFN-\u03b3 showed a defect in chitinase activity and cyst destruction (Figures 5D and 5E; Video S9).", [["macrophages", "ANATOMY", 13, 24], ["cyst", "ANATOMY", 118, 122], ["LPS", "CHEMICAL", 62, 65], ["cyst destruction", "DISEASE", 118, 134], ["macrophages", "CELL", 13, 24], ["LPS", "SIMPLE_CHEMICAL", 62, 65], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 70, 75], ["chitinase", "GENE_OR_GENE_PRODUCT", 95, 104], ["cyst", "PATHOLOGICAL_FORMATION", 118, 122], ["macrophages", "CELL_TYPE", 13, 24], ["IFN", "PROTEIN", 70, 73], ["\u03b3", "PROTEIN", 74, 75], ["chitinase", "PROTEIN", 95, 104], ["LPS", "TEST", 62, 65], ["IFN", "TEST", 70, 73], ["a defect in chitinase activity", "PROBLEM", 83, 113], ["cyst destruction", "PROBLEM", 118, 134], ["macrophages", "OBSERVATION", 13, 24], ["defect", "OBSERVATION", 85, 91], ["chitinase activity", "OBSERVATION", 95, 113], ["cyst", "OBSERVATION", 118, 122]]], ["Suggesting that polarization of macrophages is required but that chitin is the most likely source of alternative activation and not IL-4.", [["macrophages", "ANATOMY", 32, 43], ["macrophages", "CELL", 32, 43], ["chitin", "GENE_OR_GENE_PRODUCT", 65, 71], ["IL-4", "GENE_OR_GENE_PRODUCT", 132, 136], ["macrophages", "CELL_TYPE", 32, 43], ["IL-4", "PROTEIN", 132, 136], ["macrophages", "PROBLEM", 32, 43], ["chitin", "TREATMENT", 65, 71], ["polarization", "OBSERVATION_MODIFIER", 16, 28], ["macrophages", "OBSERVATION", 32, 43], ["most likely", "UNCERTAINTY", 79, 90]]], ["Taken together, these data demonstrate that macrophages lyse cysts in an AMCase-dependent manner in vitro.AMCase dependent control of parasite burden in vivo ::: ResultsThe consequences of chitinase dependent cyst lysis in the CNS could potentially benefit either the host or the parasite.", [["macrophages", "ANATOMY", 44, 55], ["cysts", "ANATOMY", 61, 66], ["cyst", "ANATOMY", 209, 213], ["CNS", "ANATOMY", 227, 230], ["macrophages", "CELL", 44, 55], ["AMCase", "GENE_OR_GENE_PRODUCT", 73, 79], ["AMCase", "SIMPLE_CHEMICAL", 106, 112], ["chitinase", "GENE_OR_GENE_PRODUCT", 189, 198], ["CNS", "ANATOMICAL_SYSTEM", 227, 230], ["macrophages", "CELL_TYPE", 44, 55], ["chitinase", "PROTEIN", 189, 198], ["these data", "TEST", 16, 26], ["macrophages lyse cysts", "PROBLEM", 44, 66], ["parasite burden", "PROBLEM", 134, 149], ["chitinase dependent cyst lysis", "TREATMENT", 189, 219], ["macrophages lyse", "OBSERVATION", 44, 60], ["cysts", "OBSERVATION", 61, 66], ["parasite burden", "OBSERVATION", 134, 149], ["dependent", "OBSERVATION_MODIFIER", 199, 208], ["cyst", "OBSERVATION_MODIFIER", 209, 213], ["lysis", "OBSERVATION", 214, 219], ["CNS", "ANATOMY", 227, 230]]], ["If the escaping bradyzoites were quickly killed by macrophages or associated immune cells, we would expect this mechanism to benefit the host and result in a lower parasite burden.", [["macrophages", "ANATOMY", 51, 62], ["immune cells", "ANATOMY", 77, 89], ["macrophages", "CELL", 51, 62], ["immune cells", "CELL", 77, 89], ["macrophages", "CELL_TYPE", 51, 62], ["immune cells", "CELL_TYPE", 77, 89], ["the escaping bradyzoites", "PROBLEM", 3, 27], ["associated immune cells", "PROBLEM", 66, 89], ["a lower parasite burden", "PROBLEM", 156, 179], ["immune cells", "OBSERVATION", 77, 89], ["lower", "OBSERVATION_MODIFIER", 158, 163], ["parasite", "OBSERVATION", 164, 172]]], ["Conversely, if bradyzoites are able to propagate and infect new cells, this could be a mechanism that promotes the persistence of the parasite in the brain.", [["cells", "ANATOMY", 64, 69], ["brain", "ANATOMY", 150, 155], ["cells", "CELL", 64, 69], ["brain", "ORGAN", 150, 155], ["bradyzoites", "PROBLEM", 15, 26], ["the parasite in the brain", "PROBLEM", 130, 155], ["parasite", "OBSERVATION", 134, 142], ["brain", "ANATOMY", 150, 155]]], ["To investigate the role of AMCase in the brain in vivo, we infected WT and AMCase deficient mice and analyzed the immune response and parasite burden in the absence of chitinase activity.", [["brain", "ANATOMY", 41, 46], ["AMCase", "GENE_OR_GENE_PRODUCT", 27, 33], ["brain", "ORGAN", 41, 46], ["AMCase", "GENE_OR_GENE_PRODUCT", 75, 81], ["mice", "ORGANISM", 92, 96], ["chitinase", "GENE_OR_GENE_PRODUCT", 168, 177], ["AMCase", "PROTEIN", 27, 33], ["AMCase", "PROTEIN", 75, 81], ["chitinase", "PROTEIN", 168, 177], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["AMCase deficient mice", "TREATMENT", 75, 96], ["parasite burden", "PROBLEM", 134, 149], ["brain", "ANATOMY", 41, 46]]], ["To determine if AMCase is required during the acute stage of infection, tissue samples from lungs were taken at day 7 and analyzed for parasite burden by qPCR.", [["tissue samples", "ANATOMY", 72, 86], ["lungs", "ANATOMY", 92, 97], ["infection", "DISEASE", 61, 70], ["AMCase", "GENE_OR_GENE_PRODUCT", 16, 22], ["tissue samples", "CANCER", 72, 86], ["lungs", "ORGAN", 92, 97], ["AMCase", "PROTEIN", 16, 22], ["infection", "PROBLEM", 61, 70], ["tissue samples from lungs", "TEST", 72, 97], ["parasite burden", "PROBLEM", 135, 150], ["qPCR", "TEST", 154, 158], ["infection", "OBSERVATION", 61, 70], ["lungs", "ANATOMY", 92, 97]]], ["No significant differences in lung parasite load were found and serum cytokine concentrations were equivalent throughout acute infection (Figure 6A\u2013F).", [["lung", "ANATOMY", 30, 34], ["serum", "ANATOMY", 64, 69], ["acute infection", "DISEASE", 121, 136], ["lung", "ORGAN", 30, 34], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["cytokine", "PROTEIN", 70, 78], ["significant differences in lung parasite load", "PROBLEM", 3, 48], ["serum cytokine concentrations", "TEST", 64, 93], ["acute infection", "PROBLEM", 121, 136], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26], ["lung", "ANATOMY", 30, 34], ["parasite load", "OBSERVATION", 35, 48], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["infection", "OBSERVATION", 127, 136]]], ["Thus a lack of AMCase does not lead to deficient immune responses early on during infection in the periphery.", [["infection", "DISEASE", 82, 91], ["AMCase", "GENE_OR_GENE_PRODUCT", 15, 21], ["AMCase", "PROTEIN", 15, 21], ["deficient immune responses", "PROBLEM", 39, 65], ["infection in the periphery", "PROBLEM", 82, 108], ["infection", "OBSERVATION", 82, 91], ["periphery", "ANATOMY_MODIFIER", 99, 108]]], ["At 5 weeks post infection, when systemic inflammation has been controlled and parasites are located solely in the brain predominantly as cysts containing bradyzoites [67], [70] parasite burden was evaluated.", [["brain", "ANATOMY", 114, 119], ["cysts", "ANATOMY", 137, 142], ["infection", "DISEASE", 16, 25], ["inflammation", "DISEASE", 41, 53], ["brain", "ORGAN", 114, 119], ["infection", "PROBLEM", 16, 25], ["systemic inflammation", "PROBLEM", 32, 53], ["parasites", "PROBLEM", 78, 87], ["cysts containing bradyzoites", "PROBLEM", 137, 165], ["parasite burden", "PROBLEM", 177, 192], ["infection", "OBSERVATION", 16, 25], ["systemic", "OBSERVATION_MODIFIER", 32, 40], ["inflammation", "OBSERVATION", 41, 53], ["parasites", "OBSERVATION_MODIFIER", 78, 87], ["brain", "ANATOMY", 114, 119], ["predominantly", "OBSERVATION_MODIFIER", 120, 133], ["cysts", "OBSERVATION", 137, 142], ["bradyzoites", "OBSERVATION_MODIFIER", 154, 165]]], ["In the absence of AMCase, there was a significant increase (p = 0.0014) of approximately 2-fold in the total number but not the size of cysts in the brain (Figures 6G and 6H).", [["cysts", "ANATOMY", 136, 141], ["brain", "ANATOMY", 149, 154], ["cysts", "DISEASE", 136, 141], ["AMCase", "GENE_OR_GENE_PRODUCT", 18, 24], ["cysts", "PATHOLOGICAL_FORMATION", 136, 141], ["brain", "ORGAN", 149, 154], ["AMCase", "PROTEIN", 18, 24], ["a significant increase", "PROBLEM", 36, 58], ["cysts in the brain", "PROBLEM", 136, 154], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["total number", "OBSERVATION_MODIFIER", 103, 115], ["size", "OBSERVATION_MODIFIER", 128, 132], ["cysts", "OBSERVATION", 136, 141], ["brain", "ANATOMY", 149, 154]]], ["Differences in cyst burden were not observed at 3 weeks post infection (Figure S6), a period representing the transition between acute and chronic infection, further suggesting that the increase in cyst burden is occurring due to events within the CNS during chronic infection.", [["cyst", "ANATOMY", 15, 19], ["cyst", "ANATOMY", 198, 202], ["CNS", "ANATOMY", 248, 251], ["infection", "DISEASE", 61, 70], ["infection", "DISEASE", 147, 156], ["chronic infection", "DISEASE", 259, 276], ["cyst", "CANCER", 15, 19], ["cyst", "CANCER", 198, 202], ["CNS", "ANATOMICAL_SYSTEM", 248, 251], ["cyst burden", "PROBLEM", 15, 26], ["infection", "PROBLEM", 61, 70], ["acute and chronic infection", "PROBLEM", 129, 156], ["cyst burden", "PROBLEM", 198, 209], ["chronic infection", "PROBLEM", 259, 276], ["cyst", "OBSERVATION", 15, 19], ["infection", "OBSERVATION", 61, 70], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["chronic", "OBSERVATION_MODIFIER", 139, 146], ["infection", "OBSERVATION", 147, 156], ["increase", "OBSERVATION_MODIFIER", 186, 194], ["cyst", "OBSERVATION", 198, 202], ["CNS", "ANATOMY", 248, 251], ["chronic", "OBSERVATION_MODIFIER", 259, 266], ["infection", "OBSERVATION", 267, 276]]], ["In addition, total parasite burden in the CNS as measured by qPCR was significantly greater by more than 2-fold (p = 0.0055) (Figure 6I) correlating with the appearance of more cysts histologically (Figure 6J).", [["CNS", "ANATOMY", 42, 45], ["cysts", "ANATOMY", 177, 182], ["cysts", "DISEASE", 177, 182], ["CNS", "ANATOMICAL_SYSTEM", 42, 45], ["total parasite burden in the CNS", "PROBLEM", 13, 45], ["qPCR", "TEST", 61, 65], ["more cysts histologically", "PROBLEM", 172, 197], ["total", "OBSERVATION_MODIFIER", 13, 18], ["parasite", "OBSERVATION_MODIFIER", 19, 27], ["burden", "OBSERVATION", 28, 34], ["CNS", "ANATOMY", 42, 45], ["significantly", "OBSERVATION_MODIFIER", 70, 83], ["greater", "OBSERVATION_MODIFIER", 84, 91], ["more", "OBSERVATION_MODIFIER", 172, 176], ["cysts", "OBSERVATION", 177, 182]]], ["In addition, parasite burden was evaluated using RT-qPCR with stage-specific primers identifying tachyzoite (SAG1), bradyzoite (SAG4), and cyst (MAG1) specific transcripts .", [["tachyzoite", "GENE_OR_GENE_PRODUCT", 97, 107], ["SAG1", "GENE_OR_GENE_PRODUCT", 109, 113], ["bradyzoite", "GENE_OR_GENE_PRODUCT", 116, 126], ["SAG4", "GENE_OR_GENE_PRODUCT", 128, 132], ["tachyzoite (SAG1), bradyzoite (SAG4), and cyst (MAG1) specific transcripts", "RNA", 97, 171], ["parasite burden", "PROBLEM", 13, 28], ["RT-qPCR", "TEST", 49, 56], ["stage-specific primers", "PROBLEM", 62, 84], ["cyst", "PROBLEM", 139, 143], ["parasite", "OBSERVATION_MODIFIER", 13, 21], ["burden", "OBSERVATION", 22, 28], ["cyst", "OBSERVATION", 139, 143]]], ["Our results show similar increases in parasite burden for all three transcripts, suggesting that cyst lysis is also an important mechanism to control the cell invasive forms of the parasite.", [["cyst", "ANATOMY", 97, 101], ["cell", "ANATOMY", 154, 158], ["cell", "CELL", 154, 158], ["parasite burden", "PROBLEM", 38, 53], ["cyst lysis", "PROBLEM", 97, 107], ["similar", "OBSERVATION_MODIFIER", 17, 24], ["increases", "OBSERVATION_MODIFIER", 25, 34], ["parasite", "OBSERVATION_MODIFIER", 38, 46], ["burden", "OBSERVATION_MODIFIER", 47, 53], ["cyst", "OBSERVATION", 97, 101]]], ["Flow cytometric analysis revealed no differences in infiltrating CD4+, CD8+ T cells, or macrophage populations (Figure 6K).", [["infiltrating CD4+, CD8+ T cells", "ANATOMY", 52, 83], ["macrophage", "ANATOMY", 88, 98], ["CD4", "GENE_OR_GENE_PRODUCT", 65, 68], ["CD8", "GENE_OR_GENE_PRODUCT", 71, 74], ["CD4", "PROTEIN", 65, 68], ["CD8", "PROTEIN", 71, 74], ["T cells", "CELL_TYPE", 76, 83], ["macrophage populations", "CELL_TYPE", 88, 110], ["Flow cytometric analysis", "TEST", 0, 24], ["infiltrating CD4", "TEST", 52, 68], ["CD8", "TEST", 71, 74], ["macrophage populations", "PROBLEM", 88, 110], ["no", "UNCERTAINTY", 34, 36], ["infiltrating", "OBSERVATION_MODIFIER", 52, 64], ["CD4", "OBSERVATION", 65, 68], ["macrophage", "OBSERVATION_MODIFIER", 88, 98]]], ["Therefore, the increase in parasite burden is not due to a defect in infiltrating effector immune cells.", [["immune cells", "ANATOMY", 91, 103], ["infiltrating effector immune cells", "CELL", 69, 103], ["infiltrating effector immune cells", "CELL_TYPE", 69, 103], ["the increase in parasite burden", "PROBLEM", 11, 42], ["a defect in infiltrating effector immune cells", "PROBLEM", 57, 103], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["parasite burden", "OBSERVATION", 27, 42], ["not due to", "UNCERTAINTY", 46, 56], ["defect", "OBSERVATION", 59, 65], ["infiltrating effector immune cells", "OBSERVATION", 69, 103]]], ["Furthermore, AMCase\u2212/\u2212 mice failed to survive and succumbed to infection beginning at six weeks (p = 0.0177) (Figure 6L).", [["infection", "DISEASE", 63, 72], ["AMCase\u2212", "GENE_OR_GENE_PRODUCT", 13, 20], ["AMCase\u2212", "PROTEIN", 13, 20], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["infection", "PROBLEM", 63, 72], ["infection", "OBSERVATION", 63, 72]]], ["Although some acute mortality was noted over several experiments significance was only achieved when chronic mortality was included.", [["some acute mortality", "PROBLEM", 9, 29], ["chronic mortality", "PROBLEM", 101, 118], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["mortality", "OBSERVATION", 20, 29]]], ["These results demonstrate that AMCase activity is required for the protective immune response to T. gondii during chronic infection in the brain and that AMCase mediated cyst lysis in the CNS is a beneficial mechanism for the host to control parasite burden at non-lethal levels.DiscussionChronic infections represent a continuous battle between the host's immune system and pathogen replication.", [["brain", "ANATOMY", 139, 144], ["cyst", "ANATOMY", 170, 174], ["CNS", "ANATOMY", 188, 191], ["chronic infection", "DISEASE", 114, 131], ["Chronic infections", "DISEASE", 289, 307], ["AMCase", "GENE_OR_GENE_PRODUCT", 31, 37], ["T. gondii", "ORGANISM", 97, 106], ["brain", "ORGAN", 139, 144], ["AMCase", "GENE_OR_GENE_PRODUCT", 154, 160], ["CNS", "ANATOMICAL_SYSTEM", 188, 191], ["immune system", "ANATOMICAL_SYSTEM", 357, 370], ["AMCase", "PROTEIN", 31, 37], ["T. gondii", "SPECIES", 97, 106], ["T. gondii", "SPECIES", 97, 106], ["T. gondii", "PROBLEM", 97, 106], ["chronic infection in the brain", "PROBLEM", 114, 144], ["AMCase mediated cyst lysis", "TREATMENT", 154, 180], ["parasite burden at non-lethal levels", "PROBLEM", 242, 278], ["Chronic infections", "PROBLEM", 289, 307], ["the host's immune system", "TREATMENT", 346, 370], ["pathogen replication", "TREATMENT", 375, 395], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["infection", "OBSERVATION", 122, 131], ["brain", "ANATOMY", 139, 144], ["cyst", "OBSERVATION", 170, 174], ["CNS", "ANATOMY", 188, 191], ["Chronic", "OBSERVATION_MODIFIER", 289, 296], ["infections", "OBSERVATION", 297, 307]]], ["Many protozoan parasites and fungal pathogens have evolved a cyst lifecycle stage that provides it with increased protection from environmental degradation as well as endogenous host mechanisms of attack [72]\u2013[74].", [["cyst", "ANATOMY", 61, 65], ["protozoan parasites", "DISEASE", 5, 24], ["Many protozoan parasites", "PROBLEM", 0, 24], ["fungal pathogens", "PROBLEM", 29, 45], ["a cyst lifecycle stage", "PROBLEM", 59, 81], ["environmental degradation", "PROBLEM", 130, 155], ["protozoan", "OBSERVATION_MODIFIER", 5, 14], ["parasites", "OBSERVATION", 15, 24], ["fungal pathogens", "OBSERVATION", 29, 45], ["cyst", "OBSERVATION", 61, 65], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["protection", "OBSERVATION", 114, 124], ["environmental degradation", "OBSERVATION", 130, 155]]], ["In the case of Toxoplasma, these cysts are predominantly found in the immune protected brain making clearance of the parasite more difficult and resulting in a lifelong infection.", [["cysts", "ANATOMY", 33, 38], ["brain", "ANATOMY", 87, 92], ["Toxoplasma", "DISEASE", 15, 25], ["infection", "DISEASE", 169, 178], ["Toxoplasma", "ORGANISM", 15, 25], ["cysts", "PATHOLOGICAL_FORMATION", 33, 38], ["brain", "ORGAN", 87, 92], ["Toxoplasma", "SPECIES", 15, 25], ["Toxoplasma", "PROBLEM", 15, 25], ["these cysts", "PROBLEM", 27, 38], ["the parasite", "PROBLEM", 113, 125], ["a lifelong infection", "PROBLEM", 158, 178], ["Toxoplasma", "OBSERVATION", 15, 25], ["cysts", "OBSERVATION", 33, 38], ["lifelong", "OBSERVATION_MODIFIER", 160, 168], ["infection", "OBSERVATION", 169, 178]]], ["Here we describe three novel findings 1) despite a dominant Th1 immune response during Toxoplasma infection there exists a population of macrophages in the infected brain which display a distinct alternatively activated phenotype; 2) these cells are responsible for chitinase dependent lysis of Toxoplasma cysts and 3) this chitinase activity is through the production of AMCase which is required for protective immune responses.DiscussionMultiple studies have demonstrated the role of CXCR3 and its ligands in the migration of activated T cells during Th1 immune responses including to sites of infection [75], [76].", [["macrophages", "ANATOMY", 137, 148], ["brain", "ANATOMY", 165, 170], ["cells", "ANATOMY", 240, 245], ["cysts", "ANATOMY", 306, 311], ["T cells", "ANATOMY", 538, 545], ["sites", "ANATOMY", 587, 592], ["Toxoplasma infection", "DISEASE", 87, 107], ["Toxoplasma cysts", "DISEASE", 295, 311], ["infection", "DISEASE", 596, 605], ["Th1", "GENE_OR_GENE_PRODUCT", 60, 63], ["Toxoplasma", "ORGANISM", 87, 97], ["macrophages", "CELL", 137, 148], ["brain", "ORGAN", 165, 170], ["cells", "CELL", 240, 245], ["chitinase", "GENE_OR_GENE_PRODUCT", 266, 275], ["Toxoplasma", "ORGANISM", 295, 305], ["cysts", "PATHOLOGICAL_FORMATION", 306, 311], ["chitinase", "GENE_OR_GENE_PRODUCT", 324, 333], ["AMCase", "GENE_OR_GENE_PRODUCT", 372, 378], ["CXCR3", "GENE_OR_GENE_PRODUCT", 486, 491], ["T cells", "CELL", 538, 545], ["Th1", "CELL", 553, 556], ["macrophages", "CELL_TYPE", 137, 148], ["chitinase", "PROTEIN", 266, 275], ["chitinase", "PROTEIN", 324, 333], ["AMCase", "PROTEIN", 372, 378], ["CXCR3", "PROTEIN", 486, 491], ["activated T cells", "CELL_TYPE", 528, 545], ["Toxoplasma", "SPECIES", 87, 97], ["a dominant Th1 immune response", "PROBLEM", 49, 79], ["Toxoplasma infection", "PROBLEM", 87, 107], ["macrophages in the infected brain", "PROBLEM", 137, 170], ["a distinct alternatively activated phenotype", "PROBLEM", 185, 229], ["these cells", "PROBLEM", 234, 245], ["chitinase dependent lysis", "TREATMENT", 266, 291], ["Toxoplasma cysts", "PROBLEM", 295, 311], ["this chitinase activity", "PROBLEM", 319, 342], ["DiscussionMultiple studies", "TEST", 429, 455], ["CXCR3", "TEST", 486, 491], ["activated T cells", "TREATMENT", 528, 545], ["infection", "PROBLEM", 596, 605], ["Toxoplasma infection", "OBSERVATION", 87, 107], ["population", "OBSERVATION_MODIFIER", 123, 133], ["macrophages", "OBSERVATION", 137, 148], ["infected brain", "ANATOMY", 156, 170], ["distinct", "OBSERVATION_MODIFIER", 187, 195], ["Toxoplasma cysts", "OBSERVATION", 295, 311], ["infection", "OBSERVATION", 596, 605]]], ["It is also known that the chemokines CXCL9 and CXCL10 are induced by the presence of the proinflammatory cytokine, IFN-\u03b3 [34], [36], [37], [77].", [["CXCL9", "GENE_OR_GENE_PRODUCT", 37, 42], ["CXCL10", "GENE_OR_GENE_PRODUCT", 47, 53], ["[36]", "SIMPLE_CHEMICAL", 127, 131], ["[37]", "SIMPLE_CHEMICAL", 133, 137], ["chemokines", "PROTEIN", 26, 36], ["CXCL9", "PROTEIN", 37, 42], ["CXCL10", "PROTEIN", 47, 53], ["proinflammatory cytokine", "PROTEIN", 89, 113], ["IFN", "PROTEIN", 115, 118], ["the chemokines CXCL9", "TEST", 22, 42], ["CXCL10", "TEST", 47, 53], ["the proinflammatory cytokine", "TEST", 85, 113], ["IFN", "TEST", 115, 118], ["proinflammatory cytokine", "OBSERVATION", 89, 113]]], ["More recently, however, the function of this family of chemokines has expanded to include neural-glial signaling following brain lesion where injured neurons upregulate CXCL10 and recruit CXCR3 expressing microglia to phagocytose denervated dendrites [33].", [["neural-glial", "ANATOMY", 90, 102], ["brain lesion", "ANATOMY", 123, 135], ["neurons", "ANATOMY", 150, 157], ["microglia", "ANATOMY", 205, 214], ["dendrites", "ANATOMY", 241, 250], ["glial", "CELL", 97, 102], ["brain", "ORGAN", 123, 128], ["neurons", "CELL", 150, 157], ["CXCL10", "GENE_OR_GENE_PRODUCT", 169, 175], ["CXCR3", "GENE_OR_GENE_PRODUCT", 188, 193], ["microglia", "CELL", 205, 214], ["chemokines", "PROTEIN", 55, 65], ["injured neurons", "CELL_TYPE", 142, 157], ["CXCL10", "PROTEIN", 169, 175], ["CXCR3", "PROTEIN", 188, 193], ["microglia", "CELL_TYPE", 205, 214], ["brain lesion", "PROBLEM", 123, 135], ["CXCL10", "TEST", 169, 175], ["CXCR3", "TEST", 188, 193], ["brain", "ANATOMY", 123, 128], ["lesion", "OBSERVATION", 129, 135]]], ["Consistent with this, another recent study has implicated CXCR3 in the function of perivascular macrophages and their ability to remodel the vasculature during stress [78].", [["perivascular macrophages", "ANATOMY", 83, 107], ["vasculature", "ANATOMY", 141, 152], ["CXCR3", "GENE_OR_GENE_PRODUCT", 58, 63], ["perivascular macrophages", "CELL", 83, 107], ["vasculature", "MULTI-TISSUE_STRUCTURE", 141, 152], ["CXCR3", "PROTEIN", 58, 63], ["perivascular macrophages", "CELL_TYPE", 83, 107], ["another recent study", "TEST", 22, 42], ["CXCR3", "TEST", 58, 63], ["perivascular", "ANATOMY_MODIFIER", 83, 95], ["macrophages", "OBSERVATION", 96, 107], ["vasculature", "ANATOMY", 141, 152]]], ["We noted upregulation of CXCR3, CXCL9 and CXCL10 in the brain during chronic Toxoplasma infection.", [["brain", "ANATOMY", 56, 61], ["Toxoplasma infection", "DISEASE", 77, 97], ["CXCR3", "GENE_OR_GENE_PRODUCT", 25, 30], ["CXCL9", "GENE_OR_GENE_PRODUCT", 32, 37], ["CXCL10", "GENE_OR_GENE_PRODUCT", 42, 48], ["brain", "ORGAN", 56, 61], ["Toxoplasma", "ORGANISM", 77, 87], ["CXCR3", "PROTEIN", 25, 30], ["CXCL9", "PROTEIN", 32, 37], ["CXCL10", "PROTEIN", 42, 48], ["Toxoplasma", "SPECIES", 77, 87], ["CXCR3", "TEST", 25, 30], ["CXCL9", "TEST", 32, 37], ["CXCL10", "TEST", 42, 48], ["chronic Toxoplasma infection", "PROBLEM", 69, 97], ["CXCR3", "ANATOMY", 25, 30], ["brain", "ANATOMY", 56, 61], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["Toxoplasma infection", "OBSERVATION", 77, 97]]], ["Furthermore, CXCR3 was preferentially expressed on macrophages expressing the scavenger receptors MMR and stabilin-1, suggesting an alternatively activated phenotype for these cells.", [["macrophages", "ANATOMY", 51, 62], ["cells", "ANATOMY", 176, 181], ["CXCR3", "GENE_OR_GENE_PRODUCT", 13, 18], ["macrophages", "CELL", 51, 62], ["MMR", "GENE_OR_GENE_PRODUCT", 98, 101], ["stabilin-1", "GENE_OR_GENE_PRODUCT", 106, 116], ["cells", "CELL", 176, 181], ["CXCR3", "PROTEIN", 13, 18], ["macrophages", "CELL_TYPE", 51, 62], ["scavenger receptors", "PROTEIN", 78, 97], ["MMR", "PROTEIN", 98, 101], ["stabilin-1", "PROTEIN", 106, 116], ["CXCR3", "TEST", 13, 18], ["the scavenger receptors MMR", "TEST", 74, 101], ["stabilin", "TEST", 106, 114], ["an alternatively activated phenotype for these cells", "PROBLEM", 129, 181], ["activated phenotype", "OBSERVATION", 146, 165]]], ["Previous studies have established important functions of AAM\u00d8 in the context of helminth infection and wound healing [43], [79], [80] however not during an infection that generates such a polarized Th1 immune response such as Toxoplasma.", [["wound", "ANATOMY", 103, 108], ["helminth infection", "DISEASE", 80, 98], ["infection", "DISEASE", 156, 165], ["AAM\u00d8", "GENE_OR_GENE_PRODUCT", 57, 61], ["wound", "PATHOLOGICAL_FORMATION", 103, 108], ["Toxoplasma", "ORGANISM", 226, 236], ["AAM\u00d8", "PROTEIN", 57, 61], ["Previous studies", "TEST", 0, 16], ["helminth infection", "PROBLEM", 80, 98], ["wound healing", "PROBLEM", 103, 116], ["an infection", "PROBLEM", 153, 165], ["Toxoplasma", "PROBLEM", 226, 236], ["helminth", "OBSERVATION_MODIFIER", 80, 88], ["infection", "OBSERVATION", 89, 98], ["infection", "OBSERVATION", 156, 165]]], ["T. gondii is known to exploit the arginine metabolic pathway and induce arginase-1 expression in macrophages thereby suppressing nitric oxide production but this does not lead to the alternative activation of these cells [46]\u2013[48].", [["macrophages", "ANATOMY", 97, 108], ["cells", "ANATOMY", 215, 220], ["arginine", "CHEMICAL", 34, 42], ["nitric oxide", "CHEMICAL", 129, 141], ["arginine", "CHEMICAL", 34, 42], ["nitric oxide", "CHEMICAL", 129, 141], ["T. gondii", "ORGANISM", 0, 9], ["arginine", "SIMPLE_CHEMICAL", 34, 42], ["arginase-1", "GENE_OR_GENE_PRODUCT", 72, 82], ["macrophages", "CELL", 97, 108], ["nitric oxide", "SIMPLE_CHEMICAL", 129, 141], ["cells", "CELL", 215, 220], ["arginase-1", "PROTEIN", 72, 82], ["macrophages", "CELL_TYPE", 97, 108], ["T. gondii", "SPECIES", 0, 9], ["T. gondii", "SPECIES", 0, 9], ["the arginine metabolic pathway", "TREATMENT", 30, 60], ["arginase", "TEST", 72, 80], ["suppressing nitric oxide production", "TREATMENT", 117, 152]]], ["Instead our data point to a role for the cyst being the source of alternative activation of macrophages and the subsequent ability of these cells to lyse cysts via destruction of the chitin in the cyst wall.", [["cyst", "ANATOMY", 41, 45], ["macrophages", "ANATOMY", 92, 103], ["cells", "ANATOMY", 140, 145], ["cysts", "ANATOMY", 154, 159], ["cyst wall", "ANATOMY", 197, 206], ["cysts", "DISEASE", 154, 159], ["cyst", "CANCER", 41, 45], ["macrophages", "CELL", 92, 103], ["cells", "CELL", 140, 145], ["chitin", "GENE_OR_GENE_PRODUCT", 183, 189], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 197, 206], ["macrophages", "CELL_TYPE", 92, 103], ["chitin", "PROTEIN", 183, 189], ["the cyst", "PROBLEM", 37, 45], ["macrophages", "PROBLEM", 92, 103], ["these cells", "PROBLEM", 134, 145], ["lyse cysts", "PROBLEM", 149, 159], ["destruction of the chitin in the cyst wall", "PROBLEM", 164, 206], ["cyst", "OBSERVATION", 41, 45], ["macrophages", "OBSERVATION", 92, 103], ["destruction", "OBSERVATION", 164, 175], ["chitin", "OBSERVATION_MODIFIER", 183, 189], ["cyst", "OBSERVATION", 197, 201], ["wall", "ANATOMY_MODIFIER", 202, 206]]], ["Thus, we observed a contact dependent significant increase in arginase activity following treatment with cysts and cystAg suggesting that this induction is not a result of infection by the replicating parasite, but rather by the presence of chitin in the cyst wall.", [["cysts", "ANATOMY", 105, 110], ["cyst wall", "ANATOMY", 255, 264], ["infection", "DISEASE", 172, 181], ["arginase", "GENE_OR_GENE_PRODUCT", 62, 70], ["cysts", "PATHOLOGICAL_FORMATION", 105, 110], ["cystAg", "GENE_OR_GENE_PRODUCT", 115, 121], ["chitin", "GENE_OR_GENE_PRODUCT", 241, 247], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 255, 264], ["arginase", "PROTEIN", 62, 70], ["chitin", "PROTEIN", 241, 247], ["a contact dependent significant increase in arginase activity", "PROBLEM", 18, 79], ["treatment", "TREATMENT", 90, 99], ["cysts", "PROBLEM", 105, 110], ["cystAg", "TREATMENT", 115, 121], ["infection", "PROBLEM", 172, 181], ["chitin in the cyst wall", "PROBLEM", 241, 264], ["contact dependent", "OBSERVATION_MODIFIER", 20, 37], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["arginase activity", "OBSERVATION", 62, 79], ["cysts", "OBSERVATION", 105, 110], ["infection", "OBSERVATION", 172, 181], ["parasite", "OBSERVATION_MODIFIER", 201, 209], ["cyst", "OBSERVATION", 255, 259], ["wall", "ANATOMY_MODIFIER", 260, 264]]], ["The weak induction of arginase activity observed also points to a limited role for arginase-1 in the chitin-induced phenotype.DiscussionChitin is found in the exoskeletons of insects, fungal cell walls, sheaths of parasitic nematodes, and is a component of the T. gondii cyst wall [49], [50].", [["cell walls", "ANATOMY", 191, 201], ["sheaths", "ANATOMY", 203, 210], ["chitin", "CHEMICAL", 101, 107], ["DiscussionChitin", "CHEMICAL", 126, 142], ["parasitic nematodes", "DISEASE", 214, 233], ["arginase", "GENE_OR_GENE_PRODUCT", 22, 30], ["arginase-1", "GENE_OR_GENE_PRODUCT", 83, 93], ["chitin", "SIMPLE_CHEMICAL", 101, 107], ["DiscussionChitin", "GENE_OR_GENE_PRODUCT", 126, 142], ["fungal cell walls", "TISSUE", 184, 201], ["sheaths", "TISSUE", 203, 210], ["T. gondii", "ORGANISM", 261, 270], ["arginase", "PROTEIN", 22, 30], ["arginase-1", "PROTEIN", 83, 93], ["chitin", "PROTEIN", 101, 107], ["T. gondii", "SPECIES", 261, 270], ["T. gondii", "SPECIES", 261, 270], ["arginase activity", "PROBLEM", 22, 39], ["arginase", "TEST", 83, 91], ["fungal cell walls", "PROBLEM", 184, 201], ["parasitic nematodes", "PROBLEM", 214, 233], ["the T. gondii cyst wall", "PROBLEM", 257, 280], ["weak", "OBSERVATION_MODIFIER", 4, 8], ["arginase activity", "OBSERVATION", 22, 39], ["fungal cell walls", "OBSERVATION", 184, 201], ["sheaths", "OBSERVATION_MODIFIER", 203, 210], ["parasitic nematodes", "OBSERVATION", 214, 233], ["gondii cyst", "OBSERVATION", 264, 275], ["wall", "ANATOMY_MODIFIER", 276, 280]]], ["The presence of this exogenous molecule can induce the recruitment of AAM\u00d8, basophils, neutrophils, and eosinophils [52], [81]\u2013[84].", [["AAM\u00d8", "ANATOMY", 70, 74], ["basophils", "ANATOMY", 76, 85], ["neutrophils", "ANATOMY", 87, 98], ["eosinophils", "ANATOMY", 104, 115], ["AAM\u00d8", "GENE_OR_GENE_PRODUCT", 70, 74], ["basophils", "CELL", 76, 85], ["neutrophils", "CELL", 87, 98], ["eosinophils", "CELL", 104, 115], ["AAM\u00d8", "PROTEIN", 70, 74], ["basophils", "CELL_TYPE", 76, 85], ["neutrophils", "CELL_TYPE", 87, 98], ["eosinophils", "CELL_TYPE", 104, 115], ["this exogenous molecule", "PROBLEM", 16, 39], ["basophils", "TEST", 76, 85], ["neutrophils", "TEST", 87, 98], ["eosinophils", "TEST", 104, 115], ["exogenous molecule", "OBSERVATION", 21, 39]]], ["Active chitinases such as AMCase and chitotriosidase are secreted by macrophages in response to chitin-containing pathogens and has been shown to inhibit hyphal growth of chitinous fungi such as Candida and Aspergillus[56], [58].", [["macrophages", "ANATOMY", 69, 80], ["hyphal", "ANATOMY", 154, 160], ["chitin", "CHEMICAL", 96, 102], ["chitinases", "GENE_OR_GENE_PRODUCT", 7, 17], ["AMCase", "GENE_OR_GENE_PRODUCT", 26, 32], ["chitotriosidase", "GENE_OR_GENE_PRODUCT", 37, 52], ["macrophages", "CELL", 69, 80], ["chitin", "SIMPLE_CHEMICAL", 96, 102], ["chitinases", "PROTEIN", 7, 17], ["AMCase", "PROTEIN", 26, 32], ["chitotriosidase", "PROTEIN", 37, 52], ["macrophages", "CELL_TYPE", 69, 80], ["Active chitinases", "PROBLEM", 0, 17], ["chitotriosidase", "PROBLEM", 37, 52], ["chitin", "TREATMENT", 96, 102], ["pathogens", "PROBLEM", 114, 123], ["hyphal growth of chitinous fungi", "PROBLEM", 154, 186], ["Candida", "PROBLEM", 195, 202], ["Aspergillus", "PROBLEM", 207, 218]]], ["Despite the link between chitin and the recruitment of type 2 inflammation in the lung [52], a recent study has demonstrated no role for AMCase in the generation of allergic airway pathology [85].", [["lung", "ANATOMY", 82, 86], ["airway", "ANATOMY", 174, 180], ["inflammation", "DISEASE", 62, 74], ["allergic airway pathology", "DISEASE", 165, 190], ["chitin", "GENE_OR_GENE_PRODUCT", 25, 31], ["lung", "ORGAN", 82, 86], ["AMCase", "GENE_OR_GENE_PRODUCT", 137, 143], ["airway", "ORGAN", 174, 180], ["AMCase", "PROTEIN", 137, 143], ["chitin", "TREATMENT", 25, 31], ["type 2 inflammation in the lung", "PROBLEM", 55, 86], ["a recent study", "TEST", 93, 107], ["AMCase", "PROBLEM", 137, 143], ["allergic airway pathology", "PROBLEM", 165, 190], ["recruitment", "OBSERVATION_MODIFIER", 40, 51], ["inflammation", "OBSERVATION", 62, 74], ["lung", "ANATOMY", 82, 86], ["no role for", "UNCERTAINTY", 125, 136], ["airway", "ANATOMY", 174, 180]]], ["In this study we demonstrate for the first time, macrophage chitinase activity in response to a protozoan pathogen.", [["macrophage chitinase", "GENE_OR_GENE_PRODUCT", 49, 69], ["macrophage chitinase", "PROTEIN", 49, 69], ["this study", "TEST", 3, 13], ["macrophage chitinase activity", "PROBLEM", 49, 78], ["a protozoan pathogen", "PROBLEM", 94, 114]]], ["Chitin recognition is thought to be a size dependent process and involve a combination of TLR2 and scavenger receptors such as MMR and dectin-1 [49], [58].", [["Chitin", "GENE_OR_GENE_PRODUCT", 0, 6], ["TLR2", "GENE_OR_GENE_PRODUCT", 90, 94], ["MMR", "GENE_OR_GENE_PRODUCT", 127, 130], ["dectin-1", "GENE_OR_GENE_PRODUCT", 135, 143], ["TLR2", "PROTEIN", 90, 94], ["scavenger receptors", "PROTEIN", 99, 118], ["MMR", "PROTEIN", 127, 130], ["dectin-1", "PROTEIN", 135, 143], ["Chitin recognition", "PROBLEM", 0, 18], ["a size dependent process", "PROBLEM", 36, 60], ["TLR2 and scavenger receptors", "TREATMENT", 90, 118], ["MMR", "TEST", 127, 130], ["thought to be", "UNCERTAINTY", 22, 35], ["size", "OBSERVATION_MODIFIER", 38, 42], ["dependent", "OBSERVATION", 43, 52]]], ["Here we have demonstrated the presence of such scavenger receptors in association with cysts and it will be of interest in future studies to determine the role of these molecules in cyst containment during Toxoplasma infection.", [["cysts", "ANATOMY", 87, 92], ["cyst", "ANATOMY", 182, 186], ["Toxoplasma infection", "DISEASE", 206, 226], ["cyst", "CANCER", 182, 186], ["Toxoplasma", "ORGANISM", 206, 216], ["scavenger receptors", "PROTEIN", 47, 66], ["Toxoplasma", "SPECIES", 206, 216], ["such scavenger receptors", "PROBLEM", 42, 66], ["cysts", "PROBLEM", 87, 92], ["future studies", "TEST", 123, 137], ["cyst containment", "PROBLEM", 182, 198], ["Toxoplasma infection", "PROBLEM", 206, 226], ["scavenger receptors", "OBSERVATION", 47, 66], ["cysts", "OBSERVATION", 87, 92], ["cyst", "OBSERVATION", 182, 186], ["Toxoplasma infection", "OBSERVATION", 206, 226]]], ["Independent of the receptors involved it is likely that this is a contact-dependent process and indeed, cysts were unable to induce urea production or chitinase activity in macrophages when separated by transwell membranes.", [["cysts", "ANATOMY", 104, 109], ["macrophages", "ANATOMY", 173, 184], ["transwell membranes", "ANATOMY", 203, 222], ["urea", "CHEMICAL", 132, 136], ["urea", "CHEMICAL", 132, 136], ["urea", "SIMPLE_CHEMICAL", 132, 136], ["chitinase", "GENE_OR_GENE_PRODUCT", 151, 160], ["macrophages", "CELL", 173, 184], ["transwell membranes", "CELLULAR_COMPONENT", 203, 222], ["chitinase", "PROTEIN", 151, 160], ["macrophages", "CELL_TYPE", 173, 184], ["a contact-dependent process", "PROBLEM", 64, 91], ["cysts", "PROBLEM", 104, 109], ["urea production", "PROBLEM", 132, 147], ["chitinase activity in macrophages", "PROBLEM", 151, 184], ["cysts", "OBSERVATION", 104, 109], ["transwell membranes", "OBSERVATION", 203, 222]]], ["Furthermore, analysis of the location of AMCase producing cells in the brain finds them reliably close to cysts and often in direct contact with reactivating or rupturing cysts.", [["cells", "ANATOMY", 58, 63], ["brain", "ANATOMY", 71, 76], ["cysts", "ANATOMY", 106, 111], ["cysts", "ANATOMY", 171, 176], ["cysts", "DISEASE", 106, 111], ["AMCase", "GENE_OR_GENE_PRODUCT", 41, 47], ["cells", "CELL", 58, 63], ["brain", "ORGAN", 71, 76], ["cysts", "CANCER", 106, 111], ["cysts", "PATHOLOGICAL_FORMATION", 171, 176], ["AMCase producing cells", "CELL_TYPE", 41, 63], ["analysis", "TEST", 13, 21], ["AMCase producing cells in the brain", "PROBLEM", 41, 76], ["cysts", "PROBLEM", 106, 111], ["rupturing cysts", "PROBLEM", 161, 176], ["brain", "ANATOMY", 71, 76], ["cysts", "OBSERVATION", 106, 111], ["rupturing", "OBSERVATION_MODIFIER", 161, 170], ["cysts", "OBSERVATION", 171, 176]]], ["These images show that despite the presence of many DAPI positive cells surrounding the cyst structure, the escape of parasites through the cyst wall occurs juxtaposed to the macrophage or AMCase activity.", [["cells", "ANATOMY", 66, 71], ["cyst structure", "ANATOMY", 88, 102], ["cyst wall", "ANATOMY", 140, 149], ["macrophage", "ANATOMY", 175, 185], ["DAPI", "CHEMICAL", 52, 56], ["DAPI", "GENE_OR_GENE_PRODUCT", 52, 56], ["cells", "CELL", 66, 71], ["cyst", "PATHOLOGICAL_FORMATION", 88, 92], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 140, 149], ["macrophage", "CELL", 175, 185], ["AMCase", "GENE_OR_GENE_PRODUCT", 189, 195], ["DAPI positive cells", "CELL_TYPE", 52, 71], ["AMCase", "PROTEIN", 189, 195], ["These images", "TEST", 0, 12], ["many DAPI positive cells", "PROBLEM", 47, 71], ["the cyst structure", "PROBLEM", 84, 102], ["the cyst wall", "PROBLEM", 136, 149], ["many", "OBSERVATION_MODIFIER", 47, 51], ["DAPI positive cells", "OBSERVATION", 52, 71], ["cyst", "OBSERVATION", 88, 92], ["escape", "OBSERVATION_MODIFIER", 108, 114], ["parasites", "OBSERVATION_MODIFIER", 118, 127], ["cyst", "OBSERVATION", 140, 144], ["wall", "ANATOMY_MODIFIER", 145, 149], ["macrophage", "OBSERVATION_MODIFIER", 175, 185]]], ["Our data suggest that the presence of cyst antigens induces alternative activation of macrophages and that these antigens are required for macrophages to produce chitinase even in the presence of IL-4.", [["cyst", "ANATOMY", 38, 42], ["macrophages", "ANATOMY", 86, 97], ["macrophages", "ANATOMY", 139, 150], ["cyst antigens", "GENE_OR_GENE_PRODUCT", 38, 51], ["macrophages", "CELL", 86, 97], ["macrophages", "CELL", 139, 150], ["chitinase", "GENE_OR_GENE_PRODUCT", 162, 171], ["IL-4", "GENE_OR_GENE_PRODUCT", 196, 200], ["cyst antigens", "PROTEIN", 38, 51], ["macrophages", "CELL_TYPE", 86, 97], ["macrophages", "CELL_TYPE", 139, 150], ["chitinase", "PROTEIN", 162, 171], ["IL-4", "PROTEIN", 196, 200], ["Our data", "TEST", 0, 8], ["cyst antigens", "PROBLEM", 38, 51], ["macrophages", "PROBLEM", 86, 97], ["these antigens", "PROBLEM", 107, 121], ["macrophages", "PROBLEM", 139, 150], ["chitinase", "PROBLEM", 162, 171], ["cyst", "OBSERVATION", 38, 42]]], ["Thus alternative activation of macrophages is not sufficient for AMCase production and chitinase activity.", [["macrophages", "ANATOMY", 31, 42], ["macrophages", "CELL", 31, 42], ["AMCase", "GENE_OR_GENE_PRODUCT", 65, 71], ["chitinase", "GENE_OR_GENE_PRODUCT", 87, 96], ["macrophages", "CELL_TYPE", 31, 42], ["AMCase", "PROTEIN", 65, 71], ["chitinase", "PROTEIN", 87, 96], ["macrophages", "PROBLEM", 31, 42], ["AMCase production", "PROBLEM", 65, 82], ["macrophages", "OBSERVATION", 31, 42]]], ["The significant increase of the non-enzymatically active chitinase-like molecule YM-1 in infected brains is consistent with previous reports of AMCase and YM-1 being co-expressed specifically in macrophages and not epithelial cells [63].DiscussionLive imaging in vitro demonstrated AMCase dependent degradation of cysts as shown using both a chitinase inhibitor and AMCase\u2212/\u2212 macrophages.", [["brains", "ANATOMY", 98, 104], ["macrophages", "ANATOMY", 195, 206], ["epithelial cells", "ANATOMY", 215, 231], ["cysts", "ANATOMY", 314, 319], ["AMCase\u2212/\u2212 macrophages", "ANATOMY", 366, 387], ["chitinase-like molecule YM-1", "GENE_OR_GENE_PRODUCT", 57, 85], ["brains", "ORGAN", 98, 104], ["AMCase", "GENE_OR_GENE_PRODUCT", 144, 150], ["YM-1", "GENE_OR_GENE_PRODUCT", 155, 159], ["macrophages", "CELL", 195, 206], ["epithelial cells", "CELL", 215, 231], ["AMCase", "SIMPLE_CHEMICAL", 282, 288], ["cysts", "PATHOLOGICAL_FORMATION", 314, 319], ["chitinase", "GENE_OR_GENE_PRODUCT", 342, 351], ["AMCase\u2212/\u2212 macrophages", "CELL", 366, 387], ["chitinase", "PROTEIN", 57, 66], ["AMCase", "PROTEIN", 144, 150], ["macrophages", "CELL_TYPE", 195, 206], ["epithelial cells", "CELL_TYPE", 215, 231], ["chitinase", "PROTEIN", 342, 351], ["AMCase\u2212/\u2212 macrophages", "CELL_LINE", 366, 387], ["the non-enzymatically active chitinase-like molecule YM", "PROBLEM", 28, 83], ["infected brains", "PROBLEM", 89, 104], ["epithelial cells", "PROBLEM", 215, 231], ["DiscussionLive imaging", "TEST", 237, 259], ["AMCase dependent degradation of cysts", "PROBLEM", 282, 319], ["a chitinase inhibitor", "TREATMENT", 340, 361], ["AMCase\u2212/\u2212 macrophages", "TREATMENT", 366, 387], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["active", "OBSERVATION_MODIFIER", 50, 56], ["chitinase", "OBSERVATION_MODIFIER", 57, 66], ["-like molecule YM", "OBSERVATION_MODIFIER", 66, 83], ["infected", "OBSERVATION", 89, 97], ["brains", "ANATOMY", 98, 104], ["consistent with", "UNCERTAINTY", 108, 123], ["macrophages", "ANATOMY", 195, 206], ["not", "UNCERTAINTY", 211, 214], ["epithelial cells", "OBSERVATION", 215, 231], ["cysts", "OBSERVATION", 314, 319], ["macrophages", "ANATOMY", 376, 387]]], ["Although there is no evidence of an active chitinase produced by T. gondii (ToxoDB), the similar cyst survival times observed for AMCase-null macrophages and chitinase-inhibited macrophages exclude the possibility that bradyzoites are the source of enzymatic activity and are breaking out of the cyst.", [["cyst", "ANATOMY", 97, 101], ["macrophages", "ANATOMY", 142, 153], ["macrophages", "ANATOMY", 178, 189], ["cyst", "ANATOMY", 296, 300], ["chitinase", "GENE_OR_GENE_PRODUCT", 43, 52], ["T. gondii", "ORGANISM", 65, 74], ["ToxoDB", "CELL", 76, 82], ["cyst", "CANCER", 97, 101], ["AMCase", "GENE_OR_GENE_PRODUCT", 130, 136], ["chitinase", "GENE_OR_GENE_PRODUCT", 158, 167], ["macrophages", "CELL", 178, 189], ["cyst", "PATHOLOGICAL_FORMATION", 296, 300], ["chitinase", "PROTEIN", 43, 52], ["AMCase-null macrophages", "CELL_LINE", 130, 153], ["chitinase-inhibited macrophages", "CELL_LINE", 158, 189], ["T. gondii", "SPECIES", 65, 74], ["T. gondii", "SPECIES", 65, 74], ["an active chitinase", "PROBLEM", 33, 52], ["T. gondii", "TEST", 65, 74], ["the similar cyst survival", "PROBLEM", 85, 110], ["AMCase", "TEST", 130, 136], ["null macrophages", "PROBLEM", 137, 153], ["chitinase-inhibited macrophages", "PROBLEM", 158, 189], ["bradyzoites", "PROBLEM", 219, 230], ["enzymatic activity", "PROBLEM", 249, 267], ["the cyst", "PROBLEM", 292, 300], ["no evidence of", "UNCERTAINTY", 18, 32], ["active", "OBSERVATION_MODIFIER", 36, 42], ["chitinase", "OBSERVATION", 43, 52], ["cyst", "OBSERVATION", 97, 101], ["macrophages", "OBSERVATION", 142, 153], ["bradyzoites", "OBSERVATION", 219, 230], ["enzymatic activity", "OBSERVATION", 249, 267], ["cyst", "OBSERVATION", 296, 300]]], ["The chitin dependent induction of chitinase activity implies that macrophages have access to the chitin in the cyst wall prior to chitinase-mediated cyst destruction.", [["macrophages", "ANATOMY", 66, 77], ["cyst wall", "ANATOMY", 111, 120], ["cyst", "ANATOMY", 149, 153], ["chitin", "CHEMICAL", 4, 10], ["cyst destruction", "DISEASE", 149, 165], ["chitin", "SIMPLE_CHEMICAL", 4, 10], ["chitinase", "GENE_OR_GENE_PRODUCT", 34, 43], ["macrophages", "CELL", 66, 77], ["chitin", "GENE_OR_GENE_PRODUCT", 97, 103], ["cyst wall", "MULTI-TISSUE_STRUCTURE", 111, 120], ["chitinase", "GENE_OR_GENE_PRODUCT", 130, 139], ["cyst", "PATHOLOGICAL_FORMATION", 149, 153], ["chitinase", "PROTEIN", 34, 43], ["macrophages", "CELL_TYPE", 66, 77], ["chitin", "PROTEIN", 97, 103], ["chitinase", "PROTEIN", 130, 139], ["The chitin dependent induction of chitinase activity", "TREATMENT", 0, 52], ["macrophages", "PROBLEM", 66, 77], ["the chitin", "TREATMENT", 93, 103], ["chitinase-mediated cyst destruction", "PROBLEM", 130, 165], ["chitin dependent", "OBSERVATION_MODIFIER", 4, 20], ["macrophages", "OBSERVATION", 66, 77], ["chitin", "OBSERVATION_MODIFIER", 97, 103], ["cyst", "OBSERVATION", 111, 115], ["wall", "ANATOMY_MODIFIER", 116, 120], ["mediated", "OBSERVATION_MODIFIER", 140, 148], ["cyst", "OBSERVATION", 149, 153]]], ["The prevailing view from ultrastructure studies is that cysts remain intracellular within neurons [15], [86], yet analysis of cyst burden over time shows a reduction in cyst numbers implying some form of effector mechanism in place [16].", [["cysts", "ANATOMY", 56, 61], ["intracellular", "ANATOMY", 69, 82], ["neurons", "ANATOMY", 90, 97], ["cyst", "ANATOMY", 126, 130], ["cyst", "ANATOMY", 169, 173], ["cysts", "PATHOLOGICAL_FORMATION", 56, 61], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["neurons", "CELL", 90, 97], ["cyst", "PATHOLOGICAL_FORMATION", 126, 130], ["cyst", "PATHOLOGICAL_FORMATION", 169, 173], ["ultrastructure studies", "TEST", 25, 47], ["cysts", "PROBLEM", 56, 61], ["cyst burden", "PROBLEM", 126, 137], ["a reduction in cyst numbers", "PROBLEM", 154, 181], ["cysts", "OBSERVATION", 56, 61], ["cyst", "OBSERVATION", 126, 130], ["reduction", "OBSERVATION_MODIFIER", 156, 165], ["cyst", "OBSERVATION", 169, 173], ["effector mechanism", "OBSERVATION", 204, 222]]], ["Several studies have demonstrated perforin dependent control of cyst burden during chronic infection [17], [18].", [["cyst", "ANATOMY", 64, 68], ["chronic infection", "DISEASE", 83, 100], ["perforin", "GENE_OR_GENE_PRODUCT", 34, 42], ["cyst", "ORGAN", 64, 68], ["perforin", "PROTEIN", 34, 42], ["Several studies", "TEST", 0, 15], ["perforin dependent control of cyst burden", "PROBLEM", 34, 75], ["chronic infection", "PROBLEM", 83, 100], ["cyst", "OBSERVATION", 64, 68], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["infection", "OBSERVATION", 91, 100]]], ["We suggest that instead of a direct effect of perforin on cysts, it is most likely that perforin production by CD8+ T cells may initiate this process by lysing the cyst infected cell, thus exposing the cyst wall to chitinase activity from macrophages.", [["cysts", "ANATOMY", 58, 63], ["T cells", "ANATOMY", 116, 123], ["cyst", "ANATOMY", 164, 168], ["cell", "ANATOMY", 178, 182], ["cyst wall", "ANATOMY", 202, 211], ["macrophages", "ANATOMY", 239, 250], ["perforin", "GENE_OR_GENE_PRODUCT", 46, 54], ["cysts", "PATHOLOGICAL_FORMATION", 58, 63], ["perforin", "GENE_OR_GENE_PRODUCT", 88, 96], ["CD8", "GENE_OR_GENE_PRODUCT", 111, 114], ["T cells", "CELL", 116, 123], ["cell", "CELL", 178, 182], ["cyst wall", "TISSUE", 202, 211], ["chitinase", "GENE_OR_GENE_PRODUCT", 215, 224], ["macrophages", "CELL", 239, 250], ["perforin", "PROTEIN", 46, 54], ["perforin", "PROTEIN", 88, 96], ["CD8", "PROTEIN", 111, 114], ["T cells", "CELL_TYPE", 116, 123], ["cyst infected cell", "CELL_TYPE", 164, 182], ["chitinase", "PROTEIN", 215, 224], ["macrophages", "CELL_TYPE", 239, 250], ["perforin on cysts", "PROBLEM", 46, 63], ["T cells", "PROBLEM", 116, 123], ["this process", "PROBLEM", 137, 149], ["the cyst infected cell", "PROBLEM", 160, 182], ["the cyst wall", "PROBLEM", 198, 211], ["cysts", "OBSERVATION", 58, 63], ["most likely", "UNCERTAINTY", 71, 82], ["cyst", "OBSERVATION", 164, 168], ["infected cell", "OBSERVATION", 169, 182], ["cyst", "OBSERVATION", 202, 206], ["chitinase activity", "OBSERVATION", 215, 233], ["macrophages", "OBSERVATION", 239, 250]]], ["This model would explain the many observations of macrophages in close association with rupturing cysts [8], [17], [19].", [["macrophages", "ANATOMY", 50, 61], ["cysts", "ANATOMY", 98, 103], ["macrophages", "CELL", 50, 61], ["macrophages", "CELL_TYPE", 50, 61], ["macrophages", "PROBLEM", 50, 61], ["rupturing cysts", "PROBLEM", 88, 103], ["macrophages", "OBSERVATION", 50, 61], ["rupturing", "OBSERVATION_MODIFIER", 88, 97], ["cysts", "OBSERVATION", 98, 103]]], ["Of note, we found that BALB/c macrophages that are more easily alternatively activated had enhanced cyst lysis activity when compared to C57Bl/6 (Figure S7).", [["BALB/c macrophages", "ANATOMY", 23, 41], ["cyst", "ANATOMY", 100, 104], ["BALB/c macrophages", "ORGANISM", 23, 41], ["cyst", "CANCER", 100, 104], ["BALB/c macrophages", "CELL_LINE", 23, 41], ["BALB/c macrophages", "PROBLEM", 23, 41], ["enhanced cyst lysis activity", "PROBLEM", 91, 119], ["cyst", "OBSERVATION", 100, 104]]], ["This may be one explanation for the increased resistance to toxoplasmic encephalitis in BALB/c mice [30], [88].DiscussionAlthough AMCase activity is not required for protective immunity during acute infection it is required for protection during the chronic stage of infection.", [["toxoplasmic encephalitis", "DISEASE", 60, 84], ["infection", "DISEASE", 199, 208], ["infection", "DISEASE", 267, 276], ["BALB/c mice", "ORGANISM", 88, 99], ["AMCase", "GENE_OR_GENE_PRODUCT", 130, 136], ["AMCase", "PROTEIN", 130, 136], ["mice", "SPECIES", 95, 99], ["the increased resistance", "PROBLEM", 32, 56], ["toxoplasmic encephalitis", "PROBLEM", 60, 84], ["protective immunity", "TREATMENT", 166, 185], ["acute infection", "PROBLEM", 193, 208], ["protection", "TREATMENT", 228, 238], ["the chronic stage of infection", "PROBLEM", 246, 276], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["infection", "OBSERVATION", 199, 208], ["chronic", "OBSERVATION_MODIFIER", 250, 257], ["infection", "OBSERVATION", 267, 276]]], ["Our observation of a higher cyst count and parasite burden as well as decreased survival in AMCase-null mice points to a specific and important role for chitinase mediated cyst lysis in the brain.", [["cyst", "ANATOMY", 28, 32], ["cyst", "ANATOMY", 172, 176], ["brain", "ANATOMY", 190, 195], ["cyst", "CANCER", 28, 32], ["AMCase", "GENE_OR_GENE_PRODUCT", 92, 98], ["chitinase", "GENE_OR_GENE_PRODUCT", 153, 162], ["brain", "ORGAN", 190, 195], ["AMCase", "PROTEIN", 92, 98], ["chitinase", "PROTEIN", 153, 162], ["mice", "SPECIES", 104, 108], ["Our observation", "TEST", 0, 15], ["a higher cyst count", "PROBLEM", 19, 38], ["parasite burden", "PROBLEM", 43, 58], ["chitinase mediated cyst lysis in the brain", "PROBLEM", 153, 195], ["higher", "OBSERVATION_MODIFIER", 21, 27], ["cyst", "OBSERVATION", 28, 32], ["parasite", "OBSERVATION_MODIFIER", 43, 51], ["cyst", "OBSERVATION", 172, 176], ["brain", "ANATOMY", 190, 195]]], ["Thus, within the brain, cyst containment seems as important as the killing of free parasites in the control of pathology.", [["brain", "ANATOMY", 17, 22], ["cyst", "ANATOMY", 24, 28], ["brain", "ORGAN", 17, 22], ["cyst", "CANCER", 24, 28], ["cyst containment", "PROBLEM", 24, 40], ["free parasites", "PROBLEM", 78, 92], ["brain", "ANATOMY", 17, 22], ["cyst", "OBSERVATION", 24, 28]]], ["In addition, continuous chitin-mediated attack by macrophages and the release of parasites from latent cysts will provide a constant source of antigenic stimulation for the immune response.", [["macrophages", "ANATOMY", 50, 61], ["cysts", "ANATOMY", 103, 108], ["chitin", "CHEMICAL", 24, 30], ["chitin", "SIMPLE_CHEMICAL", 24, 30], ["macrophages", "CELL", 50, 61], ["macrophages", "CELL_TYPE", 50, 61], ["continuous chitin-mediated attack", "TREATMENT", 13, 46], ["parasites", "PROBLEM", 81, 90], ["latent cysts", "PROBLEM", 96, 108], ["antigenic stimulation", "TREATMENT", 143, 164], ["latent", "OBSERVATION_MODIFIER", 96, 102], ["cysts", "OBSERVATION", 103, 108]]], ["This latter discovery may provide an explanation for the continuous recruitment of T cells into the brain.DiscussionIt has been apparent for some time that cyst numbers in the brain can be controlled endogenously yet identification of the exact effector mechanisms has not been so apparent.", [["T cells", "ANATOMY", 83, 90], ["brain", "ANATOMY", 100, 105], ["cyst", "ANATOMY", 156, 160], ["brain", "ANATOMY", 176, 181], ["T cells", "CELL", 83, 90], ["brain", "ORGAN", 100, 105], ["cyst", "CANCER", 156, 160], ["brain", "ORGAN", 176, 181], ["T cells", "CELL_TYPE", 83, 90], ["cyst numbers in the brain", "PROBLEM", 156, 181], ["brain", "ANATOMY", 100, 105], ["cyst", "OBSERVATION", 156, 160], ["brain", "ANATOMY", 176, 181]]], ["In these studies we demonstrate the presence of a distinct population of macrophages in the brain during chronic Toxoplasma infection, which express CXCR3, MMR, stabilin-1 and arginase-1.", [["macrophages", "ANATOMY", 73, 84], ["brain", "ANATOMY", 92, 97], ["Toxoplasma infection", "DISEASE", 113, 133], ["macrophages", "CELL", 73, 84], ["brain", "ORGAN", 92, 97], ["Toxoplasma", "ORGANISM", 113, 123], ["CXCR3", "GENE_OR_GENE_PRODUCT", 149, 154], ["MMR", "GENE_OR_GENE_PRODUCT", 156, 159], ["stabilin-1", "GENE_OR_GENE_PRODUCT", 161, 171], ["arginase-1", "GENE_OR_GENE_PRODUCT", 176, 186], ["macrophages", "CELL_TYPE", 73, 84], ["CXCR3", "PROTEIN", 149, 154], ["MMR", "PROTEIN", 156, 159], ["stabilin-1", "PROTEIN", 161, 171], ["arginase-1", "PROTEIN", 176, 186], ["Toxoplasma", "SPECIES", 113, 123], ["these studies", "TEST", 3, 16], ["a distinct population of macrophages in the brain", "PROBLEM", 48, 97], ["chronic Toxoplasma infection", "PROBLEM", 105, 133], ["CXCR3", "TEST", 149, 154], ["MMR", "TEST", 156, 159], ["stabilin", "TEST", 161, 169], ["arginase", "TEST", 176, 184], ["distinct", "OBSERVATION_MODIFIER", 50, 58], ["population", "OBSERVATION", 59, 69], ["macrophages", "OBSERVATION", 73, 84], ["brain", "ANATOMY", 92, 97], ["chronic", "OBSERVATION_MODIFIER", 105, 112], ["Toxoplasma infection", "OBSERVATION", 113, 133]]], ["Furthermore these macrophages have chitinase activity, are localized to cysts and are observed in association with cyst degradation.", [["macrophages", "ANATOMY", 18, 29], ["cysts", "ANATOMY", 72, 77], ["cyst", "ANATOMY", 115, 119], ["macrophages", "CELL", 18, 29], ["chitinase", "GENE_OR_GENE_PRODUCT", 35, 44], ["cysts", "PATHOLOGICAL_FORMATION", 72, 77], ["cyst", "CANCER", 115, 119], ["macrophages", "CELL_TYPE", 18, 29], ["chitinase", "PROTEIN", 35, 44], ["chitinase activity", "PROBLEM", 35, 53], ["cysts", "PROBLEM", 72, 77], ["cyst degradation", "PROBLEM", 115, 131], ["macrophages", "OBSERVATION", 18, 29], ["chitinase activity", "OBSERVATION", 35, 53], ["cysts", "OBSERVATION", 72, 77], ["cyst", "OBSERVATION", 115, 119]]], ["The mechanism of cyst lysis is dependent on AMCase and this enzyme is required for survival during chronic infection to reduce parasite burden.", [["cyst", "ANATOMY", 17, 21], ["chronic infection", "DISEASE", 99, 116], ["cyst", "CANCER", 17, 21], ["AMCase", "GENE_OR_GENE_PRODUCT", 44, 50], ["AMCase", "PROTEIN", 44, 50], ["cyst lysis", "PROBLEM", 17, 27], ["this enzyme", "TEST", 55, 66], ["chronic infection", "PROBLEM", 99, 116], ["parasite burden", "PROBLEM", 127, 142], ["cyst", "OBSERVATION", 17, 21], ["lysis", "OBSERVATION", 22, 27], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["infection", "OBSERVATION", 107, 116]]], ["The continuous presence of Toxoplasmic cysts in the brain and other tissues presents a constant threat of reactivation to the immune compromised patient.", [["Toxoplasmic cysts", "ANATOMY", 27, 44], ["brain", "ANATOMY", 52, 57], ["tissues", "ANATOMY", 68, 75], ["Toxoplasmic cysts", "DISEASE", 27, 44], ["Toxoplasmic cysts", "PATHOLOGICAL_FORMATION", 27, 44], ["brain", "ORGAN", 52, 57], ["tissues", "TISSUE", 68, 75], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["Toxoplasmic cysts in the brain and other tissues", "PROBLEM", 27, 75], ["Toxoplasmic", "OBSERVATION_MODIFIER", 27, 38], ["cysts", "OBSERVATION", 39, 44], ["brain", "ANATOMY", 52, 57], ["other tissues", "ANATOMY", 62, 75], ["constant", "OBSERVATION_MODIFIER", 87, 95], ["reactivation", "OBSERVATION", 106, 118], ["immune compromised", "OBSERVATION", 126, 144]]], ["Mechanisms that enhance cyst removal or prevent their reactivation during Toxoplasma or other protozoan infections would provide a novel line of anti-parasitic therapies.Ethics statement ::: MethodsThe experiments in this study were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.", [["cyst", "ANATOMY", 24, 28], ["anti-parasitic", "ANATOMY", 145, 159], ["Toxoplasma", "DISEASE", 74, 84], ["protozoan infections", "DISEASE", 94, 114], ["cyst", "CANCER", 24, 28], ["Toxoplasma", "ORGANISM", 74, 84], ["Toxoplasma", "SPECIES", 74, 84], ["cyst removal", "TREATMENT", 24, 36], ["their reactivation", "PROBLEM", 48, 66], ["Toxoplasma", "PROBLEM", 74, 84], ["other protozoan infections", "PROBLEM", 88, 114], ["a novel line of anti-parasitic therapies", "TREATMENT", 129, 169], ["Methods", "TREATMENT", 191, 198], ["this study", "TEST", 217, 227], ["cyst", "OBSERVATION", 24, 28]]], ["All efforts were made to minimize animal suffering during the course of these studies.Mice and parasites ::: Methods", [["Mice", "ORGANISM", 86, 90], ["Mice", "SPECIES", 86, 90], ["these studies", "TEST", 72, 85], ["Methods", "TREATMENT", 109, 116]]]], "bfb148569afabc8a59134aa272c39fd9eccdbc48": [["At the beginning of May 2020, people were advised to wear personal protective equipment, such as a mask, indoors and for in-person encounters when maintaining 6-feet distance from others was not possible.", [["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36], ["personal protective equipment", "TREATMENT", 58, 87], ["a mask", "TREATMENT", 97, 103], ["not possible", "UNCERTAINTY", 191, 203]]]], "PMC7513764": [], "3280e5cd0db61f40b0cea240e3cbdf6014fedb93": [["non structural protein 3 <12> (<12> ambiguous [61, 62] ) [61, 62] nonstructural protein 3 <12,14,50,51> (<12,14,50> ambiguous [38, 63, 65, 66, 67] ; <51> ambigous [4] ) [4, 38, 63, 65, 66, 67] protein NS3 <12> (<12> ambiguous [62] ) [62] scHelI <4> [26] urvD <25> [25] 2 Source Organism <1> Drosophila melanogaster [46, 49, 50] <2> Escherichia coli [10] <3> Homo sapiens [28, 36, 45, 48] <4> Saccharomyces cerevisiae [8, 26, 27] <5> Bos taurus [44] <6> Methanothermobacter thermautotrophicus [43] <7> Pisum sativum [14, 15] <8> Bacillus cereus [52] <9> Schizosaccharomyces pombe [7] <10> Enterobacteria phage T7 [47] <11> Plasmodium falciparum [55] <12> Hepatitis C virus [1, 11, 38, 61, 62, 63, 65] <13> Human herpesvirus 1 [59] <14> West Nile virus [2, 67] <15> SARS coronavirus (UNIPROT accession number: P0C6X7) [32] <16> SARS coronavirus [64] <17> Human papillomavirus type 11 (UNIPROT accession number: P04014) [58] <18> Homo sapiens (UNIPROT accession number: Q14191) [12, 31] <19> Homo sapiens (UNIPROT accession number: O14867) [34] <20> Thermus thermophilus HB8 (UNIPROT accession number: O24736) [16] <21> Homo sapiens (UNIPROT accession number: Q96RR1) [33] <22> Saccharomyces cerevisiae (UNIPROT accession number: P51979) [30] <23> Human coronavirus 229E (UNIPROT accession number: P0C6X1) [3] <24> Adeno-associated virus -2 (UNIPROT accession number: Q89270) [40] <25> Escherichia coli (UNIPROT accession number: P03018) [25] <26> Saccharomyces cerevisiae (UNIPROT accession number: P07271) [19] <27> Schizosaccharomyces pombe (UNIPROT accession number: Q9UUA2) [42] <28> Saccharomyces cerevisiae (UNIPROT accession number: P40562) [35] <29> Bacillus anthracis (UNIPROT accession number: Q81JI8) [23] <30> Escherichia coli (UNIPROT accession number: P20356) [5] <31> Escherichia coli (UNIPROT accession number: P15043) [13] <32> Arabidopsis thaliana (UNIPROT accession number: Q6Y5A8) [56] <33> Homo sapiens (UNIPROT accession number: Q9H611) [41, 51, 53] <34> Homo sapiens (UNIPROT accession number: P46063) [57] <35> Sulfolobus solfataricus (UNIPROT accession number: Q9UXG1) [43] <36> Saccharomyces cerevisiae (UNIPROT accession number: P35187) [29] <37> Bacillus anthracis (UNIPROT accession number: Q6I4A9) [20] <38> Halobacterium sp.", [["Plasmodium falciparum", "DISEASE", 622, 643], ["Hepatitis C", "DISEASE", 654, 665], ["SARS coronavirus", "DISEASE", 764, 780], ["SARS coronavirus", "DISEASE", 826, 842], ["Human papillomavirus type", "DISEASE", 853, 878], ["non structural protein 3", "GENE_OR_GENE_PRODUCT", 0, 24], ["Drosophila melanogaster", "ORGANISM", 291, 314], ["Escherichia coli", "ORGANISM", 332, 348], ["Homo sapiens", "ORGANISM", 358, 370], ["Saccharomyces cerevisiae", "ORGANISM", 392, 416], ["Bos taurus", "ORGANISM", 433, 443], ["Methanothermobacter", "ORGANISM", 453, 472], ["thermautotrophicus", "ORGANISM", 473, 491], ["Pisum sativum", "ORGANISM", 501, 514], ["Bacillus cereus [52", "ORGANISM", 528, 547], ["Schizosaccharomyces pombe [7", "ORGANISM", 553, 581], ["Enterobacteria phage T7", "ORGANISM", 588, 611], ["Plasmodium falciparum", "ORGANISM", 622, 643], ["Hepatitis C virus", "ORGANISM", 654, 671], ["Human herpesvirus 1", "ORGANISM", 705, 724], ["West Nile virus", "ORGANISM", 735, 750], ["Human", "ORGANISM", 853, 858], ["papillomavirus", "ORGANISM", 859, 873], ["Saccharomyces cerevisiae", "ORGANISM", 1175, 1199], ["Human", "ORGANISM", 1245, 1250], ["Escherichia coli", "ORGANISM", 1383, 1399], ["Saccharomyces cerevisiae", "ORGANISM", 1445, 1469], ["Schizosaccharomyces pombe", "ORGANISM", 1515, 1540], ["Saccharomyces cerevisiae", "ORGANISM", 1586, 1610], ["Bacillus anthracis", "ORGANISM", 1656, 1674], ["Escherichia coli", "ORGANISM", 1720, 1736], ["Escherichia coli", "ORGANISM", 1781, 1797], ["Sulfolobus solfataricus", "ORGANISM", 2033, 2056], ["Saccharomyces cerevisiae", "GENE_OR_GENE_PRODUCT", 2102, 2126], ["Bacillus anthracis", "ORGANISM", 2172, 2190], ["Halobacterium sp", "ORGANISM", 2236, 2252], ["NS3", "PROTEIN", 201, 204], ["Drosophila melanogaster", "SPECIES", 291, 314], ["Escherichia coli", "SPECIES", 332, 348], ["Homo sapiens", "SPECIES", 358, 370], ["Saccharomyces cerevisiae", "SPECIES", 392, 416], ["Bos taurus", "SPECIES", 433, 443], ["Methanothermobacter thermautotrophicus", "SPECIES", 453, 491], ["Pisum sativum", "SPECIES", 501, 514], ["Bacillus cereus", "SPECIES", 528, 543], ["Schizosaccharomyces pombe", "SPECIES", 553, 578], ["Plasmodium falciparum", "SPECIES", 622, 643], ["Hepatitis C virus", "SPECIES", 654, 671], ["Human", "SPECIES", 705, 710], ["West Nile virus", "SPECIES", 735, 750], ["Human", "SPECIES", 853, 858], ["Homo sapiens", "SPECIES", 927, 939], ["Homo sapiens", "SPECIES", 989, 1001], ["Thermus thermophilus", "SPECIES", 1047, 1067], ["Homo sapiens", "SPECIES", 1117, 1129], ["Saccharomyces cerevisiae", "SPECIES", 1175, 1199], ["Human", "SPECIES", 1245, 1250], ["coronavirus", "SPECIES", 1251, 1262], ["Escherichia coli", "SPECIES", 1383, 1399], ["Saccharomyces cerevisiae", "SPECIES", 1445, 1469], ["Schizosaccharomyces pombe", "SPECIES", 1515, 1540], ["Saccharomyces cerevisiae", "SPECIES", 1586, 1610], ["Bacillus anthracis", "SPECIES", 1656, 1674], ["Escherichia coli", "SPECIES", 1720, 1736], ["Escherichia coli", "SPECIES", 1781, 1797], ["Arabidopsis thaliana", "SPECIES", 1843, 1863], ["Homo sapiens", "SPECIES", 1909, 1921], ["Homo sapiens", "SPECIES", 1975, 1987], ["Sulfolobus solfataricus", "SPECIES", 2033, 2056], ["Saccharomyces cerevisiae", "SPECIES", 2102, 2126], ["Bacillus anthracis", "SPECIES", 2172, 2190], ["Drosophila melanogaster", "SPECIES", 291, 314], ["Escherichia coli", "SPECIES", 332, 348], ["Homo sapiens", "SPECIES", 358, 370], ["Saccharomyces cerevisiae", "SPECIES", 392, 416], ["Bos taurus", "SPECIES", 433, 443], ["Methanothermobacter thermautotrophicus", "SPECIES", 453, 491], ["Pisum sativum", "SPECIES", 501, 514], ["Bacillus cereus", "SPECIES", 528, 543], ["Schizosaccharomyces pombe", "SPECIES", 553, 578], ["Plasmodium falciparum", "SPECIES", 622, 643], ["Hepatitis C virus", "SPECIES", 654, 671], ["Human herpesvirus 1", "SPECIES", 705, 724], ["West Nile virus", "SPECIES", 735, 750], ["SARS coronavirus", "SPECIES", 764, 780], ["SARS coronavirus", "SPECIES", 826, 842], ["Human papillomavirus type 11", "SPECIES", 853, 881], ["Homo sapiens", "SPECIES", 927, 939], ["Homo sapiens", "SPECIES", 989, 1001], ["Thermus thermophilus", "SPECIES", 1047, 1067], ["Homo sapiens", "SPECIES", 1117, 1129], ["Saccharomyces cerevisiae", "SPECIES", 1175, 1199], ["Human coronavirus", "SPECIES", 1245, 1262], ["Escherichia coli", "SPECIES", 1383, 1399], ["Saccharomyces cerevisiae", "SPECIES", 1445, 1469], ["Schizosaccharomyces pombe", "SPECIES", 1515, 1540], ["Saccharomyces cerevisiae", "SPECIES", 1586, 1610], ["Bacillus anthracis", "SPECIES", 1656, 1674], ["Escherichia coli", "SPECIES", 1720, 1736], ["Escherichia coli", "SPECIES", 1781, 1797], ["Arabidopsis thaliana", "SPECIES", 1843, 1863], ["Homo sapiens", "SPECIES", 1909, 1921], ["Homo sapiens", "SPECIES", 1975, 1987], ["Sulfolobus solfataricus", "SPECIES", 2033, 2056], ["Saccharomyces cerevisiae", "SPECIES", 2102, 2126], ["Bacillus anthracis", "SPECIES", 2172, 2190], ["non structural protein", "TEST", 0, 22], ["nonstructural protein", "TEST", 66, 87], ["ambigous", "TEST", 154, 162], ["protein NS3", "TEST", 193, 204], ["scHelI", "TEST", 238, 244], ["urvD", "TEST", 254, 258], ["Source Organism", "TEST", 271, 286], ["Drosophila melanogaster", "TEST", 291, 314], ["Escherichia coli", "TEST", 332, 348], ["Homo sapiens", "TEST", 358, 370], ["Saccharomyces cerevisiae", "TEST", 392, 416], ["Bos taurus", "TEST", 433, 443], ["Methanothermobacter thermautotrophicus", "TEST", 453, 491], ["Pisum sativum", "TEST", 501, 514], ["Bacillus cereus", "TEST", 528, 543], ["Schizosaccharomyces pombe", "TEST", 553, 578], ["Enterobacteria phage T7", "TEST", 588, 611], ["Plasmodium falciparum", "TEST", 622, 643], ["Hepatitis C virus", "TEST", 654, 671], ["Human herpesvirus", "TEST", 705, 722], ["West Nile virus", "TEST", 735, 750], ["SARS coronavirus", "TEST", 764, 780], ["UNIPROT accession number", "TEST", 782, 806], ["P0C6X7", "TEST", 808, 814], ["SARS coronavirus", "TEST", 826, 842], ["Human papillomavirus type", "TEST", 853, 878], ["UNIPROT accession number", "TEST", 883, 907], ["Homo sapiens", "TEST", 927, 939], ["Homo sapiens", "TEST", 989, 1001], ["Thermus thermophilus HB8", "TEST", 1047, 1071], ["UNIPROT accession number", "TEST", 1073, 1097], ["Homo sapiens", "TEST", 1117, 1129], ["Saccharomyces cerevisiae", "TEST", 1175, 1199], ["Human coronavirus", "TEST", 1245, 1262], ["Adeno-associated virus", "TEST", 1312, 1334], ["Escherichia coli", "TEST", 1383, 1399], ["Saccharomyces cerevisiae", "TEST", 1445, 1469], ["Schizosaccharomyces pombe", "TEST", 1515, 1540], ["Saccharomyces cerevisiae", "TEST", 1586, 1610], ["Bacillus anthracis", "TEST", 1656, 1674], ["Escherichia coli", "TEST", 1720, 1736], ["Escherichia coli", "PROBLEM", 1781, 1797], ["Homo sapiens", "TEST", 1975, 1987], ["Sulfolobus solfataricus (UNIPROT accession", "TREATMENT", 2033, 2075], ["Bacillus anthracis", "TEST", 2172, 2190], ["Halobacterium sp", "PROBLEM", 2236, 2252]]], ["NRC-1 [54] <39> Plasmodium falciparum (UNIPROT accession number: Q8I3W6) [18] <40> Saccharomyces cerevisiae (UNIPROT accession number: Q12039) [60] <41> Streptococcus pneumoniae (UNIPROT accession number: Q8DPU8) [21] <42> Mycobacterium tuberculosis (UNIPROT accession number: P64320) [22] <43> Caenorhabditis elegans (UNIPROT accession number: Q19546) [9] <44> Mus musculus (UNIPROT accession number: Q8VID5) [17] <45> Thermotoga maritima (UNIPROT accession number: Q9WY48) [6] <46> Saccharomyces cerevisiae (UNIPROT accession number: Q06218) [24] <47> Apocynum venetum (UNIPROT accession number: A8D930) [37] <48> Rattus norvegicus (UNIPROT accession number: Q9QY16) [36] <49> Geobacillus stearothermophilus (UNIPROT accession number: P56255)", [["Plasmodium falciparum", "DISEASE", 16, 37], ["Streptococcus pneumoniae", "DISEASE", 153, 177], ["Mycobacterium tuberculosis", "DISEASE", 223, 249], ["Plasmodium falciparum", "ORGANISM", 16, 37], ["Saccharomyces cerevisiae", "ORGANISM", 83, 107], ["Streptococcus pneumoniae", "ORGANISM", 153, 177], ["Mus musculus", "ORGANISM", 362, 374], ["Thermotoga maritima", "ORGANISM", 420, 439], ["Saccharomyces cerevisiae", "ORGANISM", 484, 508], ["Rattus norvegicus", "ORGANISM", 616, 633], ["Plasmodium falciparum", "SPECIES", 16, 37], ["Saccharomyces cerevisiae", "SPECIES", 83, 107], ["Streptococcus pneumoniae", "SPECIES", 153, 177], ["Mycobacterium tuberculosis", "SPECIES", 223, 249], ["Caenorhabditis elegans", "SPECIES", 295, 317], ["Mus musculus", "SPECIES", 362, 374], ["Thermotoga maritima", "SPECIES", 420, 439], ["Saccharomyces cerevisiae", "SPECIES", 484, 508], ["Rattus norvegicus", "SPECIES", 616, 633], ["Geobacillus stearothermophilus", "SPECIES", 679, 709], ["Plasmodium falciparum", "SPECIES", 16, 37], ["Saccharomyces cerevisiae", "SPECIES", 83, 107], ["Streptococcus pneumoniae", "SPECIES", 153, 177], ["Mycobacterium tuberculosis", "SPECIES", 223, 249], ["Caenorhabditis elegans", "SPECIES", 295, 317], ["Mus musculus", "SPECIES", 362, 374], ["Thermotoga maritima", "SPECIES", 420, 439], ["Saccharomyces cerevisiae", "SPECIES", 484, 508], ["Apocynum venetum", "SPECIES", 554, 570], ["Rattus norvegicus", "SPECIES", 616, 633], ["Geobacillus stearothermophilus", "SPECIES", 679, 709], ["NRC", "TEST", 0, 3], ["Plasmodium falciparum", "TEST", 16, 37], ["Streptococcus pneumoniae", "PROBLEM", 153, 177], ["Mycobacterium tuberculosis", "TEST", 223, 249], ["pneumoniae", "OBSERVATION", 167, 177], ["musculus", "ANATOMY", 366, 374]]]], "90bf3caf925c494853bd4cd4e86153dd523c7d31": [["IntroductionTowards the end of 2019, a novel respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), was first reported from Wuhan, the capital of Hubei province in the People's Republic of China.", [["respiratory", "ANATOMY", 45, 56], ["respiratory infection", "DISEASE", 45, 66], ["acute respiratory syndrome coronavirus", "DISEASE", 84, 122], ["syndrome coronavirus", "SPECIES", 102, 122], ["severe acute respiratory syndrome coronavirus", "SPECIES", 77, 122], ["SARS-Cov-2", "SPECIES", 126, 136], ["a novel respiratory infection", "PROBLEM", 37, 66], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 77, 122], ["SARS-Cov", "TEST", 126, 134], ["respiratory", "ANATOMY", 45, 56], ["infection", "OBSERVATION", 57, 66], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory syndrome", "OBSERVATION", 90, 110]]], ["This illness has already been assigned the name coronavirus disease-19 (COVID-19) by the World Health Organization (WHO).", [["coronavirus disease", "DISEASE", 48, 67], ["the name coronavirus disease", "PROBLEM", 39, 67]]], ["1 SARS-CoV-2 belongs to a family of viruses that cause a variety of symptoms that range in severity from mild cold symptoms to more severe infections, which disproportionately account for a high mortality rate among the elderly and individuals that are immunocompromised.", [["infections", "DISEASE", 139, 149], ["CoV-2", "ORGANISM", 7, 12], ["symptoms", "PROBLEM", 68, 76], ["mild cold symptoms", "PROBLEM", 105, 123], ["more severe infections", "PROBLEM", 127, 149], ["a high mortality rate", "PROBLEM", 188, 209], ["immunocompromised", "PROBLEM", 253, 270], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["more severe", "OBSERVATION_MODIFIER", 127, 138], ["infections", "OBSERVATION", 139, 149], ["immunocompromised", "OBSERVATION", 253, 270]]], ["The pandemic has now reached almost every country on the globe (at least 199 countries at the time of writing).", [["pandemic", "OBSERVATION", 4, 12], ["globe", "ANATOMY", 57, 62]]], ["The epidemiological variability and lethality of COVID-19 in general and specific populations have been reported.", [["COVID-19", "CHEMICAL", 49, 57], ["The epidemiological variability", "TEST", 0, 31], ["lethality", "PROBLEM", 36, 45], ["COVID", "TEST", 49, 54], ["variability", "OBSERVATION_MODIFIER", 20, 31], ["lethality", "OBSERVATION_MODIFIER", 36, 45]]], ["2, 3 The world is currently witnessing substantial disruption of daily lives socially, psychologically and economically as a result of the progression of the COVID-19 pandemic.IntroductionAs the pandemic rumbles through nations leaving behind considerable death and damaged economies, no effective treatment seems to be in sight as of now.", [["rumbles", "DISEASE", 204, 211], ["death", "DISEASE", 256, 261], ["the COVID", "TEST", 154, 163], ["pandemic", "PROBLEM", 167, 175], ["considerable death", "PROBLEM", 243, 261], ["effective treatment", "TREATMENT", 288, 307], ["substantial", "OBSERVATION_MODIFIER", 39, 50], ["disruption", "OBSERVATION", 51, 61]]], ["4 Preventive measures, enveloped in public health advocacy both at the individual and societal levels, and reinforced by national regulations seem to be our best bet of shortening the life span of the pandemic.", [["Preventive measures", "TREATMENT", 2, 21]]], ["Various countries have instituted diverse policies and laws to protect their citizens as the natural history of the disease progresses.", [["the disease", "PROBLEM", 112, 123], ["disease", "OBSERVATION", 116, 123]]], ["However, just as we witness differences in the degree of public health preparedness across nations, we are also subdued by the lack of simple epidemiological tools that could capture, in broad terms, the comparative effectiveness of measures put in place by different countries to mitigate the impact of the pandemic on human lives.", [["human", "ORGANISM", 320, 325], ["human", "SPECIES", 320, 325], ["human", "SPECIES", 320, 325]]], ["In this paper, we present a simple epidemiological tool that could be utilized globally to test the relative efficiency of measures put in place to avert death resulting from COVID-19 infection.", [["death", "DISEASE", 154, 159], ["infection", "DISEASE", 184, 193], ["COVID-19", "SPECIES", 175, 183], ["avert death", "PROBLEM", 148, 159], ["COVID-19 infection", "PROBLEM", 175, 193], ["infection", "OBSERVATION", 184, 193]]], ["For simplicity, we refer to this assessment tool as the Pandemic Efficiency Index or PEI.", [["PEI", "CHEMICAL", 85, 88], ["this assessment", "TEST", 28, 43], ["the Pandemic Efficiency Index", "PROBLEM", 52, 81], ["PEI", "PROBLEM", 85, 88]]], ["The PEI could be used to potentially rank countries and assist in distilling best practices from those countries with optimal outcomes in a pandemic.", [["PEI", "CHEMICAL", 4, 7], ["PEI", "CHEMICAL", 4, 7], ["PEI", "SIMPLE_CHEMICAL", 4, 7], ["The PEI", "TREATMENT", 0, 7]]], ["The higher the PEI, the greater the efficiency of the country in protecting its citizens from death resulting from the COVID-19 pandemic.", [["death", "DISEASE", 94, 99], ["PEI", "CHEMICAL", 15, 18], ["The higher the PEI", "PROBLEM", 0, 18], ["death", "PROBLEM", 94, 99], ["the COVID", "TEST", 115, 124], ["pandemic", "PROBLEM", 128, 136], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["PEI", "OBSERVATION", 15, 18], ["greater", "OBSERVATION_MODIFIER", 24, 31], ["efficiency", "OBSERVATION_MODIFIER", 36, 46]]], ["Using PEI, nations can learn and adapt best practices in pandemic control from each other.", [["PEI", "CHEMICAL", 6, 9], ["PEI", "CHEMICAL", 6, 9], ["PEI", "TREATMENT", 6, 9], ["pandemic control", "TREATMENT", 57, 73]]], ["Nations can systematically reverseengineer the practices that countries with higher PEI used to achieve lower Covid-19-related mortality.MethodsWe collected information on current details of COVID-19 cases across the globe from Worldometer.", [["PEI", "CHEMICAL", 84, 87], ["PEI", "CHEMICAL", 84, 87], ["higher PEI", "TREATMENT", 77, 87], ["lower Covid", "TEST", 104, 115], ["COVID", "TEST", 191, 196], ["globe", "ANATOMY", 217, 222]]], ["The website has been providing live updates on COVID-19 related total cases, new cases, deaths, recoveries and critical cases by country, territory or conveyance.", [["deaths", "DISEASE", 88, 94]]], ["Worldometer gathers and compiles the information from various sources, including newspapers, government websites, and social media such as Twitter, etc. The countries with more than 5,000 cases of Coronavirus, as of March 29, 2020 were included in this study and were classified as 'high impact countries.'MethodsWe calculated the mortality rate by dividing the total deaths by total number of cases associated with the disease, for each high impact territory.", [["Coronavirus", "DISEASE", 197, 208], ["deaths", "DISEASE", 368, 374], ["Coronavirus", "PROBLEM", 197, 208], ["this study", "TEST", 248, 258], ["the disease", "PROBLEM", 416, 427], ["disease", "OBSERVATION", 420, 427]]], ["As the disease originated in China, we used China's mortality rate as the reference.", [["the disease", "PROBLEM", 3, 14], ["China's mortality rate", "TREATMENT", 44, 66], ["disease", "OBSERVATION", 7, 14]]], ["The formula for COVID-19 Pandemic Efficiency Index (PEI) for a country X was The global ranking of high-impact countries based on COVID -19 PEI is illustrated in Figure 1 .As ofGermany, a country with the fifth largest number of cases (60,659) has so far experienced 482 deaths resulting from COVID-19 infection, and had the highest PEI (5.09) among the high impact countries.", [["deaths", "DISEASE", 271, 277], ["infection", "DISEASE", 302, 311], ["PEI", "CHEMICAL", 333, 336], ["PEI", "CHEMICAL", 333, 336], ["The formula", "TREATMENT", 0, 11], ["COVID", "TEST", 16, 21], ["Pandemic Efficiency Index (PEI)", "TREATMENT", 25, 56], ["COVID", "TEST", 130, 135], ["COVID-19 infection", "PROBLEM", 293, 311], ["the highest PEI", "PROBLEM", 321, 336], ["infection", "OBSERVATION", 302, 311]]], ["The USA was 6 th on the list, with a PEI of 2.28.", [["PEI", "CHEMICAL", 37, 40], ["a PEI", "TEST", 35, 40]]], ["Italy and France were the countries with the lowest PEI of 0.4 and 0.3, respectively.Discussion and Global Health ImplicationsCOVID-19 is the latest global health threat confronting nations, research and medical communities, with national and global efforts applauded and criticized.", [["PEI", "CHEMICAL", 52, 55], ["the lowest PEI", "TREATMENT", 41, 55]]], ["6 Almost 3 months after the first confirmed case of the virus was identified in China, WHO declared the disease as a pandemic, making it the first such declaration since the 2009 H1N1 swine flu outbreak.", [["swine flu", "DISEASE", 184, 193], ["H1N1 swine flu", "SPECIES", 179, 193], ["H1N1 swine flu", "SPECIES", 179, 193], ["the virus", "PROBLEM", 52, 61], ["the disease", "PROBLEM", 100, 111], ["H1N1 swine flu outbreak", "PROBLEM", 179, 202], ["virus", "OBSERVATION", 56, 61]]], ["The WHO had estimated COVID-19 mortality rate to be 3.4% about three weeks ago 7 .", [["estimated COVID", "TEST", 12, 27], ["mortality rate", "TEST", 31, 45]]], ["However, due to the rapid progression of the disease and differential efficiency in disease and mortality prevention across affected countries, the mortality rate had risen to 4.72% as of March 29, 2020.", [["the disease", "PROBLEM", 41, 52], ["disease", "PROBLEM", 84, 91], ["the mortality rate", "TEST", 144, 162], ["rapid", "OBSERVATION_MODIFIER", 20, 25], ["progression", "OBSERVATION_MODIFIER", 26, 37], ["disease", "OBSERVATION", 45, 52], ["differential", "OBSERVATION_MODIFIER", 57, 69], ["efficiency", "OBSERVATION_MODIFIER", 70, 80]]], ["COVID-19 has been more deadly than the 2009 H1N1 swine flu pandemic, which registered a case fatality rate of 0.2%.", [["COVID-19", "CHEMICAL", 0, 8], ["flu pandemic", "DISEASE", 55, 67], ["2009 H1N1 swine", "ORGANISM", 39, 54], ["H1N1 swine flu pandemic", "SPECIES", 44, 67], ["2009 H1N1 swine flu pandemic", "SPECIES", 39, 67], ["COVID", "TEST", 0, 5], ["a case fatality rate", "TEST", 86, 106]]], ["For the first time since the outbreak, Wuhan in China reported no new cases on March 19 th 2020, while the USA acquired the status of the country reporting the largest number of new COVID-19 infections worldwide.", [["COVID-19", "CHEMICAL", 182, 190], ["infections", "DISEASE", 191, 201], ["COVID-19", "SPECIES", 182, 190], ["new COVID-19 infections", "PROBLEM", 178, 201], ["largest", "OBSERVATION_MODIFIER", 160, 167], ["new", "OBSERVATION_MODIFIER", 178, 181], ["infections", "OBSERVATION", 191, 201]]], ["According to various analyses by the U.S. Centers for Disease Control and Prevention (CDC), older adults and those with underlying comorbidities like heart disease, lung disease or diabetes are more vulnerable to the severe forms of COVID-19 and to die from the disease.", [["heart", "ANATOMY", 150, 155], ["lung", "ANATOMY", 165, 169], ["heart disease", "DISEASE", 150, 163], ["lung disease", "DISEASE", 165, 177], ["diabetes", "DISEASE", 181, 189], ["COVID", "DISEASE", 233, 238], ["COVID-19", "CHEMICAL", 233, 241], ["adults", "ORGANISM", 98, 104], ["heart", "ORGAN", 150, 155], ["lung", "ORGAN", 165, 169], ["Disease Control", "TREATMENT", 54, 69], ["underlying comorbidities", "PROBLEM", 120, 144], ["heart disease", "PROBLEM", 150, 163], ["lung disease", "PROBLEM", 165, 177], ["diabetes", "PROBLEM", 181, 189], ["COVID", "TEST", 233, 238], ["the disease", "PROBLEM", 258, 269], ["heart", "ANATOMY", 150, 155], ["disease", "OBSERVATION", 156, 163], ["lung", "ANATOMY", 165, 169], ["disease", "OBSERVATION", 170, 177], ["diabetes", "OBSERVATION", 181, 189], ["disease", "OBSERVATION", 262, 269]]], ["8 From our results, we observed that citizens of countries that performed worse on our PEI scale (i.e., had low PEI) such as Italy, Spain, UK etc. had a higher median age than their counterparts from other parts of the world.", [["PEI", "CHEMICAL", 112, 115], ["our PEI scale", "TREATMENT", 83, 96], ["low PEI", "PROBLEM", 108, 115]]], ["What was most surprising was the low mortality rate (0.79%) and the highest PEI (5.09) of Germany, in spite of the fact that it ranks 4 th in the world for the highest median age.", [["PEI", "CHEMICAL", 76, 79]]], ["9 Austria and Portugal were the other two countries with a high PEI and median age above 44 years.Discussion and Global Health ImplicationsPEI is an innovative tool to compare countries in terms of the impact of their disaster preparedness and management protocols.", [["management protocols", "TREATMENT", 244, 264]]], ["Although COVID-19 is a global affliction, different countries have adopted different approaches to confronting the pandemic.", [["COVID-19", "DNA", 9, 17], ["COVID", "TEST", 9, 14], ["a global affliction", "PROBLEM", 21, 40], ["global", "OBSERVATION_MODIFIER", 23, 29], ["affliction", "OBSERVATION", 30, 40]]], ["PEI represents a simple and intuitive epidemiologic tool to compare the efficiency of policies and strategies that various countries have been adopting to curtail the impact of the COVID-19 pandemic.", [["PEI", "CHEMICAL", 0, 3], ["PEI", "CHEMICAL", 0, 3], ["a simple and intuitive epidemiologic tool", "PROBLEM", 15, 56], ["the COVID", "TEST", 177, 186]]], ["Lessons learned from these natural experiments would allow us to identify effective measures against mortality from countries with high PEI.", [["PEI", "CHEMICAL", 136, 139], ["PEI", "CHEMICAL", 136, 139], ["high PEI", "PROBLEM", 131, 139]]], ["Due to pandemic dynamics with numbers constantly changing, it is possible that the final PEI will only be available by the end of the current pandemic.Conflicts of Interest:The authors report no conflict of interest.", [["PEI", "CHEMICAL", 89, 92], ["PEI", "CHEMICAL", 89, 92], ["PEI", "SIMPLE_CHEMICAL", 89, 92], ["the final PEI", "PROBLEM", 79, 92]]]], "PMC7172900": [["IntroductionMammalian reovirus (MRV) is the prototype member of the Reoviridae family of non-enveloped double-stranded RNA (dsRNA) viruses, with a genome composed of ten segments.", [["Mammalian reovirus", "ORGANISM", 12, 30], ["MRV", "GENE_OR_GENE_PRODUCT", 32, 35], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 68, 78], ["Reoviridae family", "PROTEIN", 68, 85], ["Mammalian reovirus", "SPECIES", 12, 30], ["MRV", "SPECIES", 32, 35], ["IntroductionMammalian reovirus", "TREATMENT", 0, 30], ["non-enveloped double-stranded RNA (dsRNA) viruses", "TREATMENT", 89, 138], ["stranded RNA", "OBSERVATION_MODIFIER", 110, 122], ["ten segments", "ANATOMY_MODIFIER", 166, 178]]], ["Reoviruses, originally referred to as \u201crespiratory enteric orphans\u201d, were first isolated from humans in the United States and Mexico in the 1950s (1).", [["Reoviruses", "GENE_OR_GENE_PRODUCT", 0, 10], ["humans", "ORGANISM", 94, 100], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 94, 100], ["Reoviruses", "PROBLEM", 0, 10]]], ["MRVs are represented by four prototype strains: type 1 Lang (T1L), type 2 Jones (T2J), type 3 Dearing (T3D) and type 4 Ndelle (T4N), with the majority of strains assigned to serogroups T1L, T2J or T3D (2).", [["MRVs", "TEST", 0, 4], ["strains", "PROBLEM", 154, 161]]], ["Reoviruses have been isolated from the respiratory and enteric tracts of children with mild respiratory or gastrointestinal symptoms (1).", [["respiratory", "ANATOMY", 39, 50], ["respiratory", "ANATOMY", 92, 103], ["gastrointestinal", "ANATOMY", 107, 123], ["respiratory and enteric tracts", "DISEASE", 39, 69], ["respiratory or gastrointestinal symptoms", "DISEASE", 92, 132], ["Reoviruses", "GENE_OR_GENE_PRODUCT", 0, 10], ["respiratory", "ORGANISM_SUBDIVISION", 39, 50], ["enteric tracts", "ORGANISM_SUBDIVISION", 55, 69], ["children", "ORGANISM", 73, 81], ["gastrointestinal", "ORGANISM_SUBDIVISION", 107, 123], ["children", "SPECIES", 73, 81], ["Reoviruses", "PROBLEM", 0, 10], ["mild respiratory or gastrointestinal symptoms", "PROBLEM", 87, 132], ["respiratory", "ANATOMY", 39, 50], ["enteric tracts", "ANATOMY", 55, 69], ["mild", "OBSERVATION_MODIFIER", 87, 91], ["respiratory", "ANATOMY", 92, 103], ["gastrointestinal", "ANATOMY", 107, 123]]], ["However, limited studies have focused on human reovirus-associated neurological disease to date (3).", [["neurological", "ANATOMY", 67, 79], ["neurological disease", "DISEASE", 67, 87], ["human", "ORGANISM", 41, 46], ["reovirus", "ORGANISM", 47, 55], ["human", "SPECIES", 41, 46], ["human reovirus", "SPECIES", 41, 55], ["limited studies", "TEST", 9, 24], ["human reovirus", "PROBLEM", 41, 55], ["associated neurological disease", "PROBLEM", 56, 87], ["neurological disease", "OBSERVATION", 67, 87]]], ["Pneumonia and other respiratory diseases in both naturally and experimentally infected primates (4), and isolation of reoviruses from children with meningitis and encephalitis are widely documented 5, 6.IntroductionMRVs infect a wide range of hosts, including livestock (pig, cattle and chickens), contributing to severe economic losses worldwide.", [["respiratory", "ANATOMY", 20, 31], ["Pneumonia", "DISEASE", 0, 9], ["respiratory diseases", "DISEASE", 20, 40], ["meningitis", "DISEASE", 148, 158], ["encephalitis", "DISEASE", 163, 175], ["primates", "ORGANISM", 87, 95], ["reoviruses", "CANCER", 118, 128], ["children", "ORGANISM", 134, 142], ["pig", "ORGANISM", 271, 274], ["cattle", "ORGANISM", 276, 282], ["chickens", "ORGANISM", 287, 295], ["children", "SPECIES", 134, 142], ["pig", "SPECIES", 271, 274], ["cattle", "SPECIES", 276, 282], ["chickens", "SPECIES", 287, 295], ["pig", "SPECIES", 271, 274], ["cattle", "SPECIES", 276, 282], ["chickens", "SPECIES", 287, 295], ["Pneumonia", "PROBLEM", 0, 9], ["other respiratory diseases", "PROBLEM", 14, 40], ["reoviruses", "PROBLEM", 118, 128], ["meningitis", "PROBLEM", 148, 158], ["encephalitis", "PROBLEM", 163, 175], ["livestock (pig, cattle and chickens", "TREATMENT", 260, 295], ["severe economic losses worldwide", "PROBLEM", 314, 346], ["respiratory diseases", "OBSERVATION", 20, 40], ["infected", "OBSERVATION", 78, 86], ["meningitis", "OBSERVATION", 148, 158], ["encephalitis", "OBSERVATION", 163, 175], ["severe", "OBSERVATION_MODIFIER", 314, 320], ["economic losses", "OBSERVATION", 321, 336]]], ["The use of antiviral agents is not commonplace because of their toxicity and high production costs.", [["toxicity", "DISEASE", 64, 72], ["antiviral agents", "TREATMENT", 11, 27], ["their toxicity", "PROBLEM", 58, 72], ["high production costs", "PROBLEM", 77, 98]]], ["Hence, effective and inexpensive alternatives to antiviral drugs remain an urgent unmet medical need (7).", [["antiviral drugs", "TREATMENT", 49, 64]]], ["Many traditional medicinal plants display strong antiviral activities, and their utility in the successful treatment of infected animals and humans has been demonstrated 8, 9.IntroductionThe life cycle of viruses is divided into several stages, including cell surface attachment, penetration, uncoating, replication (protein synthesis) and release, all of which provide targets for antiviral agents (9).", [["cell surface", "ANATOMY", 255, 267], ["humans", "ORGANISM", 141, 147], ["cell surface", "CELLULAR_COMPONENT", 255, 267], ["humans", "SPECIES", 141, 147], ["humans", "SPECIES", 141, 147], ["infected animals", "PROBLEM", 120, 136], ["viruses", "PROBLEM", 205, 212], ["cell surface attachment", "TREATMENT", 255, 278], ["penetration", "PROBLEM", 280, 291], ["replication (protein synthesis", "TREATMENT", 304, 334], ["antiviral agents", "TREATMENT", 382, 398], ["strong", "OBSERVATION_MODIFIER", 42, 48], ["antiviral activities", "OBSERVATION", 49, 69], ["infected", "OBSERVATION", 120, 128], ["viruses", "OBSERVATION", 205, 212]]], ["Currently, more than 40 antiviral drugs are licensed for the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpesviruses.", [["human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpesviruses", "DISEASE", 74, 151], ["human immunodeficiency virus", "ORGANISM", 74, 102], ["HIV", "ORGANISM", 104, 107], ["hepatitis B virus", "ORGANISM", 110, 127], ["HBV", "ORGANISM", 129, 132], ["herpesviruses", "ORGANISM", 138, 151], ["human immunodeficiency virus (HIV", "SPECIES", 74, 107], ["hepatitis B virus", "SPECIES", 110, 127], ["human immunodeficiency virus", "SPECIES", 74, 102], ["HIV", "SPECIES", 104, 107], ["hepatitis B virus", "SPECIES", 110, 127], ["HBV", "SPECIES", 129, 132], ["40 antiviral drugs", "TREATMENT", 21, 39], ["human immunodeficiency virus", "PROBLEM", 74, 102], ["HIV", "PROBLEM", 104, 107], ["hepatitis B virus (HBV)", "PROBLEM", 110, 133], ["herpesviruses", "PROBLEM", 138, 151]]], ["However, the number of licensed antiviral drugs for treatment of highly pathogenic RNA virus infections remains limited (10).", [["infections", "DISEASE", 93, 103], ["licensed antiviral drugs", "TREATMENT", 23, 47], ["treatment", "TREATMENT", 52, 61], ["highly pathogenic RNA virus infections", "PROBLEM", 65, 103], ["antiviral drugs", "OBSERVATION", 32, 47], ["pathogenic", "OBSERVATION_MODIFIER", 72, 82], ["RNA virus", "OBSERVATION", 83, 92]]], ["These viral diseases are considered difficult to treat with selective antiviral chemotherapy, highlighting the need for further refinement of antiviral drug design and development.", [["viral diseases", "DISEASE", 6, 20], ["These viral diseases", "PROBLEM", 0, 20], ["selective antiviral chemotherapy", "TREATMENT", 60, 92], ["antiviral drug design", "TREATMENT", 142, 163], ["viral diseases", "OBSERVATION", 6, 20], ["antiviral chemotherapy", "OBSERVATION", 70, 92], ["antiviral drug", "OBSERVATION", 142, 156]]], ["Medicinal plants have a variety of chemical constituents, including alkaloids, tannins, saponins, flavonoids, terpenoids, lignans and coumarins, known to inhibit the replication cycles of various DNA and RNA virus types.", [["alkaloids, tannins, saponins, flavonoids, terpenoids, lignans and coumarins", "CHEMICAL", 68, 143], ["tannins", "CHEMICAL", 79, 86], ["saponins", "CHEMICAL", 88, 96], ["flavonoids", "CHEMICAL", 98, 108], ["terpenoids", "CHEMICAL", 110, 120], ["lignans", "CHEMICAL", 122, 129], ["coumarins", "CHEMICAL", 134, 143], ["alkaloids", "SIMPLE_CHEMICAL", 68, 77], ["tannins", "SIMPLE_CHEMICAL", 79, 86], ["saponins", "SIMPLE_CHEMICAL", 88, 96], ["flavonoids", "SIMPLE_CHEMICAL", 98, 108], ["terpenoids", "SIMPLE_CHEMICAL", 110, 120], ["lignans", "SIMPLE_CHEMICAL", 122, 129], ["coumarins", "SIMPLE_CHEMICAL", 134, 143], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["Medicinal plants", "TREATMENT", 0, 16], ["alkaloids", "TREATMENT", 68, 77], ["tannins", "TREATMENT", 79, 86], ["saponins", "TREATMENT", 88, 96], ["flavonoids", "TREATMENT", 98, 108], ["terpenoids", "TREATMENT", 110, 120], ["lignans", "TREATMENT", 122, 129], ["coumarins", "TREATMENT", 134, 143], ["the replication cycles", "TREATMENT", 162, 184], ["various DNA", "PROBLEM", 188, 199], ["RNA virus types", "PROBLEM", 204, 219], ["RNA virus", "OBSERVATION", 204, 213]]], ["Compounds derived from natural sources are therefore of significant interest as possible sources of viral infection control 7, 8, 9.IntroductionDried roots of Sophora flavescens Ait.", [["roots", "ANATOMY", 150, 155], ["infection", "DISEASE", 106, 115], ["Sophora flavescens", "ORGANISM", 159, 177], ["Sophora flavescens", "SPECIES", 159, 177], ["Sophora flavescens", "SPECIES", 159, 177], ["viral infection control", "PROBLEM", 100, 123], ["viral", "OBSERVATION_MODIFIER", 100, 105], ["infection", "OBSERVATION", 106, 115], ["Sophora flavescens Ait", "OBSERVATION", 159, 181]]], ["(S. flavescens) have been historically used in traditional Chinese herbal medicine, owing their anti-inflammatory, antiarrhythmic, antipyretic, antiasthmatic, and antiulcerative effects, and for the treatment of diarrhea, gastrointestinal hemorrhage, and eczema (11).", [["gastrointestinal", "ANATOMY", 222, 238], ["diarrhea", "DISEASE", 212, 220], ["gastrointestinal hemorrhage", "DISEASE", 222, 249], ["eczema", "DISEASE", 255, 261], ["S. flavescens", "ORGANISM", 1, 14], ["gastrointestinal", "ORGANISM_SUBDIVISION", 222, 238], ["S. flavescens", "SPECIES", 1, 14], ["S. flavescens", "SPECIES", 1, 14], ["traditional Chinese herbal medicine", "TREATMENT", 47, 82], ["their anti-inflammatory", "TREATMENT", 90, 113], ["antiarrhythmic", "TREATMENT", 115, 129], ["antipyretic", "TREATMENT", 131, 142], ["antiasthmatic", "TREATMENT", 144, 157], ["diarrhea", "PROBLEM", 212, 220], ["gastrointestinal hemorrhage", "PROBLEM", 222, 249], ["eczema", "PROBLEM", 255, 261], ["flavescens", "OBSERVATION", 4, 14], ["diarrhea", "OBSERVATION", 212, 220], ["gastrointestinal", "ANATOMY", 222, 238], ["hemorrhage", "OBSERVATION", 239, 249], ["eczema", "OBSERVATION", 255, 261]]], ["Additionally, a formulation containing S. flavescens is reported to inhibit angiogenesis in a collagen-induced arthritis rat model (12).", [["arthritis", "DISEASE", 111, 120], ["S. flavescens", "ORGANISM", 39, 52], ["collagen", "GENE_OR_GENE_PRODUCT", 94, 102], ["rat", "ORGANISM", 121, 124], ["collagen", "PROTEIN", 94, 102], ["S. flavescens", "SPECIES", 39, 52], ["rat", "SPECIES", 121, 124], ["S. flavescens", "SPECIES", 39, 52], ["a formulation containing S. flavescens", "TREATMENT", 14, 52], ["a collagen-induced arthritis", "PROBLEM", 92, 120], ["arthritis", "OBSERVATION", 111, 120]]], ["In previous studies, quinolizidine alkaloids, flavonoids, and triterpenoids were isolated from the roots of S. flavescens(13).", [["roots", "ANATOMY", 99, 104], ["quinolizidine alkaloids, flavonoids, and triterpenoids", "CHEMICAL", 21, 75], ["quinolizidine alkaloids", "CHEMICAL", 21, 44], ["flavonoids", "CHEMICAL", 46, 56], ["triterpenoids", "CHEMICAL", 62, 75], ["quinolizidine alkaloids", "SIMPLE_CHEMICAL", 21, 44], ["flavonoids", "SIMPLE_CHEMICAL", 46, 56], ["triterpenoids", "SIMPLE_CHEMICAL", 62, 75], ["roots", "ORGANISM_SUBDIVISION", 99, 104], ["S. flavescens", "ORGANISM", 108, 121], ["S. flavescens", "SPECIES", 108, 121], ["S. flavescens", "SPECIES", 108, 121], ["previous studies", "TEST", 3, 19], ["quinolizidine alkaloids", "TREATMENT", 21, 44], ["flavonoids", "TREATMENT", 46, 56], ["triterpenoids", "TREATMENT", 62, 75], ["flavescens", "OBSERVATION_MODIFIER", 111, 121]]], ["Recently, quinolizidine alkaloids and flavonoids have been shown to exhibit a wide spectrum of pharmacological activities, including anticancer, anti-inflammatory, antitumor, cardioprotective, neuroprotective, antibacterial, and anti-influenza properties 11, 13, 14, 15, 16, 17, 18, 19, 20, 21.", [["anticancer", "ANATOMY", 133, 143], ["antitumor", "ANATOMY", 164, 173], ["quinolizidine alkaloids", "CHEMICAL", 10, 33], ["flavonoids", "CHEMICAL", 38, 48], ["quinolizidine alkaloids", "CHEMICAL", 10, 33], ["flavonoids", "CHEMICAL", 38, 48], ["quinolizidine alkaloids", "SIMPLE_CHEMICAL", 10, 33], ["flavonoids", "SIMPLE_CHEMICAL", 38, 48], ["anticancer", "CANCER", 133, 143], ["antitumor", "CANCER", 164, 173], ["quinolizidine alkaloids", "TREATMENT", 10, 33], ["flavonoids", "TREATMENT", 38, 48], ["anticancer", "TREATMENT", 133, 143], ["anti-inflammatory", "TREATMENT", 145, 162], ["cardioprotective", "TREATMENT", 175, 191], ["neuroprotective", "TREATMENT", 193, 208], ["antibacterial", "TREATMENT", 210, 223], ["anti-influenza properties", "TEST", 229, 254], ["pharmacological activities", "OBSERVATION", 95, 121]]], ["However, the potential anti-reovirus activities of extracts and compounds isolated from S. flavescens have not been examined to date.", [["extracts", "ANATOMY", 51, 59], ["extracts", "ORGANISM_SUBSTANCE", 51, 59], ["S. flavescens", "ORGANISM", 88, 101], ["S. flavescens", "SPECIES", 88, 101], ["S. flavescens", "SPECIES", 88, 101], ["the potential anti-reovirus activities of extracts", "PROBLEM", 9, 59], ["S. flavescens", "PROBLEM", 88, 101]]], ["In the current investigation, we evaluated the abilities of the MeOH extract, EtOAc fraction and kuraridin isolated from S. flavescens to inhibit human type 1\u20133 reoviruses (HRV1\u20133) and Korean porcine reovirus (PRV).", [["MeOH extract, EtOAc", "CHEMICAL", 64, 83], ["kuraridin", "CHEMICAL", 97, 106], ["MeOH", "CHEMICAL", 64, 68], ["EtOAc", "CHEMICAL", 78, 83], ["kuraridin", "CHEMICAL", 97, 106], ["MeOH", "SIMPLE_CHEMICAL", 64, 68], ["EtOAc", "SIMPLE_CHEMICAL", 78, 83], ["kuraridin", "SIMPLE_CHEMICAL", 97, 106], ["S. flavescens", "ORGANISM", 121, 134], ["human", "ORGANISM", 146, 151], ["type 1\u20133 reoviruses", "ORGANISM", 152, 171], ["HRV1\u20133", "ORGANISM", 173, 179], ["porcine reovirus", "ORGANISM", 192, 208], ["S. flavescens", "SPECIES", 121, 134], ["human", "SPECIES", 146, 151], ["porcine reovirus", "SPECIES", 192, 208], ["S. flavescens", "SPECIES", 121, 134], ["human type 1\u20133 reoviruses", "SPECIES", 146, 171], ["HRV1\u20133", "SPECIES", 173, 179], ["Korean porcine reovirus", "SPECIES", 185, 208], ["PRV", "SPECIES", 210, 213], ["the MeOH extract", "TREATMENT", 60, 76], ["EtOAc fraction", "TREATMENT", 78, 92], ["kuraridin", "TREATMENT", 97, 106], ["S. flavescens", "PROBLEM", 121, 134], ["human type 1\u20133 reoviruses", "PROBLEM", 146, 171], ["Korean porcine reovirus", "TREATMENT", 185, 208], ["porcine reovirus", "OBSERVATION", 192, 208]]], ["Antiviral assays were employed to determine whether the S. flavescens compounds alter reovirus activity by inhibiting virus attachment and/or replication.Analytical equipment ::: Materials and methodsThe 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were obtained on JEOL ECS400 spectrometer, with CD3OD as a solvent.", [["1H", "CHEMICAL", 204, 206], ["13C", "CHEMICAL", 225, 228], ["CD3OD", "CHEMICAL", 299, 304], ["S. flavescens", "ORGANISM", 56, 69], ["reovirus", "ORGANISM", 86, 94], ["13C", "SIMPLE_CHEMICAL", 225, 228], ["CD3OD", "SIMPLE_CHEMICAL", 299, 304], ["S. flavescens", "SPECIES", 56, 69], ["S. flavescens", "SPECIES", 56, 69], ["Antiviral assays", "TEST", 0, 16], ["the S. flavescens", "PROBLEM", 52, 69], ["alter reovirus activity", "PROBLEM", 80, 103], ["inhibiting virus attachment", "PROBLEM", 107, 134], ["The 1H NMR", "TEST", 200, 210], ["13C NMR", "TEST", 225, 232]]], ["The ESI-MS was determined using an Agilent 6430 LC/MS/MS and 1100 LC/MS spectrometer.", [["MS", "PROBLEM", 54, 56], ["MS spectrometer", "TEST", 69, 84]]], ["Reversed-phase CC was carried out using RP-C18 silica gel (Cosmosil 140C18-PREP, 140 \u03bcm, Nacalai tesque, INC.).", [["CC", "CHEMICAL", 15, 17], ["RP-C18 silica", "CHEMICAL", 40, 53], ["Cosmosil 140C18-PREP", "CHEMICAL", 59, 79], ["RP-C18 silica gel", "CHEMICAL", 40, 57], ["RP-C18 silica", "SIMPLE_CHEMICAL", 40, 53], ["RP-C18 silica gel", "TREATMENT", 40, 57], ["Cosmosil", "TEST", 59, 67]]], ["Silica gel CC was conducted using Kieselgel 60 (70\u2013230 and 230\u2013400 mesh, Merck).", [["Silica gel", "CHEMICAL", 0, 10], ["CC", "CHEMICAL", 11, 13], ["Silica gel", "CHEMICAL", 0, 10], ["Silica", "SIMPLE_CHEMICAL", 0, 6], ["Silica gel CC", "TREATMENT", 0, 13], ["Kieselgel", "TEST", 34, 43]]], ["TLC was conducted using Kieselgel 60 F254 plates (Merck).Extract and isolation ::: Materials and methodsThe S. flavescens were purchased at an herbal market in Jeongeup, Korea.", [["S. flavescens", "ORGANISM", 108, 121], ["S. flavescens", "SPECIES", 108, 121], ["S. flavescens", "SPECIES", 108, 121], ["TLC", "TREATMENT", 0, 3], ["Kieselgel 60 F254 plates", "TREATMENT", 24, 48], ["The S. flavescens", "PROBLEM", 104, 121], ["flavescens", "OBSERVATION", 111, 121]]], ["A voucher specimen (PB-012\u2013012) has been deposited in the Korea Plant Extract Bank, Korea Research Institute of Bioscience and Biotechnology.", [["specimen", "ANATOMY", 10, 18], ["PB-012\u2013012", "CHEMICAL", 20, 30], ["PB-012\u2013012", "CELL", 20, 30]]], ["Dried roots of S. flavescens (5 kg) were extracted with MeOH (10 L) for 7 days at room temperature.", [["roots", "ANATOMY", 6, 11], ["MeOH", "CHEMICAL", 56, 60], ["MeOH", "CHEMICAL", 56, 60], ["roots", "ORGANISM_SUBDIVISION", 6, 11], ["S. flavescens", "ORGANISM", 15, 28], ["MeOH", "SIMPLE_CHEMICAL", 56, 60], ["S. flavescens", "SPECIES", 15, 28], ["S. flavescens", "SPECIES", 15, 28], ["roots", "OBSERVATION_MODIFIER", 6, 11], ["flavescens", "OBSERVATION_MODIFIER", 18, 28]]], ["The MeOH extract was evaporated in vacuo, yielding a residue (193 g).", [["MeOH extract", "CHEMICAL", 4, 16], ["MeOH", "CHEMICAL", 4, 8], ["MeOH", "SIMPLE_CHEMICAL", 4, 8], ["The MeOH extract", "TREATMENT", 0, 16]]], ["The residue was suspended in distilled water (1 L) and extracted with n-hexane, CHCl3, EtOAc and BuOH.", [["n-hexane, CHCl3, EtOAc", "CHEMICAL", 70, 92], ["BuOH", "CHEMICAL", 97, 101], ["n-hexane", "CHEMICAL", 70, 78], ["CHCl3", "CHEMICAL", 80, 85], ["EtOAc", "CHEMICAL", 87, 92], ["BuOH", "CHEMICAL", 97, 101], ["n-hexane", "SIMPLE_CHEMICAL", 70, 78], ["CHCl3", "SIMPLE_CHEMICAL", 80, 85], ["EtOAc", "SIMPLE_CHEMICAL", 87, 92], ["BuOH", "SIMPLE_CHEMICAL", 97, 101], ["The residue", "PROBLEM", 0, 11], ["n-hexane", "TREATMENT", 70, 78], ["CHCl3", "TREATMENT", 80, 85], ["BuOH", "TREATMENT", 97, 101]]], ["In this process, n-hexane (3.9 g), CHCl3 (22 g), EtOAc (33.5 g) and BuOH (38.9 g) layers were obtained respectively.", [["n-hexane", "CHEMICAL", 17, 25], ["CHCl3", "CHEMICAL", 35, 40], ["EtOAc", "CHEMICAL", 49, 54], ["BuOH", "CHEMICAL", 68, 72], ["n-hexane", "CHEMICAL", 17, 25], ["CHCl3", "CHEMICAL", 35, 40], ["EtOAc", "CHEMICAL", 49, 54], ["BuOH", "CHEMICAL", 68, 72], ["n-hexane", "SIMPLE_CHEMICAL", 17, 25], ["CHCl3", "SIMPLE_CHEMICAL", 35, 40], ["EtOAc", "SIMPLE_CHEMICAL", 49, 54], ["BuOH", "SIMPLE_CHEMICAL", 68, 72], ["n-hexane", "TEST", 17, 25], ["CHCl3", "TEST", 35, 40], ["EtOAc", "TEST", 49, 54]]], ["The EtOAc layer was submitted to open column chromatography on silica gel (230\u2013400 mesh, 300 g, Merck) using gradient solvent system CHCl3-EtOAc (100:1, 80:1, 50:1, 30:1, 10:1, 1:1, 1:10, 1:100; v/v, each 1L) as eluent to yield 21 fractions (F1\u2013F21) by TLC profile.", [["silica gel", "CHEMICAL", 63, 73], ["CHCl3-EtOAc", "CHEMICAL", 133, 144], ["EtOAc", "CHEMICAL", 4, 9], ["silica gel", "CHEMICAL", 63, 73], ["CHCl3-EtOAc", "CHEMICAL", 133, 144], ["silica", "SIMPLE_CHEMICAL", 63, 69], ["CHCl3-EtOAc", "SIMPLE_CHEMICAL", 133, 144], ["The EtOAc layer", "TREATMENT", 0, 15], ["open column chromatography", "TEST", 33, 59], ["silica gel", "TREATMENT", 63, 73], ["gradient solvent system", "TREATMENT", 109, 132], ["TLC profile", "TEST", 253, 264], ["EtOAc layer", "OBSERVATION", 4, 15]]], ["F15 (2 g) was subjected to column chromatography on ODS (70 g, Cosmosil 140C18-PREP, 140 \u03bcm, Nacalai tesque, INC.) eluted with MeOH\u2013H2O (50:50, 60:40, 70:30, 80:20, 90:10, 100:0; v/v, each 200 mL) to yielded 12 fractions (F15\u20131\u223c12) based on the TLC profile.", [["Cosmosil 140C18-PREP", "CHEMICAL", 63, 83], ["MeOH\u2013H2O", "CHEMICAL", 127, 135], ["MeOH\u2013H2O", "CHEMICAL", 127, 135], ["MeOH\u2013H2O", "SIMPLE_CHEMICAL", 127, 135], ["ODS", "TEST", 52, 55], ["Cosmosil", "TEST", 63, 71], ["the TLC profile", "TEST", 241, 256]]], ["F15\u20139 (120 mg) was chromatographed on reverse-phase (10 g) column using a MeOH\u2013H2O solvent gradient (70:30, 80:20, 90:10, 100:0; v/v, each 50 mL) to yield compound 1 (53 mg).", [["F15\u20139", "CHEMICAL", 0, 5], ["MeOH\u2013H2O", "CHEMICAL", 74, 82], ["F15\u20139", "SIMPLE_CHEMICAL", 0, 5], ["MeOH\u2013H2O", "SIMPLE_CHEMICAL", 74, 82], ["a MeOH\u2013H2O solvent gradient", "TREATMENT", 72, 99]]], ["Compound 1 was obtained as orange oil, it exhibited a molecular ion peak at m/z 438 [M+H]+ in the ESI-MS and molecular formula was determined as C26H30O6.", [["C26H30O6", "CHEMICAL", 145, 153], ["[M+H]+", "CHEMICAL", 84, 90], ["C26H30O6", "CHEMICAL", 145, 153], ["orange oil", "SIMPLE_CHEMICAL", 27, 37], ["C26H30O6", "SIMPLE_CHEMICAL", 145, 153], ["M+H", "TEST", 85, 88], ["the ESI", "TEST", 94, 101]]], ["The presence of lavandulyl group was inferred from three methyl protons [\u03b4 1.55 (3H, s, H-6\u2033), 1.62 (3H, s, H-7\u2033), 1.70 (3H, s, H-10\u2033)], three olefinic protons [\u03b4 5.03 (1H, m, H-4\u2033), 4.58 (1H, br s, H-9\u2033a), 4.53 (1H, br s, H-9\u2033b)], two methylene protons [\u03b4 2.53 (1H, m, H-2\u2033), 2.06 (2H, m, H-3\u2033)] and a multiple at \u03b4 2.61 (2H, m, H-1\u2033).", [["lavandulyl", "CHEMICAL", 16, 26], ["methyl", "CHEMICAL", 57, 63], ["\u03b4 1.55 (3H, s, H-6\u2033), 1.62 (3H, s, H-7\u2033), 1.70 (3H, s, H-10\u2033", "CHEMICAL", 73, 133], ["\u03b4 5.03 (1H, m, H-4\u2033), 4.58 (1H, br s, H-9\u2033a), 4.53 (1H, br s, H-9\u2033b", "CHEMICAL", 161, 228], ["methylene", "CHEMICAL", 236, 245], ["lavandulyl", "CHEMICAL", 16, 26], ["methyl", "CHEMICAL", 57, 63], ["\u03b4 1.55 (3H, s, H-6\u2033), 1.62 (3H, s, H-7\u2033), 1.70 (3H, s, H-10\u2033)", "CHEMICAL", 73, 134], ["\u03b4 5.03 (1H, m, H-4\u2033), 4.58 (1H, br s, H-9\u2033a), 4.53 (1H, br s, H-9\u2033b)]", "CHEMICAL", 161, 230], ["methylene", "CHEMICAL", 236, 245], ["\u03b4 2.53 (1H, m, H-2\u2033), 2.06 (2H, m, H-3\u2033)]", "CHEMICAL", 255, 296], ["lavandulyl", "SIMPLE_CHEMICAL", 16, 26], ["methyl protons", "SIMPLE_CHEMICAL", 57, 71], ["\u03b4 1.55 (3H, s, H-6\u2033), 1.62 (3H, s, H-7\u2033), 1.70 (3H, s, H-10\u2033)", "SIMPLE_CHEMICAL", 73, 134], ["olefinic protons", "SIMPLE_CHEMICAL", 143, 159], ["\u03b4 5.03 (1H, m, H-4\u2033), 4.58 (1H, br s, H-9\u2033a), 4.53 (1H, br s, H-9\u2033b)]", "SIMPLE_CHEMICAL", 161, 230], ["methylene protons", "SIMPLE_CHEMICAL", 236, 253], ["\u03b4 2.53 (1H, m, H-2\u2033), 2.06 (2H, m, H-3\u2033)]", "SIMPLE_CHEMICAL", 255, 296], ["H-1\u2033", "SIMPLE_CHEMICAL", 330, 334], ["three methyl protons", "TEST", 51, 71], ["s", "TEST", 105, 106], ["H", "TEST", 108, 109], ["3H", "TEST", 121, 123], ["s", "TEST", 125, 126], ["H", "TEST", 128, 129], ["olefinic protons", "TEST", 143, 159], ["m", "TEST", 173, 174], ["H", "TEST", 176, 177], ["1H", "TEST", 189, 191], ["br s", "TEST", 193, 197], ["H", "TEST", 199, 200], ["1H", "TEST", 213, 215], ["br s", "TEST", 217, 221], ["H", "TEST", 223, 224], ["\u2033b", "TEST", 226, 228], ["methylene protons", "TEST", 236, 253], ["\u03b4", "TEST", 255, 256], ["1H", "TEST", 263, 265], ["m", "TEST", 267, 268], ["H", "TEST", 270, 271], ["2H", "TEST", 283, 285], ["m", "TEST", 287, 288], ["H", "TEST", 290, 291], ["a multiple", "TEST", 301, 311], ["\u03b4", "TEST", 315, 316], ["2H", "TEST", 323, 325], ["m", "TEST", 327, 328]]], ["The 13C NMR spectrum revealed the presence of 26 carbons as one carbonyl group, three methylene carbons, four methyl carbons, eight methines and ten quaternary carbons.", [["methylene", "CHEMICAL", 86, 95], ["methyl carbons", "CHEMICAL", 110, 124], ["methines", "CHEMICAL", 132, 140], ["13C", "CHEMICAL", 4, 7], ["carbons", "CHEMICAL", 49, 56], ["carbonyl", "CHEMICAL", 64, 72], ["methylene carbons", "CHEMICAL", 86, 103], ["methyl carbons", "CHEMICAL", 110, 124], ["methines", "CHEMICAL", 132, 140], ["carbons", "CHEMICAL", 160, 167], ["13C", "SIMPLE_CHEMICAL", 4, 7], ["carbonyl", "SIMPLE_CHEMICAL", 64, 72], ["methylene carbons", "SIMPLE_CHEMICAL", 86, 103], ["methyl carbons", "SIMPLE_CHEMICAL", 110, 124], ["methines", "SIMPLE_CHEMICAL", 132, 140], ["quaternary carbons", "SIMPLE_CHEMICAL", 149, 167], ["The 13C NMR spectrum", "TEST", 0, 20], ["one carbonyl group", "TREATMENT", 60, 78], ["three methylene carbons", "TREATMENT", 80, 103], ["four methyl carbons", "TREATMENT", 105, 124], ["eight methines", "TREATMENT", 126, 140], ["ten quaternary carbons", "TREATMENT", 145, 167], ["quaternary carbons", "OBSERVATION", 149, 167]]], ["Thus, the structure of compound 1 was determined by spectroscopic analysis (MS and NMR) and compared with the data published in the literature (22).", [["spectroscopic analysis", "TEST", 52, 74], ["MS", "TEST", 76, 78], ["NMR", "TEST", 83, 86], ["the data", "TEST", 106, 114]]], ["The compound identified was kuraridin (Fig. 1).Extract and isolation ::: Materials and methods", [["kuraridin", "CHEMICAL", 28, 37], ["kuraridin", "CHEMICAL", 28, 37], ["kuraridin", "SIMPLE_CHEMICAL", 28, 37], ["kuraridin (Fig", "TREATMENT", 28, 42]]]], "ba1a34ae67fb2dcd9ad6cdf6d5b5e1fc32202839": [["Transmissible gastroenteritis virus (TGEV), an enteropathogenic coronavirus (CoV) of porcine, causes lethal watery diarrhea and severe dehydration in piglets and leads to severe economic losses in the swine industry.", [["Transmissible gastroenteritis", "DISEASE", 0, 29], ["enteropathogenic coronavirus", "DISEASE", 47, 75], ["watery diarrhea", "DISEASE", 108, 123], ["dehydration", "DISEASE", 135, 146], ["Transmissible gastroenteritis virus", "ORGANISM", 0, 35], ["TGEV", "ORGANISM", 37, 41], ["enteropathogenic coronavirus", "ORGANISM", 47, 75], ["CoV", "ORGANISM", 77, 80], ["porcine", "ORGANISM", 85, 92], ["piglets", "ORGANISM", 150, 157], ["Transmissible gastroenteritis virus", "SPECIES", 0, 35], ["TGEV", "SPECIES", 37, 41], ["enteropathogenic coronavirus", "SPECIES", 47, 75], ["porcine", "SPECIES", 85, 92], ["piglets", "SPECIES", 150, 157], ["swine", "SPECIES", 201, 206], ["Transmissible gastroenteritis virus", "SPECIES", 0, 35], ["TGEV", "SPECIES", 37, 41], ["enteropathogenic coronavirus", "SPECIES", 47, 75], ["CoV", "SPECIES", 77, 80], ["porcine", "SPECIES", 85, 92], ["swine", "SPECIES", 201, 206], ["Transmissible gastroenteritis virus", "PROBLEM", 0, 35], ["an enteropathogenic coronavirus", "PROBLEM", 44, 75], ["porcine", "TREATMENT", 85, 92], ["lethal watery diarrhea", "PROBLEM", 101, 123], ["severe dehydration in piglets", "PROBLEM", 128, 157], ["severe economic losses in the swine industry", "PROBLEM", 171, 215], ["gastroenteritis", "OBSERVATION", 14, 29], ["enteropathogenic coronavirus", "OBSERVATION", 47, 75], ["lethal", "OBSERVATION_MODIFIER", 101, 107], ["watery", "OBSERVATION_MODIFIER", 108, 114], ["diarrhea", "OBSERVATION", 115, 123], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["dehydration", "OBSERVATION", 135, 146], ["severe", "OBSERVATION_MODIFIER", 171, 177], ["economic", "OBSERVATION_MODIFIER", 178, 186], ["losses", "OBSERVATION", 187, 193]]], ["Unlike most CoVs that antagonize type I interferon (IFN) production, previous studies showed that TGEV infection induces IFN-I production both in vivo and in vitro.", [["TGEV infection", "DISEASE", 98, 112], ["CoVs", "SIMPLE_CHEMICAL", 12, 16], ["type I interferon", "GENE_OR_GENE_PRODUCT", 33, 50], ["IFN", "GENE_OR_GENE_PRODUCT", 52, 55], ["TGEV", "ORGANISM", 98, 102], ["IFN-I", "GENE_OR_GENE_PRODUCT", 121, 126], ["CoVs", "PROTEIN", 12, 16], ["type I interferon", "PROTEIN", 33, 50], ["IFN", "PROTEIN", 52, 55], ["IFN", "PROTEIN", 121, 124], ["TGEV", "SPECIES", 98, 102], ["type I interferon (IFN) production", "PROBLEM", 33, 67], ["previous studies", "TEST", 69, 85], ["TGEV infection", "PROBLEM", 98, 112], ["IFN", "PROBLEM", 121, 124], ["TGEV", "OBSERVATION_MODIFIER", 98, 102], ["infection", "OBSERVATION", 103, 112]]], ["In this study, we found that TGEV infection significantly facilitated IFN-\u03b2 production as well as activation of the transcription factors IFN regulatory factor 3 (IRF3) and nuclear factor-kappaB (NF-\u03baB) in porcine kidney (PK-15) cells.", [["kidney (PK-15) cells", "ANATOMY", 214, 234], ["TGEV infection", "DISEASE", 29, 43], ["TGEV", "ORGANISM", 29, 33], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 70, 75], ["IFN regulatory factor 3", "GENE_OR_GENE_PRODUCT", 138, 161], ["IRF3", "GENE_OR_GENE_PRODUCT", 163, 167], ["nuclear factor-kappaB", "GENE_OR_GENE_PRODUCT", 173, 194], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 196, 201], ["porcine", "ORGANISM", 206, 213], ["kidney", "ORGAN", 214, 220], ["PK-15) cells", "CELL", 222, 234], ["IFN", "PROTEIN", 70, 73], ["\u03b2", "PROTEIN", 74, 75], ["transcription factors", "PROTEIN", 116, 137], ["IFN regulatory factor 3", "PROTEIN", 138, 161], ["IRF3", "PROTEIN", 163, 167], ["nuclear factor-kappaB", "PROTEIN", 173, 194], ["NF-\u03baB", "PROTEIN", 196, 201], ["porcine kidney (PK-15) cells", "CELL_LINE", 206, 234], ["TGEV", "SPECIES", 29, 33], ["this study", "TEST", 3, 13], ["TGEV infection", "PROBLEM", 29, 43], ["IFN regulatory factor", "TEST", 138, 159], ["IRF3", "TEST", 163, 167], ["nuclear factor", "TEST", 173, 187], ["kappaB", "TEST", 188, 194], ["NF", "TEST", 196, 198], ["PK", "TEST", 222, 224], ["TGEV", "OBSERVATION_MODIFIER", 29, 33], ["infection", "OBSERVATION", 34, 43], ["kidney", "ANATOMY", 214, 220]]], ["Screening of TGEV-encoded proteins demonstrated that non-structural protein 14 (nsp14) was the most potent IFN-\u03b2 inducer and induced IFN-\u03b2 production mainly by activating NF-\u03baB but not IRF3.", [["TGEV", "ORGANISM", 13, 17], ["non-structural protein 14", "GENE_OR_GENE_PRODUCT", 53, 78], ["nsp14", "GENE_OR_GENE_PRODUCT", 80, 85], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 107, 112], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 133, 138], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 171, 176], ["IRF3", "GENE_OR_GENE_PRODUCT", 185, 189], ["TGEV-encoded proteins", "PROTEIN", 13, 34], ["non-structural protein 14", "PROTEIN", 53, 78], ["nsp14", "PROTEIN", 80, 85], ["IFN", "PROTEIN", 107, 110], ["IFN", "PROTEIN", 133, 136], ["NF-\u03baB", "PROTEIN", 171, 176], ["IRF3", "PROTEIN", 185, 189], ["TGEV", "SPECIES", 13, 17], ["TGEV", "TEST", 13, 17], ["non-structural protein", "TEST", 53, 75], ["IRF3", "PROBLEM", 185, 189], ["most potent", "OBSERVATION_MODIFIER", 95, 106]]], ["Further analysis showed that nsp14 interacted with DDX1, a member of the DExD/H helicase family.", [["nsp14", "GENE_OR_GENE_PRODUCT", 29, 34], ["DDX1", "GENE_OR_GENE_PRODUCT", 51, 55], ["DExD/H helicase", "GENE_OR_GENE_PRODUCT", 73, 88], ["nsp14", "PROTEIN", 29, 34], ["DDX1", "PROTEIN", 51, 55], ["DExD/H helicase family", "PROTEIN", 73, 95], ["Further analysis", "TEST", 0, 16]]], ["Knockdown of DDX1 by specific small interfering RNA (siRNA) significantly decreased nsp14-induced IFN-\u03b2 production and NF-\u03baB activation.", [["nsp14", "CHEMICAL", 84, 89], ["DDX1", "GENE_OR_GENE_PRODUCT", 13, 17], ["nsp14", "GENE_OR_GENE_PRODUCT", 84, 89], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 98, 103], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 119, 124], ["DDX1", "PROTEIN", 13, 17], ["nsp14", "PROTEIN", 84, 89], ["IFN", "PROTEIN", 98, 101], ["NF-\u03baB", "PROTEIN", 119, 124], ["Knockdown of DDX1", "PROBLEM", 0, 17], ["specific small interfering RNA (siRNA)", "PROBLEM", 21, 59], ["nsp14", "TEST", 84, 89], ["IFN", "TEST", 98, 101], ["NF", "PROBLEM", 119, 121], ["small", "OBSERVATION_MODIFIER", 30, 35], ["interfering RNA", "OBSERVATION", 36, 51], ["decreased", "OBSERVATION_MODIFIER", 74, 83]]], ["Furthermore, TGEV-induced IFN-\u03b2 production and IFN-stimulated gene (ISG) expression were decreased in cells transfected with DDX1-specific siRNA, indicating the vital role of DDX1 to TGEV-induced IFN-\u03b2 responses.", [["cells", "ANATOMY", 102, 107], ["TGEV", "ORGANISM", 13, 17], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["IFN-stimulated gene", "GENE_OR_GENE_PRODUCT", 47, 66], ["ISG", "GENE_OR_GENE_PRODUCT", 68, 71], ["cells", "CELL", 102, 107], ["DDX1", "GENE_OR_GENE_PRODUCT", 125, 129], ["DDX1", "GENE_OR_GENE_PRODUCT", 175, 179], ["TGEV", "ORGANISM", 183, 187], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 196, 201], ["IFN", "PROTEIN", 26, 29], ["IFN", "PROTEIN", 47, 50], ["ISG", "DNA", 68, 71], ["DDX1", "PROTEIN", 125, 129], ["DDX1", "PROTEIN", 175, 179], ["IFN", "PROTEIN", 196, 199], ["\u03b2", "PROTEIN", 200, 201], ["TGEV", "SPECIES", 13, 17], ["TGEV", "SPECIES", 183, 187], ["TGEV", "TEST", 13, 17], ["IFN", "TEST", 26, 29], ["\u03b2 production", "PROBLEM", 30, 42], ["IFN", "TREATMENT", 47, 50], ["DDX1", "TEST", 125, 129]]], ["In summary, our data revealed a potential coactivator role of host RNA helicase DDX1 to the induction of IFN-\u03b2 response initiated by TGEV and demonstrated that nsp14 is an important IFN inducer among the TGEVencoded proteins.", [["DDX1", "GENE_OR_GENE_PRODUCT", 80, 84], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 105, 110], ["TGEV", "ORGANISM", 133, 137], ["nsp14", "GENE_OR_GENE_PRODUCT", 160, 165], ["IFN", "GENE_OR_GENE_PRODUCT", 182, 185], ["host RNA helicase", "PROTEIN", 62, 79], ["DDX1", "PROTEIN", 80, 84], ["IFN", "PROTEIN", 105, 108], ["\u03b2", "PROTEIN", 109, 110], ["nsp14", "PROTEIN", 160, 165], ["IFN", "PROTEIN", 182, 185], ["TGEVencoded proteins", "PROTEIN", 204, 224], ["TGEV", "SPECIES", 133, 137], ["our data", "TEST", 12, 20], ["IFN", "TREATMENT", 105, 108]]]], "PMC7498563": [["IntroductionThe Covid-19 pandemic is fundamentally altering outlooks in many parts of society.", [["The Covid", "TREATMENT", 12, 21], ["fundamentally altering outlooks", "PROBLEM", 37, 68], ["many", "OBSERVATION_MODIFIER", 72, 76], ["parts", "OBSERVATION_MODIFIER", 77, 82], ["society", "OBSERVATION", 86, 93]]], ["With the immediate health implications playing out across the globe, the economic impact is starting to show in labor markets as well.", [["globe", "ANATOMY", 62, 67]]], ["The effects of the expected downturn are likely to be felt differently across industries and segments of the population.", [["likely to be", "UNCERTAINTY", 41, 53], ["population", "OBSERVATION_MODIFIER", 109, 119]]], ["In past crises, especially the young have suffered (see, e.g., Bell and Blanchflower 2011), albeit with marked differences between countries.", [["marked", "OBSERVATION_MODIFIER", 104, 110]]], ["In 2010, as much of the world was dealing with what has been termed the Great Recession, the unemployment rate for the youngest labor market cohort (15\u201324 year-olds) mounted to 41.6% in Spain, but was only at 9.9% in Germany (European Commission 2012).", [["Great", "OBSERVATION_MODIFIER", 72, 77], ["Recession", "OBSERVATION", 78, 87]]], ["If such vocational education and training (VET) programs appear more robust to economic downturns, they may plausibly play a larger role in supporting the labor market as a whole.", [["training (VET) programs", "TREATMENT", 33, 56]]], ["Thus far, research has outlined theoretical possibilities for both pro-cyclical effects, largely driven by reduced staffing needs during an economic downturn, as well as counter-cyclical outcomes, caused, for example, by lowered opportunity costs of training during less productive periods.", [["both pro-cyclical effects", "PROBLEM", 62, 87]]], ["Most empirical studies to date suggest a pro-cyclical, but small to moderate effect (see, e.g., M\u00fchlemann et al. 2009).", [["Most empirical studies", "TEST", 0, 22], ["a pro-cyclical", "PROBLEM", 39, 53], ["small to moderate effect", "PROBLEM", 59, 83], ["small to moderate", "OBSERVATION_MODIFIER", 59, 76]]], ["Subsequently, we attempt to project the likely short-term impact of Covid-19 on the German apprenticeship system, based on currently available information.", [["Covid", "TEST", 68, 73]]], ["We employ annual data on the number of firm-sponsored apprenticeship contracts between 2007 and 2018, processed by the Federal Statistical Office (DESTATIS) and provided by the Federal Institute for Vocational Education and Training (BIBB).", [["firm", "OBSERVATION", 39, 43]]], ["In investigating business cycle effects on this particularly relevant portion of the labor market and deriving a first estimate of the exceptional impact of the current Covid-19-linked downturn, we join a highly timely debate (see L\u00fcthi and Wolter 2020b; Maier 2020 for initial contributions), while there are still possibilities for policy makers and organizational stakeholders to react to what is unfolding.IntroductionThe succeeding sections are organized as follows.", [["sections", "ANATOMY", 437, 445], ["sections", "MULTI-TISSUE_STRUCTURE", 437, 445]]], ["Subsequently, we offer a summary of the literature on business cycle effects on training provision.", [["training provision", "TREATMENT", 80, 98]]], ["Chapters 4 and 5 follow with descriptive statistics and further details on our main variables, as well as the identification strategy used in our analysis.", [["our analysis", "TEST", 142, 154]]], ["We then present our results and conclude with an outlook on the impact of current economic expectations on apprenticeship contracts this fall.The German apprenticeship system and its reliance on firms to offer training positionsVET in Germany is offered through a publicly regulated \u201cdual\u201d system.", [["VET", "DISEASE", 228, 231], ["training positions", "TREATMENT", 210, 228]]], ["We will discuss theoretical motivations for firms to offer training positions in greater detail below, but such motivations may be heavily affected by firms\u2019 expectations about the future business cycle.", [["training positions", "TREATMENT", 59, 77]]], ["Once apprenticeships have begun, contractual training agreements can in effect not be terminated prematurely, unless for extraordinary circumstances.", [["contractual training agreements", "TREATMENT", 33, 64]]], ["Dismissal is significantly easier during the first one to four months of the apprenticeship, a period referred to as \u201cprobation\u201d.", [["significantly", "OBSERVATION_MODIFIER", 13, 26], ["easier", "OBSERVATION_MODIFIER", 27, 33]]], ["The wage floor was initially set at EUR 515 per month and designed to subsequently rise gradually to EUR 620 in 2023 (monthly wage in the first year of the apprenticeship program; BMBF 2019).3 While contracts typically also contain an option to transition into regular employment, they formally end upon completion of the apprenticeship and publication of final examination results (BMBF 2018).", [["final examination", "TEST", 356, 373]]], ["We do not know when exactly those decisions are made, but, depending on the individual industry, recruitment cycles start as early as one year prior to the commencement of the apprenticeship program and go all the way through August or September (see, e.g., Azubiyo GmbH 2020).4 Therefore, current, shorter-term expectations about economic prospects can be assumed to still factor heavily into this year\u2019s capacity considerations.", [["the apprenticeship program", "TREATMENT", 172, 198], ["economic prospects", "TREATMENT", 331, 349]]], ["This has principally been confirmed in previous empirical analysis as well (Dietrich and Gerner 2007).Relevant literatureResearch has identified two relevant underlying motivations for companies to hire apprentices: productivity, i.e. reasons driven by today\u2019s production requirements, or investment, i.e. reasons driven by tomorrow\u2019s production requirements (L\u00fcthi and Wolter 2020a; Merrilees 1983; Wolter and Ryan 2011).", [["previous empirical analysis", "TEST", 39, 66]]], ["The production motive (Lindley 1975) looks at apprentices essentially as just another input factor in the production process, a substitute for other labor, albeit often a less effective one.", [["other labor", "PROBLEM", 143, 154]]], ["The more forward-looking investment variant (Stevens 1994) has its roots in Becker\u2019s (1964) human capital theory and looks at apprentices mainly as future skilled workers.", [["roots", "ANATOMY", 67, 72], ["human", "ORGANISM", 92, 97], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97]]], ["In this regard, firms are willing to incur net costs during the initial training phase, in order to benefit in the future, for example, from secured or cheaper access to skilled labor.", [["skilled labor", "PROBLEM", 170, 183], ["labor", "OBSERVATION", 178, 183]]], ["Prior research contributions have established certain characteristics of the labor market, such as information asymmetries (Acemoglu and Pischke 1999), mobility costs and a resulting reluctance to relocate (Beckmann 2002; Harhoff and Kane 1997), or rigidities associated with trade unions and works councils (Dustmann and Sch\u00f6nberg 2009; Kriechel et al. 2014), which may allow companies to suppress wage levels around the provision of training and recover their investment.", [["rigidities", "PROBLEM", 249, 259]]], ["The investment motive, thus, helps to explain findings in empirical studies that have demonstrated a willingness by German firms to incur substantial net costs during vocational training programs (Dionisius et al. 2009).Relevant literatureBased on these motivations, the effect of business cycle developments on training provision remains ambiguous ex-ante.", [["empirical studies", "TEST", 58, 75], ["vocational training programs", "TREATMENT", 167, 195], ["training provision", "TREATMENT", 312, 330]]], ["Naturally, an economic downturn may lead to fewer transactions, lowered productivity and, therefore, a decrease in demand for labor, including apprentices.", [["a decrease in demand", "PROBLEM", 101, 121], ["labor", "PROBLEM", 126, 131], ["lowered", "OBSERVATION_MODIFIER", 64, 71], ["productivity", "OBSERVATION_MODIFIER", 72, 84], ["decrease", "OBSERVATION_MODIFIER", 103, 111]]], ["Furthermore, as unemployment increases, so does the availability of skilled labor in the labor market, which may alter investment considerations and cause a pro-cyclical response of apprenticeships to business cycles.", [["skilled labor", "PROBLEM", 68, 81]]], ["If, on the other hand, skilled workers can be replaced by apprentices as a means to lower costs, a counter-cyclical movement could also seem plausible.", [["a counter-cyclical movement", "TREATMENT", 97, 124]]], ["Moreover, increasing training efforts during an economic slump can represent a prudent strategy from an investment perspective, if opportunity costs for training tasks of skilled employees are lowered and potential rewards for increased productivity are high, once the economy picks up again (Brunello 2009).", [["an economic slump", "TREATMENT", 45, 62], ["training tasks", "TREATMENT", 153, 167], ["increased productivity", "PROBLEM", 227, 249], ["increasing", "OBSERVATION_MODIFIER", 10, 20]]], ["Additionally, exit options may be relatively poor for apprentices during a recession, which may lower the perceived risks around a firm\u2019s training investments (Bellmann et al. 2014).", [["a recession", "PROBLEM", 73, 84], ["a firm\u2019s training investments", "TREATMENT", 129, 158]]], ["Likely, the temporal dimension of the expected downturn plays a significant role.", [["temporal", "OBSERVATION_MODIFIER", 12, 20], ["dimension", "OBSERVATION_MODIFIER", 21, 30], ["significant", "OBSERVATION_MODIFIER", 64, 75]]], ["Furthermore, in Germany, an estimated 62% of training costs are wage costs of apprentices and only about 23% of training costs are associated with the wage costs of the instructors (Sch\u00f6nfeld et al. 2016), suggesting that opportunity cost reduction plays only a secondary role.", [["opportunity cost reduction", "TREATMENT", 222, 248]]], ["To the extent that a recession is expected to be of short duration, however, firms may still hire new apprentices in 2020, if they expect that they will need to fill skilled-worker positions by 2023.", [["a recession", "PROBLEM", 19, 30], ["recession", "OBSERVATION", 21, 30], ["short duration", "OBSERVATION_MODIFIER", 52, 66]]], ["Of course, even though our focus is on the demand side, with the firm\u2019s decision to provide apprenticeships, it should not be left unmentioned that there is a supply side to this problem as well.", [["course", "OBSERVATION_MODIFIER", 3, 9], ["firm", "OBSERVATION", 65, 69]]], ["Here, too, several effects are conceivable, as unemployment increases the supply of applicants for skilled positions or, on the other hand, interest in apprenticeship positions may decrease, as school graduates opt for further schooling instead of attempting to enter the VET labor market in times of increased unemployment (We\u00dfling et al. 2015).Relevant literatureBased on these theoretical foundations, empirical studies mostly describe a positive (pro-cyclical) effect of business cycle developments on the number of apprenticeship contracts offered.", [["empirical studies", "TEST", 405, 422]]], ["This effect, however, is estimated to be small to moderate in size.", [["small", "OBSERVATION_MODIFIER", 41, 46], ["moderate", "OBSERVATION_MODIFIER", 50, 58], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["Brunello (2009) provides a useful overview of empirical research.", [["empirical research", "TREATMENT", 46, 64]]], ["The relationship is estimated to be small and largely overshadowed by more important demographic drivers (i.e. number of school graduates; M\u00fchlemann et al. 2009).", [["small", "OBSERVATION_MODIFIER", 36, 41]]], ["While they conclude pro-cyclical effects as well, their evaluation provides a more nuanced picture.", [["their evaluation", "TEST", 50, 66]]], ["Emphasizing the importance of longer-term expectations, they argue that unemployment changes largely only lead to postponing of training activities, while GDP changes have a more sustained, moderate effect.", [["GDP", "CHEMICAL", 155, 158], ["GDP", "SIMPLE_CHEMICAL", 155, 158]]], ["Compared to Germany, however, the Swiss labor market may put greater emphasis on productivity-related training motivations (M\u00fchlemann et al. 2010), leaving us with some question marks regarding the transferability of these findings to our empirical context.Relevant literatureWhen looking specifically at the German labor market, research has yet to produce conclusive interpretations of empirical data.", [["empirical data", "TEST", 388, 402]]], ["In what is probably the study covering the longest time period to date, Baldi et al. (2014) investigate business cycle related drivers of apprenticeship contracts offered in Germany between 1999 and 2012.", [["the study", "TEST", 20, 29]]], ["Their analysis shows that the effects of income growth and unemployment rates are small to none during what they refer to as \u201cnormal times\u201d (p.", [["Their analysis", "TEST", 0, 14], ["income growth", "PROBLEM", 41, 54], ["small", "OBSERVATION_MODIFIER", 82, 87]]], ["Their findings indicate that while training activities declined during the crisis years, they did so irrespective of whether the firm was directly affected by the recession, driven more by the general macroeconomic outlook.", [["the firm", "PROBLEM", 125, 133], ["the recession", "PROBLEM", 159, 172], ["firm", "OBSERVATION", 129, 133], ["recession", "OBSERVATION", 163, 172]]], ["Dietrich and Gerner (2007) offer the most directly applicable precedent to our study.", [["our study", "TEST", 75, 84]]], ["In contrast to the previously mentioned publications, they do not look at actual economic developments, as measured by (lagged) income growth or unemployment rates, but instead look at the relationship between short-term business expectations and training provision.", [["training provision", "TREATMENT", 247, 265]]], ["They show a pro-cyclical effect on the amount of training provided by firms, arguing mainly based on corresponding changes in assumptions about future transaction and opportunity cost.Relevant literatureWe build on these prior contributions and offer the first long-term empirical analysis of business cycle effects on the German apprenticeship market that includes both the period of the Great Recession and initial data on economic expectations in the anticipated downturn caused by the Covid-19 pandemic.", [["a pro-cyclical effect", "PROBLEM", 10, 31], ["the Great Recession", "PROBLEM", 385, 404], ["the Covid", "TEST", 485, 494], ["pandemic", "PROBLEM", 498, 506], ["Great", "OBSERVATION_MODIFIER", 389, 394], ["Recession", "OBSERVATION", 395, 404]]], ["L\u00fcthi and Wolter (2020b) have put forward a first projection of likely, decisively negative impacts of current economic developments on the Swiss apprenticeship market.", [["impacts", "OBSERVATION_MODIFIER", 92, 99]]], ["They argue that especially bankruptcies may push the decrease of offered training positions beyond what we have observed during past downturns.", [["decrease", "OBSERVATION_MODIFIER", 53, 61]]], ["We offer an initial view of what can be expected for the German VET labor market based on current business cycle expectations.ifo Business Climate Index (BCI) and ifo Employment Barometer (EB) ::: MethodOur main explanatory variable captures the expectation of firms about the business cycle at a particular point in time, as surveyed on a monthly basis by the ifo Institute.", [["the German VET labor market", "TREATMENT", 53, 80]]], ["It is one of Germany\u2019s most relevant indicators about business cycle developments and a valid predictor of future GDP (Sauer and Wohlrabe 2020).", [["GDP", "CHEMICAL", 114, 117], ["GDP", "SIMPLE_CHEMICAL", 114, 117]]], ["However, Sauer and Wohlrabe (2020, p.93) report that changes in the business expectation variables are highly correlated across states, where regional data is available.ifo Business Climate Index (BCI) and ifo Employment Barometer (EB) ::: MethodBoth indices reflect a significant drop during 2008 (the start of the financial crisis) and illustrate the subsequent recovery.5 In recent years, business cycle expectations continued to increase until August 2018, when both the BCI and the EB reached their peaks.", [["MethodBoth indices", "TEST", 240, 258], ["a significant drop", "PROBLEM", 267, 285], ["the BCI", "TEST", 471, 478], ["significant", "OBSERVATION_MODIFIER", 269, 280], ["drop", "OBSERVATION_MODIFIER", 281, 285]]], ["They then decreased steadily but continuously, until the start of the coronavirus outbreak and the associated lockdown in Germany in March 2020.", [["coronavirus", "DISEASE", 70, 81], ["the coronavirus outbreak", "PROBLEM", 66, 90], ["decreased", "OBSERVATION_MODIFIER", 10, 19]]], ["The BCI (EB) subsequently dropped to 74.3 (86.3) points in April 2020, their lowest values since January 2005.", [["The BCI", "TEST", 0, 7]]], ["In May 2020, the indices recovered slightly to 79.5 (88.6) points and increased further in June 2020 to 86.2 (92.3).", [["the indices", "TEST", 13, 24]]], ["Thus, the average BCI (EB) is 80.1 (89.0) for the second quarter, which is 18.6 (11.7) points lower than the average of the second quarter in 2019.ifo Business Climate Index (BCI) and ifo Employment Barometer (EB) ::: MethodAs we only observe the yearly number of apprenticeship contracts, the indices need to be redefined on an annual basis as well.", [["the average BCI", "TEST", 6, 21]]]], "PMC7409282": [], "PMC7243823": [["IntroductionSince December 2019, China has been experiencing an outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["COVID-19", "CHEMICAL", 76, 84], ["acute respiratory syndrome coronavirus", "DISEASE", 103, 141], ["SARS-CoV-2", "ORGANISM", 145, 155], ["COVID-19", "SPECIES", 76, 84], ["severe acute respiratory syndrome coronavirus", "SPECIES", 96, 141], ["SARS-CoV-2", "SPECIES", 145, 155], ["COVID", "TEST", 76, 81], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 96, 141], ["CoV", "TEST", 150, 153], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory syndrome", "OBSERVATION", 109, 129]]], ["This disease has spread rapidly to multiple countries and become responsible for the greatest pandemic of the century, as declared by the WHO.", [["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12]]], ["The clinical spectrum encompasses asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure (1), with a high mortality estimated around 2% in diagnosed patients (2).", [["upper respiratory tract", "ANATOMY", 63, 86], ["respiratory", "ANATOMY", 128, 139], ["infection", "DISEASE", 47, 56], ["upper respiratory tract illness", "DISEASE", 63, 94], ["viral pneumonia", "DISEASE", 107, 122], ["respiratory failure", "DISEASE", 128, 147], ["tract", "ORGANISM_SUBDIVISION", 81, 86], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["asymptomatic infection", "PROBLEM", 34, 56], ["mild upper respiratory tract illness", "PROBLEM", 58, 94], ["severe viral pneumonia", "PROBLEM", 100, 122], ["respiratory failure", "PROBLEM", 128, 147], ["a high mortality", "PROBLEM", 158, 174], ["asymptomatic", "OBSERVATION_MODIFIER", 34, 46], ["infection", "OBSERVATION", 47, 56], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["upper", "ANATOMY_MODIFIER", 63, 68], ["respiratory tract", "ANATOMY", 69, 86], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["pneumonia", "OBSERVATION", 113, 122], ["respiratory failure", "OBSERVATION", 128, 147], ["high", "OBSERVATION_MODIFIER", 160, 164]]], ["Identification of an efficient therapy has now become a major health emergency to avoid health system saturation, especially the medical capabilities of respiratory resuscitation.", [["respiratory", "ANATOMY", 153, 164], ["an efficient therapy", "TREATMENT", 18, 38], ["respiratory resuscitation", "TREATMENT", 153, 178], ["efficient therapy", "OBSERVATION", 21, 38], ["respiratory resuscitation", "OBSERVATION", 153, 178]]], ["A large number of clinical trials is currently underway, but no treatment of proven efficacy is known at present.", [["clinical trials", "TREATMENT", 18, 33], ["treatment", "TREATMENT", 64, 73], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["The lack of data from large-scale clinical trials involving COVID-19 patients hampers reliable statistical analyses.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["COVID", "TEST", 60, 65]]], ["In this context of emergency, an in-depth analysis of published preliminary data may help to improve our understanding of disease outcomes and shed light upon potentially efficacious treatment strategies.The Initial Focus on HydroxychloroquineSince the discovery that the anti-malarial drug hydroxychloroquine (h-CQ) efficiently inhibits SARS-CoV-2 infection in vitro (3), numerous clinical studies have been undertaken to test its safety and efficacy in the treatment of COVID-19 associated pneumonia (4).", [["HydroxychloroquineSince", "CHEMICAL", 225, 248], ["hydroxychloroquine", "CHEMICAL", 291, 309], ["h-CQ", "CHEMICAL", 311, 315], ["infection", "DISEASE", 349, 358], ["COVID-19", "CHEMICAL", 472, 480], ["pneumonia", "DISEASE", 492, 501], ["HydroxychloroquineSince", "CHEMICAL", 225, 248], ["hydroxychloroquine", "CHEMICAL", 291, 309], ["h-CQ", "CHEMICAL", 311, 315], ["COVID-19", "CHEMICAL", 472, 480], ["HydroxychloroquineSince", "SIMPLE_CHEMICAL", 225, 248], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 291, 309], ["h-CQ", "SIMPLE_CHEMICAL", 311, 315], ["SARS-CoV-2", "ORGANISM", 338, 348], ["COVID-19", "SIMPLE_CHEMICAL", 472, 480], ["SARS-CoV-2", "SPECIES", 338, 348], ["disease outcomes", "PROBLEM", 122, 138], ["efficacious treatment strategies", "TREATMENT", 171, 203], ["HydroxychloroquineSince", "TREATMENT", 225, 248], ["the anti-malarial drug hydroxychloroquine (h-CQ)", "TREATMENT", 268, 316], ["SARS", "PROBLEM", 338, 342], ["CoV-2 infection", "PROBLEM", 343, 358], ["numerous clinical studies", "TEST", 373, 398], ["COVID-19 associated pneumonia", "PROBLEM", 472, 501], ["pneumonia", "OBSERVATION", 492, 501]]], ["Although preliminary observations from China claimed h-CQ benefit (4), two subsequent publications reported contradictory results on its ability to reduce viral carriage (5, 6).Hydroxychloroquine in ChinaIn Shanghai, Chen et al. evaluated the efficacy of h-CQ (400 mg daily for 5 days) in the treatment of 30 symptomatic Chinese patients with COVID-19 (5).", [["Hydroxychloroquine", "CHEMICAL", 177, 195], ["h-CQ", "CHEMICAL", 255, 259], ["Hydroxychloroquine", "CHEMICAL", 177, 195], ["h-CQ", "CHEMICAL", 255, 259], ["COVID-19", "CHEMICAL", 343, 351], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 177, 195], ["h-CQ", "SIMPLE_CHEMICAL", 255, 259], ["patients", "ORGANISM", 329, 337], ["patients", "SPECIES", 329, 337], ["viral carriage", "PROBLEM", 155, 169], ["Hydroxychloroquine", "TREATMENT", 177, 195], ["h-CQ", "TREATMENT", 255, 259], ["COVID", "TEST", 343, 348]]], ["They demonstrated that the viral carriage of nasopharyngeal samples (evaluated by PCR at day 7 post-inclusion) was not statistically different between h-CQ and control groups at the end of the follow up.", [["nasopharyngeal samples", "ANATOMY", 45, 67], ["CQ", "CHEMICAL", 153, 155], ["nasopharyngeal samples", "CANCER", 45, 67], ["CQ", "SIMPLE_CHEMICAL", 153, 155], ["the viral carriage of nasopharyngeal samples", "PROBLEM", 23, 67], ["PCR", "TEST", 82, 85], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["nasopharyngeal", "ANATOMY", 45, 59]]], ["Given that the median duration of viral shedding in COVID-19 has been reported to be around 20 days in Chinese patients (1), it is interesting to note that the viral carriage rapidly decreased in both groups after 4 days of treatment, with 90% of patients proved to be SARS-CoV-2 negative at day 7.", [["COVID-19", "CHEMICAL", 52, 60], ["SARS", "DISEASE", 269, 273], ["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 247, 255], ["CoV-2", "ORGANISM", 274, 279], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 247, 255], ["viral shedding", "PROBLEM", 34, 48], ["the viral carriage", "PROBLEM", 156, 174], ["treatment", "TREATMENT", 224, 233], ["SARS", "TEST", 269, 273], ["CoV", "TEST", 274, 277], ["decreased", "OBSERVATION_MODIFIER", 183, 192]]], ["Interestingly, all patients included in this study also received some therapies recommended by the National Health Commission (NHC) of China, in particular 100% of them received inhalation of the antiviral cytokine interferon (IFN)-\u03b1-2b.Type I Interferon Nebulization in the treatment of COVID-19 patientsType I IFNs (including IFN-\u03b1 and IFN-\u03b2) are antiviral cytokines produced by bronchial epithelial cells in response to viral infection.", [["bronchial epithelial cells", "ANATOMY", 381, 407], ["viral infection", "DISEASE", 423, 438], ["patients", "ORGANISM", 19, 27], ["interferon (IFN)-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 215, 236], ["Type I Interferon", "GENE_OR_GENE_PRODUCT", 237, 254], ["patients", "ORGANISM", 297, 305], ["Type I IFNs", "GENE_OR_GENE_PRODUCT", 305, 316], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 328, 333], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 338, 343], ["bronchial epithelial cells", "CELL", 381, 407], ["antiviral cytokine interferon (IFN)-\u03b1-2b", "PROTEIN", 196, 236], ["Type I IFNs", "PROTEIN", 305, 316], ["IFN", "PROTEIN", 328, 331], ["\u03b1", "PROTEIN", 332, 333], ["IFN", "PROTEIN", 338, 341], ["-\u03b2", "PROTEIN", 341, 343], ["antiviral cytokines", "PROTEIN", 349, 368], ["bronchial epithelial cells", "CELL_TYPE", 381, 407], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 297, 305], ["this study", "TEST", 40, 50], ["some therapies", "TREATMENT", 65, 79], ["inhalation", "TREATMENT", 178, 188], ["the antiviral cytokine interferon (IFN)", "TREATMENT", 192, 231], ["Type I Interferon Nebulization", "TREATMENT", 237, 267], ["Type I IFNs", "PROBLEM", 305, 316], ["IFN", "TEST", 328, 331], ["\u03b1", "PROBLEM", 332, 333], ["IFN", "PROBLEM", 338, 341], ["antiviral cytokines", "PROBLEM", 349, 368], ["bronchial epithelial cells", "PROBLEM", 381, 407], ["viral infection", "PROBLEM", 423, 438], ["Interferon Nebulization", "OBSERVATION", 244, 267], ["antiviral cytokines", "OBSERVATION", 349, 368], ["bronchial", "ANATOMY", 381, 390], ["epithelial cells", "OBSERVATION", 391, 407], ["viral infection", "OBSERVATION", 423, 438]]], ["They display the ability to bind the surface of infected and neighboring cells and promote the induction of around 300 different IFN-inducible genes (ISGs) that subsequently prevent virus protein trafficking, virus RNA synthesis or virion assembly and release (7).Type I Interferon Nebulization in the treatment of COVID-19 patientsIn vitro, type I IFN inhibits the replication of both SARS-CoV (8) and SARS-CoV-2 (9) (pre-printed publication).", [["surface", "ANATOMY", 37, 44], ["cells", "ANATOMY", 73, 78], ["surface", "CELLULAR_COMPONENT", 37, 44], ["cells", "CELL", 73, 78], ["IFN-inducible genes", "GENE_OR_GENE_PRODUCT", 129, 148], ["Type I Interferon", "GENE_OR_GENE_PRODUCT", 264, 281], ["patients", "ORGANISM", 324, 332], ["type I IFN", "GENE_OR_GENE_PRODUCT", 342, 352], ["SARS-CoV", "ORGANISM", 386, 394], ["infected and neighboring cells", "CELL_TYPE", 48, 78], ["IFN-inducible genes", "DNA", 129, 148], ["ISGs", "DNA", 150, 154], ["type I IFN", "PROTEIN", 342, 352], ["patients", "SPECIES", 324, 332], ["SARS-CoV", "SPECIES", 386, 394], ["SARS-CoV-2", "SPECIES", 403, 413], ["infected and neighboring cells", "PROBLEM", 48, 78], ["the induction", "TREATMENT", 91, 104], ["inducible genes (ISGs)", "PROBLEM", 133, 155], ["virus protein trafficking", "PROBLEM", 182, 207], ["virus RNA synthesis", "TREATMENT", 209, 228], ["Type I Interferon Nebulization", "TREATMENT", 264, 294], ["type I IFN", "PROBLEM", 342, 352], ["both SARS", "TEST", 381, 390], ["CoV", "TEST", 391, 394], ["SARS", "TEST", 403, 407], ["CoV", "TEST", 408, 411], ["infected", "OBSERVATION", 48, 56], ["Interferon Nebulization", "OBSERVATION", 271, 294]]], ["Therefore, the rapid decrease of SARS-CoV-2 carriage observed in the patients of the Chen et al. study may be linked to atomized IFN-\u03b1-2b therapy (5).", [["SARS", "DISEASE", 33, 37], ["atomized IFN-\u03b1-2b", "CHEMICAL", 120, 137], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 33, 43], ["patients", "ORGANISM", 69, 77], ["IFN-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 129, 137], ["IFN", "PROTEIN", 129, 132], ["\u03b1", "PROTEIN", 133, 134], ["patients", "SPECIES", 69, 77], ["the rapid decrease of SARS", "PROBLEM", 11, 37], ["study", "TEST", 97, 102], ["IFN", "TEST", 129, 132], ["2b therapy", "TREATMENT", 135, 145], ["rapid", "OBSERVATION_MODIFIER", 15, 20], ["decrease", "OBSERVATION_MODIFIER", 21, 29]]], ["In line with this hypothesis, Liu et al. claimed that a combination therapy of low-dose systematic corticosteroids, lopinavir/ritonavir, and atomization inhalation of IFN-\u03b1-2b participated to the observed 0% mortality in their COVID-19 patients in Shenzen, China (10).", [["lopinavir/ritonavir", "CHEMICAL", 116, 135], ["IFN-\u03b1-2b", "CHEMICAL", 167, 175], ["lopinavir", "CHEMICAL", 116, 125], ["ritonavir", "CHEMICAL", 126, 135], ["lopinavir", "SIMPLE_CHEMICAL", 116, 125], ["ritonavir", "SIMPLE_CHEMICAL", 126, 135], ["IFN-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 167, 175], ["patients", "ORGANISM", 236, 244], ["IFN", "PROTEIN", 167, 170], ["patients", "SPECIES", 236, 244], ["a combination therapy", "TREATMENT", 54, 75], ["low-dose systematic corticosteroids", "TREATMENT", 79, 114], ["lopinavir", "TREATMENT", 116, 125], ["ritonavir", "TREATMENT", 126, 135], ["atomization inhalation", "TREATMENT", 141, 163], ["IFN", "TREATMENT", 167, 170]]], ["According to Chen et al., the use of inhaled IFN is also associated with decreased mortality in COVID-19 patients from Wuhan (OR = 2,32 IC95% [1,36;3,97] calculated by our group using the Miettinen method) (11).", [["IFN", "CHEMICAL", 45, 48], ["patients", "ORGANISM", 105, 113], ["IFN", "PROTEIN", 45, 48], ["patients", "SPECIES", 105, 113], ["inhaled IFN", "TREATMENT", 37, 48], ["decreased mortality", "PROBLEM", 73, 92]]], ["More recently, Maiti et al. suggested that a polymorphism in the gene encoding IFIH1 (InterFeron-Induced Helicase 1), a host protein that senses the presence of viral RNA and subsequently promotes IFN production, may render African-American more vulnerable to SARS-CoV-2 infection.", [["SARS", "DISEASE", 260, 264], ["infection", "DISEASE", 271, 280], ["IFIH1", "GENE_OR_GENE_PRODUCT", 79, 84], ["InterFeron-Induced Helicase 1", "GENE_OR_GENE_PRODUCT", 86, 115], ["IFN", "GENE_OR_GENE_PRODUCT", 197, 200], ["SARS-CoV-2", "ORGANISM", 260, 270], ["IFIH1", "PROTEIN", 79, 84], ["InterFeron", "PROTEIN", 86, 96], ["Induced Helicase 1", "PROTEIN", 97, 115], ["viral RNA", "RNA", 161, 170], ["IFN", "PROTEIN", 197, 200], ["SARS-CoV", "SPECIES", 260, 268], ["a polymorphism", "PROBLEM", 43, 57], ["the gene encoding IFIH1 (InterFeron-Induced Helicase", "TREATMENT", 61, 113], ["a host protein", "TREATMENT", 118, 132], ["viral RNA", "PROBLEM", 161, 170], ["SARS", "PROBLEM", 260, 264], ["CoV-2 infection", "PROBLEM", 265, 280], ["viral RNA", "OBSERVATION", 161, 170], ["infection", "OBSERVATION", 271, 280]]], ["This observation lead the author to suggest that type I IFN supplement could be developed as an effective treatment for SARS-CoV-2 (12).Type I Interferon Nebulization in the treatment of COVID-19 patientsAtomized IFN-\u03b1-2b is currently the first treatment cited by the Chinese NHC for COVID-19 (13).", [["IFN", "CHEMICAL", 56, 59], ["SARS", "DISEASE", 120, 124], ["IFN-\u03b1-2b", "CHEMICAL", 213, 221], ["COVID-19", "CHEMICAL", 284, 292], ["type I IFN", "GENE_OR_GENE_PRODUCT", 49, 59], ["SARS-CoV-2", "ORGANISM", 120, 130], ["Type I Interferon", "GENE_OR_GENE_PRODUCT", 136, 153], ["patients", "ORGANISM", 196, 204], ["IFN-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 213, 221], ["IFN", "PROTEIN", 56, 59], ["IFN", "PROTEIN", 213, 216], ["\u03b1", "PROTEIN", 217, 218], ["patients", "SPECIES", 196, 204], ["SARS-CoV", "SPECIES", 120, 128], ["type I IFN supplement", "TREATMENT", 49, 70], ["an effective treatment", "TREATMENT", 93, 115], ["SARS", "PROBLEM", 120, 124], ["CoV", "TEST", 125, 128], ["Type I Interferon Nebulization", "TREATMENT", 136, 166], ["IFN", "TEST", 213, 216], ["COVID", "TEST", 284, 289], ["Interferon Nebulization", "OBSERVATION", 143, 166]]], ["Indeed, clinical nebulization of IFN-\u03b1 has been historically used in China to treat viral pneumonia associated with SARS-CoV, middle east respiratory syndrome coronavirus (MERS) and respiratory syncytial virus (14, 15).", [["IFN-\u03b1", "CHEMICAL", 33, 38], ["viral pneumonia", "DISEASE", 84, 99], ["SARS-CoV", "DISEASE", 116, 124], ["respiratory syndrome coronavirus", "DISEASE", 138, 170], ["respiratory syncytial virus", "DISEASE", 182, 209], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 33, 38], ["SARS-CoV", "ORGANISM", 116, 124], ["middle east respiratory syndrome coronavirus", "ORGANISM", 126, 170], ["respiratory syncytial virus", "ORGANISM", 182, 209], ["IFN-\u03b1", "PROTEIN", 33, 38], ["respiratory syncytial virus", "SPECIES", 182, 209], ["SARS-CoV", "SPECIES", 116, 124], ["middle east respiratory syndrome coronavirus", "SPECIES", 126, 170], ["respiratory syncytial virus", "SPECIES", 182, 209], ["clinical nebulization of IFN", "TREATMENT", 8, 36], ["viral pneumonia", "PROBLEM", 84, 99], ["SARS", "PROBLEM", 116, 120], ["CoV", "PROBLEM", 121, 124], ["middle east respiratory syndrome coronavirus", "PROBLEM", 126, 170], ["respiratory syncytial virus", "PROBLEM", 182, 209], ["pneumonia", "OBSERVATION", 90, 99], ["middle", "ANATOMY_MODIFIER", 126, 132], ["respiratory syndrome", "OBSERVATION", 138, 158], ["respiratory", "ANATOMY", 182, 193], ["syncytial virus", "OBSERVATION", 194, 209]]], ["Its efficiency in treating severe bronchiolitis appears to be superior to the parenteral route1 and to expose to fewer undesirable effects, including hematological toxicity, fever, and depression (15).Hydroxychloroquine in FranceH-CQ was also evaluated in France, and the conclusion of the authors differed from the Chinese study.", [["bronchiolitis", "DISEASE", 34, 47], ["hematological toxicity", "DISEASE", 150, 172], ["fever", "DISEASE", 174, 179], ["depression", "DISEASE", 185, 195], ["Hydroxychloroquine", "CHEMICAL", 201, 219], ["FranceH-CQ", "CHEMICAL", 223, 233], ["Hydroxychloroquine", "CHEMICAL", 201, 219], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 201, 219], ["FranceH-CQ", "SIMPLE_CHEMICAL", 223, 233], ["severe bronchiolitis", "PROBLEM", 27, 47], ["the parenteral route1", "TREATMENT", 74, 95], ["hematological toxicity", "PROBLEM", 150, 172], ["fever", "PROBLEM", 174, 179], ["depression", "PROBLEM", 185, 195], ["Hydroxychloroquine", "TREATMENT", 201, 219], ["the Chinese study", "TEST", 312, 329], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["bronchiolitis", "OBSERVATION", 34, 47], ["fewer", "OBSERVATION_MODIFIER", 113, 118], ["undesirable", "OBSERVATION", 119, 130], ["hematological toxicity", "OBSERVATION", 150, 172]]], ["On March 20th of 2020, Gautret et al. undertook an open label, non-randomized clinical trial in 42 patients with confirmed COVID-19, aimed to evaluate the effect of h-CQ (200 mg TID for 10 days) on SARS-CoV-2 respiratory viral load (6).", [["h-CQ", "CHEMICAL", 165, 169], ["TID", "CHEMICAL", 178, 181], ["h-CQ", "CHEMICAL", 165, 169], ["TID", "CHEMICAL", 178, 181], ["patients", "ORGANISM", 99, 107], ["h-CQ", "SIMPLE_CHEMICAL", 165, 169], ["patients", "SPECIES", 99, 107], ["COVID", "TEST", 123, 128], ["h-CQ", "TREATMENT", 165, 169], ["SARS", "TEST", 198, 202], ["CoV", "TEST", 203, 206], ["respiratory viral load", "TEST", 209, 231]]], ["They observed that h-CQ treatment led to a reduction of viral carriage at day 6.", [["h-CQ", "CHEMICAL", 19, 23], ["h-CQ", "CHEMICAL", 19, 23], ["h-CQ", "SIMPLE_CHEMICAL", 19, 23], ["h-CQ treatment", "TREATMENT", 19, 33], ["viral carriage", "PROBLEM", 56, 70]]], ["However, when excluding asymptomatic patients as well as patients symptomatic for more than 8 days (potentially in remission phase) none of the seven patients in the control group and only two among the 10 patients treated with h-CQ alone became viral carriage negative (NS; p = 0.48) at day 6 (statistical sensitivity analysis performed ourselves).", [["h-CQ", "CHEMICAL", 228, 232], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 206, 214], ["h-CQ", "SIMPLE_CHEMICAL", 228, 232], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 206, 214], ["viral carriage", "PROBLEM", 246, 260], ["NS", "TREATMENT", 271, 273], ["statistical sensitivity analysis", "TEST", 295, 327]]], ["In contrast, a subgroup of six patients treated with both h-CQ and azithromycin (500 mg on day 1, followed by 250 mg daily for the subsequent 4 days) converted to viral carriage negative status at day 6.", [["h-CQ", "CHEMICAL", 58, 62], ["azithromycin", "CHEMICAL", 67, 79], ["h-CQ", "CHEMICAL", 58, 62], ["azithromycin", "CHEMICAL", 67, 79], ["patients", "ORGANISM", 31, 39], ["h-CQ", "SIMPLE_CHEMICAL", 58, 62], ["azithromycin", "SIMPLE_CHEMICAL", 67, 79], ["patients", "SPECIES", 31, 39], ["both h-CQ", "TREATMENT", 53, 62], ["azithromycin", "TREATMENT", 67, 79]]], ["In line with this observation, a subsequent set of data published by Gautret et al. on March 27th of 2020 showed a rapid fall of nasopharyngeal viral load in 80 patients (5 asymptomatic) treated exclusively with a combination of h-CQ and azithromycin, with 74% of patients becoming SARS-CoV-2 negative at day 6 and 83% negative at day 7 (16).Azithromycin in the Treatment of COVID-19 PatientsApart from its anti-bacterial role, azithromycin has been reported to increase rhinovirus-induced type I and type III IFN response in bronchial epithelial cells from healthy donors (17) asthmatic individuals (18) and patients with chronic obstructive pulmonary disease (19).", [["nasopharyngeal", "ANATOMY", 129, 143], ["bronchial epithelial cells", "ANATOMY", 526, 552], ["pulmonary", "ANATOMY", 643, 652], ["h-CQ", "CHEMICAL", 229, 233], ["azithromycin", "CHEMICAL", 238, 250], ["SARS", "DISEASE", 282, 286], ["Azithromycin", "CHEMICAL", 342, 354], ["azithromycin", "CHEMICAL", 428, 440], ["chronic obstructive pulmonary disease", "DISEASE", 623, 660], ["h-CQ", "CHEMICAL", 229, 233], ["azithromycin", "CHEMICAL", 238, 250], ["Azithromycin", "CHEMICAL", 342, 354], ["azithromycin", "CHEMICAL", 428, 440], ["nasopharyngeal", "ORGAN", 129, 143], ["patients", "ORGANISM", 161, 169], ["h-CQ", "SIMPLE_CHEMICAL", 229, 233], ["azithromycin", "SIMPLE_CHEMICAL", 238, 250], ["patients", "ORGANISM", 264, 272], ["Azithromycin", "SIMPLE_CHEMICAL", 342, 354], ["Patients", "ORGANISM", 384, 392], ["azithromycin", "SIMPLE_CHEMICAL", 428, 440], ["rhinovirus", "ORGANISM", 471, 481], ["type III IFN", "GENE_OR_GENE_PRODUCT", 501, 513], ["bronchial epithelial cells", "CELL", 526, 552], ["donors", "ORGANISM", 566, 572], ["patients", "ORGANISM", 609, 617], ["pulmonary", "ORGAN", 643, 652], ["IFN", "PROTEIN", 510, 513], ["bronchial epithelial cells", "CELL_TYPE", 526, 552], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 264, 272], ["Patients", "SPECIES", 384, 392], ["patients", "SPECIES", 609, 617], ["a rapid fall of nasopharyngeal viral load", "PROBLEM", 113, 154], ["h-CQ", "TREATMENT", 229, 233], ["azithromycin", "TREATMENT", 238, 250], ["SARS", "PROBLEM", 282, 286], ["CoV", "TEST", 287, 290], ["Azithromycin", "TREATMENT", 342, 354], ["COVID", "TEST", 375, 380], ["its anti-bacterial role", "TREATMENT", 403, 426], ["azithromycin", "TREATMENT", 428, 440], ["rhinovirus", "PROBLEM", 471, 481], ["type I", "PROBLEM", 490, 496], ["type III IFN response", "PROBLEM", 501, 522], ["bronchial epithelial cells", "PROBLEM", 526, 552], ["asthmatic individuals", "PROBLEM", 578, 599], ["chronic obstructive pulmonary disease", "PROBLEM", 623, 660], ["nasopharyngeal", "ANATOMY", 129, 143], ["viral load", "OBSERVATION", 144, 154], ["rhinovirus", "OBSERVATION", 471, 481], ["bronchial epithelial cells", "OBSERVATION", 526, 552], ["chronic", "OBSERVATION_MODIFIER", 623, 630], ["obstructive", "OBSERVATION_MODIFIER", 631, 642], ["pulmonary", "ANATOMY", 643, 652], ["disease", "OBSERVATION", 653, 660]]], ["Azithromycin amelioration of viral-induced IFN also protects against Zika virus infection (20) and reduces the recurrence of severe lower respiratory tract illnesses in children (21).", [["lower respiratory tract", "ANATOMY", 132, 155], ["Azithromycin", "CHEMICAL", 0, 12], ["IFN", "CHEMICAL", 43, 46], ["Zika virus infection", "DISEASE", 69, 89], ["lower respiratory tract illnesses", "DISEASE", 132, 165], ["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["IFN", "GENE_OR_GENE_PRODUCT", 43, 46], ["Zika virus", "ORGANISM", 69, 79], ["lower", "ORGANISM_SUBDIVISION", 132, 137], ["respiratory tract", "ORGANISM_SUBDIVISION", 138, 155], ["children", "ORGANISM", 169, 177], ["IFN", "PROTEIN", 43, 46], ["children", "SPECIES", 169, 177], ["Zika virus", "SPECIES", 69, 79], ["Azithromycin amelioration", "TREATMENT", 0, 25], ["viral-induced IFN", "TREATMENT", 29, 46], ["Zika virus infection", "PROBLEM", 69, 89], ["severe lower respiratory tract illnesses", "PROBLEM", 125, 165], ["viral", "OBSERVATION", 29, 34], ["recurrence", "OBSERVATION_MODIFIER", 111, 121], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["lower", "ANATOMY_MODIFIER", 132, 137], ["respiratory tract", "ANATOMY", 138, 155]]], ["In the study by Gautret et al. (6, 16), the potential anti-viral role of azithromycin was mentioned but not discussed in detail since they mainly focused on h-CQ.", [["azithromycin", "CHEMICAL", 73, 85], ["azithromycin", "CHEMICAL", 73, 85], ["azithromycin", "SIMPLE_CHEMICAL", 73, 85], ["h-CQ", "SIMPLE_CHEMICAL", 157, 161], ["h-CQ", "PROTEIN", 157, 161], ["the study", "TEST", 3, 12], ["azithromycin", "TREATMENT", 73, 85]]], ["However, the possibility must be considered that azithromycin may be responsible for the rapid reduction of viral carriage in this subgroup of h-CQ-treated French patients.Anti-Inflammatory Properties of Both Atomized Type I IFN and AzithromycinBeyond the viral infection, accumulating evidence suggests that a subgroup of patients with severe COVID-19 develop a severe inflammatory syndrome (associated with a dramatical rise in type II IFN and IL-6 serum levels), enhancing disease severity and mortality (22).", [["serum", "ANATOMY", 451, 456], ["azithromycin", "CHEMICAL", 49, 61], ["h-CQ", "CHEMICAL", 143, 147], ["viral infection", "DISEASE", 256, 271], ["inflammatory syndrome", "DISEASE", 370, 391], ["azithromycin", "CHEMICAL", 49, 61], ["azithromycin", "SIMPLE_CHEMICAL", 49, 61], ["h-CQ", "SIMPLE_CHEMICAL", 143, 147], ["patients", "ORGANISM", 163, 171], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 218, 228], ["AzithromycinBeyond", "SIMPLE_CHEMICAL", 233, 251], ["patients", "ORGANISM", 323, 331], ["type II IFN", "GENE_OR_GENE_PRODUCT", 430, 441], ["IL-6", "GENE_OR_GENE_PRODUCT", 446, 450], ["serum", "ORGANISM_SUBSTANCE", 451, 456], ["Atomized Type I IFN", "PROTEIN", 209, 228], ["type II IFN", "PROTEIN", 430, 441], ["IL", "PROTEIN", 446, 448], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 323, 331], ["azithromycin", "TREATMENT", 49, 61], ["viral carriage", "PROBLEM", 108, 122], ["Anti-Inflammatory Properties", "TREATMENT", 172, 200], ["Atomized Type I IFN", "TREATMENT", 209, 228], ["AzithromycinBeyond", "TREATMENT", 233, 251], ["the viral infection", "PROBLEM", 252, 271], ["severe COVID", "PROBLEM", 337, 349], ["a severe inflammatory syndrome", "PROBLEM", 361, 391], ["a dramatical rise in type II IFN", "PROBLEM", 409, 441], ["IL", "TEST", 446, 448], ["serum levels", "TEST", 451, 463], ["enhancing disease severity", "PROBLEM", 466, 492], ["rapid", "OBSERVATION_MODIFIER", 89, 94], ["reduction", "OBSERVATION_MODIFIER", 95, 104], ["viral carriage", "OBSERVATION", 108, 122], ["Inflammatory", "OBSERVATION_MODIFIER", 177, 189], ["viral", "OBSERVATION_MODIFIER", 256, 261], ["infection", "OBSERVATION", 262, 271], ["severe", "OBSERVATION_MODIFIER", 363, 369], ["inflammatory syndrome", "OBSERVATION", 370, 391], ["enhancing", "OBSERVATION_MODIFIER", 466, 475], ["disease", "OBSERVATION", 476, 483]]], ["In this condition both atomized type I IFN and azithromycin may be beneficial as they can also downregulate inflammation (7, 23) and in particular type II IFN pathway in vitro (18, 24).DiscussionThese very recent preliminary data suggest a potential therapeutic benefit of type I IFN pathway stimulation, which may become a key approach in treating COVID-19, possibly in association with direct antiviral agents.", [["IFN", "CHEMICAL", 39, 42], ["azithromycin", "CHEMICAL", 47, 59], ["inflammation", "DISEASE", 108, 120], ["COVID-19", "CHEMICAL", 349, 357], ["azithromycin", "CHEMICAL", 47, 59], ["COVID-19", "CHEMICAL", 349, 357], ["type I IFN", "GENE_OR_GENE_PRODUCT", 32, 42], ["azithromycin", "SIMPLE_CHEMICAL", 47, 59], ["type II IFN", "GENE_OR_GENE_PRODUCT", 147, 158], ["type I IFN", "GENE_OR_GENE_PRODUCT", 273, 283], ["COVID-19", "CELL", 349, 357], ["atomized type I IFN", "PROTEIN", 23, 42], ["IFN", "PROTEIN", 155, 158], ["IFN", "PROTEIN", 280, 283], ["azithromycin", "TREATMENT", 47, 59], ["inflammation", "PROBLEM", 108, 120], ["type I IFN pathway stimulation", "TREATMENT", 273, 303], ["COVID", "TEST", 349, 354], ["direct antiviral agents", "TREATMENT", 388, 411], ["inflammation", "OBSERVATION", 108, 120]]], ["The currently ongoing Solidarity and Discovery clinical trials, both of which include an arm of patients treated with IFN-\u03b2-1a administered subcutaneously in combination with ritonavir and lopinavir, will help to explore this hypothesis (25).", [["subcutaneously", "ANATOMY", 140, 154], ["IFN-\u03b2-1a", "CHEMICAL", 118, 126], ["ritonavir", "CHEMICAL", 175, 184], ["lopinavir", "CHEMICAL", 189, 198], ["ritonavir", "CHEMICAL", 175, 184], ["lopinavir", "CHEMICAL", 189, 198], ["patients", "ORGANISM", 96, 104], ["IFN-\u03b2-1a", "GENE_OR_GENE_PRODUCT", 118, 126], ["ritonavir", "SIMPLE_CHEMICAL", 175, 184], ["lopinavir", "SIMPLE_CHEMICAL", 189, 198], ["IFN", "PROTEIN", 118, 121], ["patients", "SPECIES", 96, 104], ["IFN", "TREATMENT", 118, 121], ["\u03b2", "TREATMENT", 122, 123], ["ritonavir", "TREATMENT", 175, 184], ["lopinavir", "TREATMENT", 189, 198], ["arm", "ANATOMY", 89, 92]]], ["In comparison with this strategy, atomized IFN, which has already shown benefit in China, has the advantage to directly target the lungs and to reduce the risks of systemic side effects.", [["lungs", "ANATOMY", 131, 136], ["IFN", "CHEMICAL", 43, 46], ["lungs", "ORGAN", 131, 136], ["atomized IFN", "PROTEIN", 34, 46], ["systemic side effects", "PROBLEM", 164, 185], ["lungs", "ANATOMY", 131, 136]]], ["However, it might raise concerns about nebulization side effects, including preservative toxicity, pharmacokinetics, and potential viral dispersion.", [["toxicity", "DISEASE", 89, 97], ["nebulization side effects", "PROBLEM", 39, 64], ["preservative toxicity", "PROBLEM", 76, 97], ["potential viral dispersion", "PROBLEM", 121, 147], ["potential", "UNCERTAINTY", 121, 130], ["viral dispersion", "OBSERVATION", 131, 147]]], ["For these reasons, we suggest that pulmonary nebulization of type I IFN may be useful for patients with a moderate to severe form of the disease and that azithromycin may represent an interesting strategy for patients with less aggressive forms.", [["pulmonary", "ANATOMY", 35, 44], ["type I IFN", "CHEMICAL", 61, 71], ["azithromycin", "CHEMICAL", 154, 166], ["azithromycin", "CHEMICAL", 154, 166], ["pulmonary", "ORGAN", 35, 44], ["type I IFN", "GENE_OR_GENE_PRODUCT", 61, 71], ["patients", "ORGANISM", 90, 98], ["azithromycin", "SIMPLE_CHEMICAL", 154, 166], ["patients", "ORGANISM", 209, 217], ["type I IFN", "PROTEIN", 61, 71], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 209, 217], ["pulmonary nebulization of type I IFN", "TREATMENT", 35, 71], ["the disease", "PROBLEM", 133, 144], ["azithromycin", "TREATMENT", 154, 166], ["pulmonary", "ANATOMY", 35, 44], ["disease", "OBSERVATION", 137, 144]]], ["In favor of this strategy, azithromycin presents the advantage of being cheap, easily applicable to outpatient care and raising less safety concerns than h-CQ, in particular cardiovascular complications.", [["cardiovascular", "ANATOMY", 174, 188], ["azithromycin", "CHEMICAL", 27, 39], ["cardiovascular complications", "DISEASE", 174, 202], ["azithromycin", "CHEMICAL", 27, 39], ["azithromycin", "SIMPLE_CHEMICAL", 27, 39], ["h-CQ", "SIMPLE_CHEMICAL", 154, 158], ["cardiovascular", "ANATOMICAL_SYSTEM", 174, 188], ["this strategy", "TREATMENT", 12, 25], ["azithromycin", "TREATMENT", 27, 39], ["outpatient care", "TREATMENT", 100, 115], ["particular cardiovascular complications", "PROBLEM", 163, 202], ["cardiovascular", "ANATOMY", 174, 188], ["complications", "OBSERVATION", 189, 202]]], ["Regarding drug safety, it has to be underlined that under specific conditions type I IFN response can increase the susceptibility to bacterial assault (26, 27).", [["bacterial assault", "DISEASE", 133, 150], ["type I IFN", "GENE_OR_GENE_PRODUCT", 78, 88], ["IFN", "PROTEIN", 85, 88], ["the susceptibility to bacterial assault", "PROBLEM", 111, 150], ["bacterial", "OBSERVATION_MODIFIER", 133, 142], ["assault", "OBSERVATION", 143, 150]]], ["In particular, bacterial infections have been noted in patients receiving prolonged systemic IFN-\u03b1-2b therapy for chronic hepatitis C virus infection (28\u201330).", [["bacterial infections", "DISEASE", 15, 35], ["IFN-\u03b1-2b", "CHEMICAL", 93, 101], ["chronic hepatitis C virus infection", "DISEASE", 114, 149], ["patients", "ORGANISM", 55, 63], ["IFN-\u03b1-2b", "GENE_OR_GENE_PRODUCT", 93, 101], ["chronic hepatitis C virus", "ORGANISM", 114, 139], ["IFN", "PROTEIN", 93, 96], ["patients", "SPECIES", 55, 63], ["hepatitis C virus", "SPECIES", 122, 139], ["hepatitis C virus", "SPECIES", 122, 139], ["bacterial infections", "PROBLEM", 15, 35], ["prolonged systemic IFN", "TREATMENT", 74, 96], ["2b therapy", "TREATMENT", 99, 109], ["chronic hepatitis C virus infection", "PROBLEM", 114, 149], ["bacterial", "OBSERVATION_MODIFIER", 15, 24], ["infections", "OBSERVATION", 25, 35], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["hepatitis", "OBSERVATION", 122, 131]]], ["Since preliminary data obtained in China suggest that patients under type I IFN therapy may rapidly become viral carriage negative, a close monitoring of the viral load may be useful to limit treatment duration and subsequent bacterial infection.", [["bacterial infection", "DISEASE", 226, 245], ["patients", "ORGANISM", 54, 62], ["type I IFN", "GENE_OR_GENE_PRODUCT", 69, 79], ["IFN", "PROTEIN", 76, 79], ["patients", "SPECIES", 54, 62], ["preliminary data", "TEST", 6, 22], ["type I IFN therapy", "TREATMENT", 69, 87], ["viral carriage", "PROBLEM", 107, 121], ["a close monitoring", "TEST", 132, 150], ["the viral load", "PROBLEM", 154, 168], ["treatment duration", "TREATMENT", 192, 210], ["subsequent bacterial infection", "PROBLEM", 215, 245], ["bacterial", "OBSERVATION_MODIFIER", 226, 235], ["infection", "OBSERVATION", 236, 245]]], ["In this context, the use of azithromycin for outpatient care may even be more favorable than the use of type I IFN itself, given that its anti-bacterial properties may also prevent secondary infections that can occur in association with COVID-19.", [["azithromycin", "CHEMICAL", 28, 40], ["infections", "DISEASE", 191, 201], ["azithromycin", "CHEMICAL", 28, 40], ["COVID-19", "CHEMICAL", 237, 245], ["azithromycin", "SIMPLE_CHEMICAL", 28, 40], ["type I IFN", "GENE_OR_GENE_PRODUCT", 104, 114], ["type I IFN", "PROTEIN", 104, 114], ["azithromycin", "TREATMENT", 28, 40], ["outpatient care", "TREATMENT", 45, 60], ["type I IFN", "TREATMENT", 104, 114], ["its anti-bacterial properties", "TREATMENT", 134, 163], ["secondary infections", "PROBLEM", 181, 201], ["COVID", "TEST", 237, 242], ["secondary", "OBSERVATION_MODIFIER", 181, 190], ["infections", "OBSERVATION", 191, 201]]], ["Nevertheless, the risk of antibiotic resistance linked to an excessive use of azithromycin should not be neglected.", [["azithromycin", "CHEMICAL", 78, 90], ["azithromycin", "CHEMICAL", 78, 90], ["azithromycin", "SIMPLE_CHEMICAL", 78, 90], ["antibiotic resistance", "PROBLEM", 26, 47], ["azithromycin", "TREATMENT", 78, 90], ["antibiotic resistance", "OBSERVATION", 26, 47]]], ["Further researches are clearly needed to examine these hypotheses.Author ContributionsThe authors shared their multidisciplinary skills on the analysis of the best possible therapeutic options to treat COVID-19, based on published or pre-printed data.", [["COVID", "DISEASE", 202, 207], ["COVID", "TEST", 202, 207]]], ["AM, LH, and MB developed the initial hypotheses and wrote the manuscript.", [["MB", "TEST", 12, 14]]], ["J-PL and J-LS validated the proposed therapeutic approach and critically reviewed the manuscript.Conflict of InterestAM declares travel and accommodation support from Pfizer.", [["accommodation support", "TREATMENT", 140, 161]]], ["J-PL declares financial support from Sanofi, MSD, Pfizer, Gilead, Janssen-Cilag, Mylan, Eumedica.", [["Mylan", "TREATMENT", 81, 86]]], ["J-LS declares financial support from Astellas, MSD, Abbvie, Astellas, Overcome, Mylan and Mundipharma.", [["financial support", "TREATMENT", 14, 31], ["MSD, Abbvie, Astellas", "PROBLEM", 47, 68], ["MSD", "ANATOMY", 47, 50], ["Mundipharma", "ANATOMY", 90, 101]]], ["These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.", [["data collection", "TEST", 43, 58], ["analysis", "TEST", 63, 71]]]]}